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ABSTRACT 
Introduction Psychotic disorders are known for their wide variability in clinical and social 
outcomes beginning from illness onset and throughout their course. Our current lack of 
understanding of the origins for this heterogeneity is further compounded by dearth in 
knowledge on how patients come to the attention of mental health services and 
methodological incongruity across different studies. Employing samples of first episode 
psychosis (FEP) patients, the aims of this thesis were to: 1) look back on the pathways to 
care patients used to enter mental health services and the use of prodromal services in 
South London; and 2) examine trajectories of the psychotic disorders and potential predictors 
of their longitudinal outcomes.  
Methods Two large samples of patients with FEP (i.e., GAP and EU-GEI) were utilised in 
this thesis. For the study 1, information on pathways to care undertaken prior to coming to 
generic services for FEP was extracted from the Biomedical Research Centre (BRC) Case 
Register Interactive Search (CRIS) system. For studies 2, 3 and 4, using electronic clinical 
records, extensive information in three domains-clinical, social and service uses-was collated 
over 4-5 years after contact with mental health services.  
Results Only a small fraction of individuals (4.1%) who present with FEP to the main 
secondary mental health provider have previously been in contact with prodromal services 
and made a subsequent transition to psychotic disorder; 77% this sub-group of patients 
entered their pathway to care via referral from General Practice or other health professional. 
In contrast, 45% of FEP group without prior contact with the prodromal services made first 
contact with mental health services via emergency services and 18% of this group were 
referred by the criminal justice system. Further, combining the baseline schizophrenia 
diagnosis with five symptom dimensions (i.e., positive, negative, excited, 
disorganised/concrete and depressed dimensions) generated the best model fit for predicting 
time to first remission.  
During the 5-year follow up after first contact with mental health services, a higher proportion 
of Black African and Black Caribbean ethnicity had compulsory re-admissions  and instances 
of police involvement during an admission to a psychiatric unit compared with White British 
ethnic group. Patients of Black African and Black Caribbean ethnicity did not differ from 
White British ethnic group in overall functional disability and illness severity, or frequency of 
remission or recovery during the follow up period. However, patients of Black ethnicity 
become increasing socially excluded as their illness progress. 
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In a sample of first-episode schizophrenia spectrum patients, 35% of the sample met the 
criteria for treatment resistance (TR) at the end of the first 5 years of follow up. Of these TR 
patients, 70% of these were treatment resistant from illness onset. Those who subsequently 
developed TR were more likely to have an early illness onset (<20 years) compared to those 
with non-TR. The relationship between an early age of onset (<20 years) and TR was 
specific to patients of Black ethnicity and patients of male gender.  
Conclusions Very few of those who come to FEP services come after being seen for an at-
risk-mental state by prodromal services suggesting that the scope for reducing or delaying 
onset of psychosis by this means may still be limited. My results indicate that supplementing 
the baseline categorical schizophrenia diagnosis with ratings on five symptom dimensions 
improves the prediction of delayed treatment response as measured by time to first 
remission. Further, the longitudinal trajectory of psychosis in patients of Black ethnicity did 
not show greater clinical or functional deterioration than white patients. However, their course 
remains characterised by more compulsion, and longer periods of admission. Finally, I 
showed that for the majority of the TR group, lack of response to antipsychotic treatment is 
present from illness onset, necessitating a consideration for an earlier use of clozapine. 
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CHAPTER 1 INTRODUCTION 
1.1. Introduction  
Over the past century, research into causes and treatment of many neuropsychiatric 
diseases has been marked with important successes. For example, such illnesses as 
pellagra and neurosyphilis, that have prominent underlying psychiatric manifestations, are 
now rare in many parts of the world1. These triumphs stand in sharp contrast to decades of 
frustration in elucidating the aetiology of psychotic disorders 1. 
1.2. Overview of “Psychosis” 
The term “Psychosis” indicates a mental state characterised by a set of “psychotic” 
symptoms which can be classified as positive and negative. Positive symptoms involve 
impaired reality testing and may encompass strong false beliefs held against evidence of the 
contrary; these are also referred to as “delusions”. Abnormal perceptions, including illusions, 
in any of the five sensory modalities, are known as hallucinations 2. Negative symptoms 
include emotional and social withdrawal, loss of motivation, poverty of speech, inability to 
experience pleasure and apathy 3. The pathophysiology of negative symptoms is still poorly 
understood, which may partially explain their resistance to the currently available 
treatments4. Depending on severity, all psychotic symptoms can lead to unusual or bizarre 
behaviours, impaired social interaction and poor self-care ultimately causing a decline in 
level of functioning 4.  
As shown in the Figure 1, not surprisingly, psychotic disorders as a whole, and 
schizophrenia (SZ) in particular, are leading causes of disability worldwide 5. They are 
associated with a tremendous personal, social and economic burden 6 most of which is due 
to the functional disabilities 7. Indeed, patients affected with SZ have difficulties in obtaining 
or maintaining a job, having enjoyable social or interpersonal relationships, living 
independently and for some patients taking care of their basic daily needs becomes 
increasingly challenging. 
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Figure 1. Contribution by different non-communicable diseases to disability-adjusted life-
years worldwide in 2005 
 
This figure is adopted from Prince et al (2007)
5 
1.3. Diagnostic of Psychotic Disorders 
The current classification systems of psychotic disorders, such as the World Health 
Organization’s International Statistical Classification of Diseases and Related Health 
Problems, 10th Edition or ICD-10 for short 8 and American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, or DSM-IV for short 9, are 
derived from the work of Kraepelin (1919), Bleuler (1911) and Schneider (1959) 10,4. 
Kraepelin described Dementia Praecox (this concept will gradually become known as 
Schizophrenia) as a disorder characterised by a chronic and deteriorating course and rapid 
cognitive disintegration10. He considered it a unique disease entity with a single aetiology 
and defined pathology 4. Bleuler rechristened the disorder as SZ and deemed its essence 
was not delusions and hallucinations but rather a disintegration of different psychic functions. 
These in turn were believed to lead to its fundamental symptoms of loosening of association, 
blunt or incongruous affect, ambivalence and autism (Bleuler's 4 As) which were present in 
all cases 10. Schneider (1959) defined 11 first-rank symptoms which he believed to be 
pathognomonic 2-these symptoms are now considered as positive symptoms of SZ 4. 
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While attempting to identify ‘true’ SZ from the pseudo-schizophrenia or schizophreniform 
psychoses by the 1960s the USA adopted the Bleulerian perspective when diagnosing 
patients with SZ; whereas, the Kraepelinian and Schneiderian concepts prevailed in the rest 
of the world. These differences led to wide discrepancies in rates of diagnosing SZ between 
the USA and the rest of the world. However, the American concept of SZ was narrowed with 
the introduction of DSM-III. Consequently, now according to the ICD-10 classification system 
8, a diagnosis of SZ is given if psychotic symptoms continuously persisted for one month or 
longer; whereas, the DSM-IV requires a minimum duration of six months 9.  
As for diagnoses of other psychotic disorders, an ICD-10 and DSM-IV diagnosis of 
Schizoaffective disorder (SAD) is reached when the criteria for both a mood episode and SZ 
have been reported by patients for two weeks or longer. Psychotic symptoms which occur 
only in the context of a mood disorder are classified as Affective Disorders which are, 
according to the ICD-10, further subdivided into 1) Mania with psychotic symptoms; 2) 
Bipolar Affective Disorder, manic with psychotic symptoms; 3) Bipolar Affective Disorder, 
Severe Depression with psychotic symptoms; 4) Severe Depressive Episode with psychotic 
symptoms; and 5) Recurrent Depressive Disorder, severe with psychotic symptoms. The 
reclassification of the affective disorders according to the DSM-IV is as follows: 1) Bipolar-I 
Disorder, most recent episode (i.e., Manic or Mixed or Depressive, all severe with psychotic 
features); 2) Major Depressive Disorder, single episode, severe with psychotic features: 3) 
Major Depressive Disorder, recurrent, severe with psychotic features. 
1.4. Symptom Dimensions1  
The supporters of the dimensional approach to psychotic disorders argue that the currently 
endorsed nosologies are founded on the common practice of grouping a diverse set of 
patients into a single diagnostic category 11. Although a subdivision of SZ into positive and 
negative syndromes was believed to enhance its diagnostic validity 12, 13, further 
investigations have consistently demonstrated that this dichotomy was an oversimplification 
12-14 with important implications for research, diagnostics and treatment 15. Instead, it is 
postulated that the phenomenology of psychotic disorders may be better conceptualised by 
a number of symptom dimensions 13 (although the ideal number and features of these 
                                                          
1
 This section was published in David, A S. and Ajnakina, O. (2016). Psychosis as a continuous 
phenotype in the general population: The thin line between normality and pathology. World 
Psychiatry, 15(2):129-30. doi: 10.1002/wps.20327. 
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dimensions is not confirmed), as this approach acknowledges an existence of distinct 
subgroups of symptoms 16, 17 that are unique in their clinical presentation and trajectory 13. 
The concept of the dimensional approach offers a number of unique opportunities. Firstly, 
recognising the psychosis phenotype as a gradual infusion of quantitative traits into clinical 
syndromes provides an elegant explanation for variation in the degree of severity of 
psychotic symptoms observed across different patients. Secondly, the dimensional approach 
implies that it is not restricted to any specific psychotic disorder but rather represents a 
continuous expression across the psychosis spectrum. This may explain the overlap in 
psychopathological presentation observed across mental disorders and therefore may 
provide a foundation for cross-disorder analyses. The latter in turn would tackle the 
indistinctness of current diagnostic categories that are marked by a lack of clear boundaries 
between themselves and with normality 18. Although the idea of considering 
psychopathology in terms of psychosis dimensions may still be perceived as agnostic with 
respect to traditional diagnostic systems, using these two approaches in combination may 
allow for a more accurate classification of affected individuals 19, 20. The dimensional 
approach may also have important advantages in scientific research. In research carried out 
by my group employing psychosis dimensions, a degree of specificity was found in the 
relationships between different types of childhood trauma and psychosis symptom 
dimensions in adulthood suggesting that distinct pathways may be involved in the 
relationship between the childhood trauma and psychosis 21. Similarly, Jones et al 22 have 
demonstrated the importance of different dimensions in exploring how an increased genetic 
risk for SZ expresses itself during early teens among the general public. Certainly, building 
on these findings, future studies may shed some light on the pathways between the genetic 
liability for SZ and phenotypical expression of this illness in childhood, adolescence and 
throughout adulthood.  
1.4.1. Symptom dimensions: Wallwork/Fortgang’sfive factor model 
To-date a number of multidimensional models with five factors have been reported 14, 23-25. 
Based on previous work, Wallwork et al 26 derived a consensus five factor model of 
psychosis that comprised of the positive (e.g., delusions, hallucinatory behaviour), negative 
(e.g., blunted affect, emotional withdrawal), disorganised/concrete (e.g., conceptual 
disorganisation, difficulty in abstract thinking), excited (e.g., excitement, hostility) and 
depressed (e.g., depression, guilt feeling) dimensions. Langeveld’s et al 27 further 
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comparative analyses have highlighted that the Wallwork/Fortgang’s model 26 was the most 
robust model for exploring the symptom profiles in patients who have not been affected by 
factors associated with a long-term course of illness. Therefore, I will utilise this model in my 
analysis (Chapter 4, Study 2, pages93-113)  
1.5. Onset and course 
As Figure 2 illustrates, SZ is characterised by a sequential trajectory that involves a 
premorbid phase with subtle and nonspecific cognitive, motor and/or social dysfunction, a 
prodromal phase characterised by attenuated positive symptoms or basic symptoms and 
decline in functioning, and the first psychotic episode (FEP) indicating formal onset of the 
psychotic disorders. In this PhD thesis, I will focus on the prodromal and FEP phases.  
Figure 2. Onset and course of Schizophrenia: Premorbid phase, Prodromal phase and 
onset of First psychotic episode 
 
This figure is adopted from Tandon et al. (2004) 
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1.5.1. Prodromal Phase 
As outlined in Figure 3, the FEP is often (but not always) proceeded by the At Risk Mental 
State (ARMS) (this phase is also referred to as Ultra High Risk) 28. The ARMS is 
characterised by either ‘attenuated’ psychotic symptoms the severity of which do not warrant 
the diagnosis of a clinically defined psychotic disorder, full yet brief and self-limiting 
psychotic symptoms, or a significant decrease in functioning in the context of a genetic risk 
for SZ 29, 30. It is further defined by subtle subjective disturbances of cognitive processes, 
thinking, perception, mood, affect and behaviour. The ARMS phase was initially shown to 
associate with up to a 30-45% chance of developing a full-blown psychotic disorder in the 
following 24 months 31; this risk further increased to 54% within 31 months 28, 30, 32. However, 
more recent studies have reported a lower transition rate33. Identification of ARMS 
individuals provides a unique opportunity to reduce the duration of untreated psychosis 
(DUP), which in turn may improve the overall prognosis of psychosis 34, deferring or 
decreasing transition to psychotic disorders and reducing the financial or emotional burdens 
associated with these disorders 28, 34, 35. This recognition has ignited new interest in 
prodromal services for those individuals who are perceived to be at high risk for developing 
psychosis.  
Figure 3. Depicting that the vulnerability to psychosis distributed on a continuum in the 
general population 
 
This figure is adopted from Fusar-Poli et al (2013) 
28
.  
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1.5.2. ARMS and Pathways to Care 
The ARMS services in South London (UK) provide comprehensive care to young individuals 
age 14-35 years old meeting criteria for the ARMS 28, 30, 36, 37. Having established close links 
with primary care providers and non-health related community services, such as school 
counsellors and emergency and criminal justice services, the ARMS services claim to have 
created an accessible and acceptable service for help-seeking young people who are at risk 
for psychosis 28, 38. Although up to 8% of the general population meet the criteria for the 
ARMS 39, the proportion of individuals with FEP who access the mental health care via the 
ARMS services is still unknown. Current knowledge of pathways to care for those at high risk 
of psychosis remains relatively sparse 40. It is also unclear whether pathways to care in 
prodromal cases differ from those patients who present to conventional mental health 
services for FEP. A better understanding of how different groups interact with healthcare 
systems may allow us to more effectively target interventions aimed at reducing DUP and 
improve pathways to care 41. To access the prodromal services, however, patients are 
expected to demonstrate active help-seeking. This condition may introduce a bias whereby 
those individuals who are at high risk for transition and who presented to the prodromal 
teams may be unrepresentative of the overall population of people with ARMS. Additionally, 
earlier studies showed that a high proportion of those referred to prodromal services were 
already in a frank first episode at the time of the contact 28. Yet, it is not known whether this 
subgroup of FEP patients constitutes the same subgroup of patients as those FEP cases 
who did not have prior contact with prodromal services, or whether prodromal teams perform 
a useful function in detecting FEP patients who otherwise might not be referred to regular 
FEP care. 
1.5.3. First psychotic episode (FEP): Definitions and challenges 
The FEP studies recruit all individuals presenting to mental health teams for the first time 
with psychotic symptoms over a specified period. Defining the onset of FEP can however be 
challenging due to substantial variations in the definition of what constitutes an onset of the 
illness (i.e., first sign of mental disturbance, positive symptom, evidence of social 
dysfunction, clinical contact or hospitalisation). A few studies applied the first hospital 
admissions as a selection criterion for FEP42-48. However, this criterion for FEP is associated 
with a number of important limitations. By recruiting patients on the first admission, these 
studies potentially omit about 10-20% of affected individuals who will never be admitted to 
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psychiatric wards 49, 50. This selection criterion could also lead to female patients being 
under-represented in these studies as women tend to have a less severe illness course and 
may therefore be more often treated on an outpatient basis 49. Additionally, applying the first 
hospital admission as a selection criterion for FEP may bias recruitment in favour of patients 
with a more severe presentation and poorer outcomes 50. Further, there is a large 
discrepancy in the age limits in inclusion criteria of potential research participants. A few 
studies limited their inclusion criteria to patients aged 15-54 years 48, 51-55; whereas others 
indicated a lower age limit (i.e., 12-13 years old) 44, 56, 57. An arbitrary age cut-offs may 
jeopardise generalisability of the findings 58. Studies of unselected samples of incident cases 
with all psychotic disorders remain relatively rare.  
1.6. Psychosis and Ethnicity 
Psychiatric epidemiology has consistently demonstrated elevated rates of psychotic 
disorders among those of Black ethnicity residing in the UK 59-61. This contrasts with lower 
rates of psychosis found among Irish people and conflicting results in Asian populations 62, 63. 
With a significant influx of immigrants of African and Caribbean descent, it was originally 
postulated that those who tended to migrate from their native country were already 
vulnerable to developing psychosis 64, 65. This theory however did not stand the test of time 
as the rates pf reported psychosis remained high among the generations born in the UK 66, 
67. Subsequently, it was suggested that individuals of Black ethnicity were more likely to be 
misdiagnosed with psychosis 59, others blamed a stronger genetic predisposition to this 
disorder 67, 68. Without reliable evidence being produced 66, 69, these theories have lost their 
prominence. Further research has shown elevated rates of psychosis occur among those of 
lower social class 70, 71. This relationship is not a simple consequence of geographic drift or 
segregation 72 but rather an area marked by social deprivations in itself may be a risk factor 
for psychosis 53. The evidence suggests that a majority of Black ethnic minorities in the UK 
live within a toxic environment characterised by high levels of deprivation, unemployment 
and social exclusion 73. However, despite the importance of investigating the potential 
causes for this relationship between the ethnicity and the elevated risk for psychosis, 
research in this area is marked by dearth of studies, methodological heterogeneity and flaws 
74.  
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1.7. The importance of follow up studies  
The FEP studies recruit all individuals presenting for the first time with psychotic symptoms 
over a specified period and mental health teams, and then follow them over a specified 
period. The follow up studies have a two-fold purpose 49. First, this study design aims to 
identify the patterns of variability in the course and outcomes of the illness; this is referred to 
as natural-history studies 49. Second, this study design can be used to identify factors that 
may either modify outcomes or identify the risks for poorer outcomes (prediction-of-outcome 
studies) 49. Such studies reflect the continuous interplay between an individual, the illness 
and the environment 49, they are important for the research and ultimately clinical practice. 
For example, they may be able to deepen our current understanding of prognostic factors, or 
identity factors that are linked to poorer treatment response. This in turn will help identify 
specific patient populations that may be less or more likely to respond to a treatment, and as 
such will help clinicians select treatments that are more likely to succeed. So far a number of 
longitudinal studies have been conducted exploring course and outcomes in patients with 
FEP and I will present them in Tables 1 and 3 (pages 29 and 49).  
1.8. Why is it important to use a FEP sample in this study design? 
Studies that examine the longitudinal outcomes of psychotic disorders measure dynamic and 
multidimensional relationships between the patients and treatments. Therefore, it is 
important to focus on a sample of patients whose symptomatology is not affected by 
chronicity of illness or prolonged medication use25. The sample recruited at the time when 
the first episode occurred represents a patient population that clinicians see in everyday 
clinical practice. This type of sample stands in sharp contrast to patients with an established 
diagnosis of SZ who represent the severe end of the psychosis phenotype75. FEP patients 
have a common starting point in their illness course, and are thus more suited to studying 
the variability and determinants of course and outcome over a period of time 74, 76.  
1.9. Definition of Outcomes  
The ‘Outcome’ refers to the longitudinal trajectory of illness. The outcome studies generally 
include a baseline assessment (referring to the assessments conducted at study entry) and 
follow-up assessments that can take place at any point during the follow up period. It is 
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important to note that this definition of the outcome does not imply that the illness process 
has an endpoint49. Instead, it indicates that an end point in any given study design is the end 
of the follow up period49. There are no limitations on what may constitute an outcome, as an 
outcome can be measured in different dimensions, such as cognitive or psychosocial 
function, as well as in clinical terms e.g. number of hospitalisations, remission and recovery.  
1.10. Longitudinal outcomes in FEP patients: Systematic literature review  
I have conducted a systematic review of all studies that were published on recovery and 
remission as well as service utilisation and social outcomes, in accord with the Meta-analysis 
of Observational Studies in Epidemiology guidelines 77 and the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses standard 78. The main aim of the systematic review 
was to provide a comprehensive overview of all available studies conducted on clinical 
outcomes (i.e., remission and recovery), social outcomes (i.e., living arrangements, 
employment and relationship status) and service utilization over illness course after onset of 
FEP, and whether the reported results across studies were consistent; notably I did not 
assess the published studies in terms of their methodological robustness and importance of 
their findings in this review as this was not my aim.  
1.10.1. Inclusion criteria for the studies  
I included studies of longitudinal observational design both retrospective and prospective 
studies in patients with FEP (including FES and first episode affective psychosis) without 
upper or lower age limit who fulfilled the following criteria: 
I. Reporting remission rates recovery rates, in people with a FEP irrespective of 
clinical setting (i.e., inpatient, outpatient or mixed).  
II. Individuals with FEP who were making their first treatment contact or in their first 
admission for FEP  
III. Using a specified standardised diagnostic system (e.g. ICD, versions 8,9 and 10), 
DSM (versions III and IV), Bleuler's diagnostic criteria, Kraepelin & Feighner’s 
diagnostic criteria, Royal Park Multidiagnostic Instrument for Psychosis, and the 
Research Diagnostic Criteria (RDC)   
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IV. Studies that reported information on social outcomes such as employment, living 
arrangement and relationship status  
V. Studies that reported information on service use such as number of total hospital re-
admissions and total length of inpatients stay during the follow up period  
VI. English language articles published in a peer reviewed journal from inception to July 
2016  
VII. A prospective follow up of >12 months  
1.10.2. Exclusion criteria 
I excluded from this systematic review all studies that were:  
I. Randomised controlled trials (RCTs); although these might have reported rates of 
remission and/recovery, they did not represent a naturalistic progression of the 
illness due to their non-naturalistic design 
II. Studies that examined efficiency of clinical treatments such as psychotherapies or 
antipsychotic medications  
III. Studies that did not include people with psychosis 
IV. Studies that were not FEP cohorts 
V. Studies of organic psychosis 
1.10.3. Search criteria 
I searched PubMed, Medline, and Scopus without language restrictions from database 
inception. Key words used were “first episode psychosis” OR “early episode psychosis” OR 
“schizophrenia” OR “schiz*” AND “remission” OR “recovery” AND “outcome” OR “follow-up” 
OR “hospital admission” OR “treatment” OR “social outcomes”.  
1.10.4. Results of systematic literature review 
Comprehensive descriptions of all identified studies that examined clinical outcomes are 
presented in Table 1 and all the longitudinal studies that examined services use and social 
outcomes in FEP cases are presented in Table 3. I will give an overview of the main findings 
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for each outcome below in the subsequent sections. All identified studies are listed in Tables 
1 and 3 in the alphabetical order; for every identified study I outlined study design sample 
characteristics and proportion of patients who met criteria for each outcome (i.e., remission 
or recovery, etc.) and rates of patients who were successfully followed up. In Table 1, I 
aimed to provide definitions of recovery and remission used for comparison across the 
studies; if the outcome was examined, but a definitions used were not stated in the original 
article “not stated” phrase is used in the table.  
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Table 1 A review of previous longitudinal studies examining social and clinical outcomes, and services use in a sample of patients with first 
episode psychosis 
Author 




























Definition of recovery 
Remission 
FU (%) 










3 240 61.3 147 82 18 24.5    
 







FEP 2 54 90.7 49 46.3 53.7 24.2    
 
77.8 
Asymptomatic for 4 weeks or 
longer 








5 468 46.6 
54.4
872 
56.1 43.9 26 29  15.7 
Remission of both negative and 
psychotic symptoms, no hospitalisations 
and not living in a supported housing 
facility, GAF score >60 and employed (or 
studying) during the past 2 years. 










7.5 307 68.1 209 73.2 26.8 21.9 79.9 9.6 26 
Symptomatic remission (as adopted 
from Andreassen et al, 2005) with the 
exception of 6 month duration 
component and vocational functioning 
defined as independent living and peer 
contact more than once per week. No 







FEP 10 496 61.3 304 55 45 26.2   30 
Remission of both negative and positive 
symptoms, no psychiatric admissions to 
hospital or living in supported 
accommodation for the past two years. 
Additionally, engaged in work or study 
and a GAF score >60 at the end of 
follow up 
64 
Symptom remission was 
defined as the display of 
minimal–mild positive and 
negative symptoms on the 
global scores for SAPS and 
SANS for at least 6 months 








1   70 75.7 24.3 23    
 
24.3 RSWG 2005 criteria 
































Definition of recovery 
Remission 
FU (%) 
Definition of remission 













5 100 93 93 49 51   94 8.6 
Patients no longer presented any of the 
SZ processes, once more entered into a 
successful social relationship, exhibited 
wholesome interest in life and ability to 
deal with its problems 
  





 5 547 48.4 265 65 35 26 53  18 
Symptomatic remission (as adopted 
from Andreassen et al, 2005), living 
independently, working and GAF>59 









4 123 86.2 106 47.2 52.8 29.5     83.7 
Patient did not meet DSM-IV 
criteria for a mood disorder for 
8 weeks or longer 












2   53 69.6 30.4 18.3     74.4  







FEP 3 700 77 539 51.6 48.4 21 28.6  17.4 
In the last 12 months of study period: (i) 
CGI-S scores < 3 for both positive and 
negative symptoms; (ii) no psychiatric 
admission; (iii) functional remission. 
 
58.8 
CGI-S scores < 3 for both 
positive and negative 
symptoms in the last 6 months 












1 104 70.2 73 55.8 44.2 25.8     59.6 RSWG 2005 criteria 
































Definition of recovery 
Remission 
FU (%) 












FES 37 1642 18 289 31.8 68.2 75.5   27 Bleuler (1972) criteria   





FEP 4 166 79.5 132 58 42 28.5  14.6   57.6 
No score higher than 3 over 
the previous month on any 
PANSS items at follow up 








FEP 2 349  335 66.5 33.5 26     47.5 not stated 





























2 57 9.1 28 49 51 28     40 RSWG 2005 criteria 

































Definition of recovery 
Remission 
FU (%) 
Definition of remission 






FEP 10 301 61.8 184 56.4 43.6 28.1   24.4 
A combination of symptom remission 
and 3 functional dimensions from the 
SCLFS (independent living, role 
functioning and social interactions) for 
12 months 






FEP 2 149 86.6 129 68.5 31.5 25.7   19.4  52.4 
RSWG 2005 criteria with an 
observational period of the last 
9 months of a 2-year follow up 
period and no relapse within 6 












FES 3 933 60.3 563 62.8 37.2 37.5 55.8 27.7   60.6 
A score of 3 or less on the 
CGI-SCH for 6 months or more 
(i.e. RSWG 2005 criteria) 






FE Mania 4 101 80.2 81 47.5 52.5 22.3 27.4 6.4 100 
A virtual absence of depressive and 
manic or hypomanic symptoms for 8 
weeks 
98.8 
Criteria for a mood episode 
were no longer met 





FEP 15 1633 61.5 
100
5 
50.6 49.4 47.5   26.1 
Bleuler scale & GAF(d) > 60, excluding 
those with a recent (in the past 2 years) 
episode of treatment 
  
               
































Definition of recovery 
Remission 
FU (%) 
Definition of remission 





FEP 7.5 276 51.1 141 51 49 23.1 




Both the absence of major 
symptoms and adequate 
psychosocial functioning at any 
point during the early clinical 
course 





FEP 15 274 57.3 157 50 50 22.8 
  
54.3 
Absence of major symptoms, employed 
(part/full-time) and adequate 
psychosocial functioning for >1 year, 
plus no psychiatric re-hospitalisation 













FES 21 107 75.7 81 50.5 49.5 33.5     29 
complete psychopathological 
remission or minor 
psychopathological symptoms 
whether in or not in treatment 






FES 21 107 75.7 81 50.5 49.5 33.5     29 
complete psychopathological 
remission or minor 
psychopathological symptoms 
whether in or not in treatment 














FES 22.4 758 66.2 502 42.6 57.4 22.4     22.1 
Established according to 
criteria established by Bleuler 
(1972) 
































Definition of recovery 
Remission 
FU (%) 







FEP 7 723 66.9 484 67.4 32.6 21.9   25.6 
The first item was social interactions with 
people outside of the family (QLS item 4; 
social activity score ≥4). The second 
was appropriate role function, defined as 
paid employment, attending school at 
least half-time, or, if a homemaker, 
performing that role adequately (QLS 
item 9; occupational role functioning 
score ≥ 4). The third was the ability to 
perform basic living tasks and to engage 
in certain activities (QLS item 19; 
commonplace activities score ≥ 4; eg, 
shopped for food, paid a bill, gone to a 
movie or play) 
 
59 
The symptomatic severity 
component  but not the 6-moth 
duration component of RSWG 
2005 criteria applied 





FES 1.5-2.5 1379 78.2 
107
8 
54 46 27.9 74    29.4 
Complete remission for 76-




















2 278 57.2 159 67.9 32.1 22.8  8.8   41.5 
Scores of ≤ 2 on all 4 SAPS 
global subscale items 
(hallucinations, delusions, 
bizarre behaviour, thought 
disorder) and SANS global 
subscale items (affective 
flattening, alogia, apathy-
avolition, asociality-anhedonia). 
































Definition of recovery 
Remission 
FU (%) 







EPET 16.8   278 100 0 17.1     93.9 
Psychotic symptoms of 
insignificant severity (no more 
than 3 points in the PANSS) 







FEP 15 97 53.6 52 55.7 44.3 24.8  18.6 32.7 
The state of no symptoms or signs of a 
psychotic episode for at least 4 weeks 
  






FES 20 402 53.7 216 60.7 39.3 23.3 40  28.3 
Patient not receiving treatment, well and 
working (duration not stated) 
  






FES 20 402 53.7 216 60.7 39.3 23.3 40  28.3 
Patient not receiving treatment, well and 
working (duration not stated) 
  
















FEP 1.5 786 81.8 643 77 33 21.6 49.8    Not stated 
No positive symptoms as 
measured with PANSS for at 8 






FEP 3 2960 96.1 
284
2 
49.1 50.9 42.1 43  8.1 
Simultaneous fulfilment of the following 
criteria over a period of at least 
24 months: 1) Symptomatic recovery; 2) 
Functional recovery 
  
































Definition of recovery 
Remission 
FU (%) 







FES 2 2960 74.7 
221
0 
49.4 50.6 42.3 42.6    47.2 
symptomatic remission defined as 
receiving a CGI-SZ severity score of 
absent or mild  (score=/<3) for 6b 
months or longer 








2 225 83.1 187 62.7 37.3 27.1 44.9    77 
A period of at least 1 week without 
positive psychotic symptoms 
corresponding to PANSS score of 3 or 
below on positive  symptom items 
1,3,5 or 6, or general subscale 9 






FES 5   70 56 44 24.3   84.3  74 










FES 5 120 58.3 70 55.7 44.3 24.3  10 84  74 
No rating >3 on any of the SADS-C + 
PD positive psychotic symptoms items, 
a CGI severity item rating of g3 (mild), 
a CGI improvement item rating of 2 
(much improved) or better, and the 
maintenance of this level of 










FES 5 120 58.3 70 55.7 44.3 24.3  10 84  74 
No rating >3 on any of the SADS-C + 
PD positive psychotic symptoms items, 
a CGI severity item rating of g3 (mild), 
a CGI improvement item rating of 2 
(much improved) or better, and the 
maintenance of this level of 
improvement for 8 weeks. 
 






FEP 5 63 46 29   28.5     72.4 
Patients were considered to be non-
remitters if all psychiatric records 
described a state of permanent 
psychosis and if that were psychotic at 
the time of re-investigation 
































Definition of recovery 
Remission 
FU (%) 






FEP 2 159 57.2 91 71.6 28.4 26.1  74.6 42.1 
Rating of 0 on all subscales of SAPS by 
the end of 1 year in PEPP and 
maintaining this rating at 2-year follow-
up; no period of recurrence of positive 
symptoms between 1 and 2 years based 
on consensus rating of independent 
chart review using a modified version of 
the Life Chart Schedule 
 
37.5  










Patient is alive, free of psychotic 
symptoms, no disability, no on treatment 
in the last 2-years of follow up 
  







FEP 5 175 40.6 71 47.9 52.1 29.1   72.2 
Living a normal life’’ with or without 
antipsychotic medication and with no 
need for daily support from 
professionals. The GAF score had to 
have been stable at >60 for at least 6 
months and they had to have worked or 









FEP 10 532 72.7 387 57.9 42.1 30.8 23.6  46 Sustained remission for at least 2 years 77 
Absence of overt psychotic 
symptoms (operationalized as 
a score of 2 or 3 on Rating 
Scale 2 in the SCAN; 
0=absence, 1=symptom 
occurred, but fleeting, 
2=symptom definitely present, 
3=symptom present more or 
less continuously) for a period 











4 87  87 41.4 58.6 31.1     69 
A period of 8 weeks in which 
Ps were asymptomatic 
regardless of treatment status 
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Author 




























Definition of recovery 
Remission 
FU (%) 
Definition of remission 














FES 5 110 86.4 95 65.5 34.5 25.9 35  8 









FES 22.5 94   53 47 31.3     16 Not stated 










2 191 37.7 72 80.1 19.9 22.4     58.3 
Patients who met the following 
criteria for 4 consecutive weeks 
were classified as remitters: no 
rating of >3 (mild) on items P1, 
P2, P3, P5, and P6 of the 
PANSS; and a CGI Severity 







FEP 2 47 83 39 29.8 70.2 29.7 60 42.6   71.8 
PANSS scores were </=60 and 
GAF score were >80 at the end 








FES 25 90 52.2 47 50 50 24.5   14.9 
Patients did not have further episodes 
since the index episode and were 
functioning well 
68.1 
At least three consecutive 
months without psychotic 
symptoms 









42 48 25.2 
  
16.4 
University of California at Los Angeles 
recovery criteria. Full recovery required 
patients fulfilled criteria for both 
symptomatic remission and adequate 
social/vocational functioning 
54.9 
RSWG 2005 criteria without 
the duration criteria 

































Definition of recovery 
Remission 
FU (%) 
Definition of remission 





FEP 10 301 86.7 261 57 43      79.7 
Absence of psychotic 





















FEP 1.5 115 86.1 99 48.5 51.5 16.2 57.6    50 
Absence of positive symptoms 
for 12 weeks (Kane et al 






FES 5 121 88.4 107 65 35 34.4 48 76   22 
After the key episode became 
symptom free and remained so 






FES 10 200 50.5 101 73.3 26.7 28.8   60 
Good compliance (less than 80%), not 
being hospitalized for a minimum of two 
preceding years, GAF score greater than 
80, QOL score greater than 80, AIMS 
score less than 2, scores greater than 3 
on scales of social functions, 
independent living, education, and social 
burden (reverse scored) 
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Author 




























Definition of recovery 
Remission 
FU (%) 







FEP 2 301 94.5 293 59.7 40.3 27.8     50.1 
Symptoms with score of <4 on 
any of the PANSS positve 
subscales items 1, 3, 5, or 6 
and on general subscale item 9 






FES 10 200 50.5 101      30.5 
Assessed with Clinical Global 
Impression Scale (definition as such not 
stated) 
  





FEP 13 153 62.7 96 46 44 31.7 59 25 16.7 
Symptomatic remission plus adequate 
functioning 
47 
RSWG 2005 criteria duration 
not stated 






FES 10 90 84 76 50 50 24 
  
14.5 
Had not suffered any further psychotic 
symptoms after the initial admission 
48.7 
Total absence of all positive 








5 578 52.1 301    39.8  16.9 
No psychotic or negative symptoms, 
GAF(F)>59, in job or education, living 
independently for the last two years 
 
Minimal–mild positive and 
negative symptoms on the 
global scores for SAPS and 
SANS for at least 6 months 


































Definition of recovery 
Remission 
FU (%) 












2 56 87.5 49 50 50 36.3  23.2 92.1 
A severity rating ≤3 for the DSM-IV A 
criterion for mania (range 1–7), with no B 
criterion rated greater than 3 and no two 
B criteria rated at 3. Patients with initial 
mixed episodes fulfilled recovery criteria 
for a manic and a depressive episode 
(no depression criterion >3, nor more 
than three at 3). In addition, CGI ratings 
had to be ≤2; maintained for at least 8 
weeks 
40.1 
Scores < 3 for BPRS-E-
Depression subscale items 
(anhedonia, appetite, care, 
depression, dysphoria, fatigue, 
guilt, indecisiveness and poor 
concentration, motor 
retardation, suicidal ideation or 
behaviours) and for BPRS-E-
Psychosis subscale items 
(blunted affect, thought-
broadcasting, -control or -
withdrawal, conceptual 
disorganization, disorientation, 
hallucinations, mannerisms or 
posturing, suspiciousness, 














2 219 90.9 199 56.2 43.8 34.1   97.5 
A severity rating ≤3 for the DSM-IV A 
criterion for mania (range=1–7), with no 
B criterion rated greater than 3 and no 
two B criteria rated at 3. Patients with 
initial mixed episodes fulfilled recovery 
criteria for a manic and a depressive 
episode (no depression criterion >3, nor 
more than three at 3). In addition, CGI 
ratings had to be ≤2; maintained for at 
least 8 weeks 
  






FES 2 93 47.3 44 52.1 47.9 21.1 43.7    29.5 RSWG 2005 criteria 





























p BL (%) 
Recovered 
FU (%) 
Definition of recovery 
Remission 
FU (%) 
Definition of remission 






FES 2 28 89.3 25 60.7 39.3 21   16 
Symptomatic remission (as adopted 
from Andreassen et al, 2005), plus at 
least part-time work or school, living 
independently and at least once 
weekly socialising with peers or 
otherwise involved in recreational 
activities that are age-appropriate 
and independent of professional 
supervision all during the last 2 
years. 
 
64 RSWG 2005 criteria 






FEP 1.5 191 87 166 64 36 26.4  12 45 
Sustained remission for at least 2 
years 
60 
Absence of overt psychotic 
symptoms (operationalized as 
a score of 2 or 3 on Rating 
Scale 2 in the SCAN; 
0 = absence, 1 = symptom 
occurred, but fleeting, 
2 = symptom definitely present, 
3 = symptom present more or 
less continuously) for a period 








FES 3 86 88.3 76 48.7 51.3  48.7    31.6 
Total absence of all psychotic 








FEP 2 1175 66 776 51.3 48.7 28 31.6 22.2 29.4 
Patients who fulfilled the criteria for 
both symptomatic and functional 
remission 
54.1 RSWG 2005 criteria 






























Definition of recovery 
Remission 
FU (%) 






FEP 1   103 71 29 21.6     95.1 
A score of 3 or less on all of 
the BPRS psychotic subscale 
items for at least 2 weeks 






FEP 4 171 75.4 129 65 35 25.5 30    43 
no PANSS items >3 for 4 
weeks 









15 496 70.4 349 49 51 42 26 30   40 
After one or more episodes no 
residual symptoms and return 
to pre-morbid functioning over 
the first 2 years of follow up 





FES 15 82 76.8 63 52 48 25 37    27 
Absence of psychotic 
symptoms, presence of usual 
pre-morbid functioning for at 
least 30 days 





FES 15 82 76.8 63 52 48 25 37    27 
Absence of psychotic 
symptoms, presence of usual 
pre-morbid functioning for at 






FEP 2 125 100 125 68.8 31.2 25.7  15.2 19.2 
If both criteria for symptomatic 
remission (according to 
RSWG 2005) and GSDS role 
of functioning score were ≤1, 
without the symptomatic and 




RSWG 2005 criteria for 9 
months 





FE SZ & 
schizophre
niform 
2 30 73.3 22 63.3 36.7 28.9 3.3  86.4 
No DSM-III-R ‘A’ criteria rated 
>2, and fewer than three 
criteria rated ≥2 rated on 
BPRS with duration of 8 
weeks or longer 
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FU, follow up period; n, number; FES, first episode schizophrenia; FEP, first episode psychosis; FEAP, first episode affective psychosis; DSM, 
Diagnostic and Statistical Manual of Mental Disorders; GAF, Global Assessment of Functioning; GAF(d), Global Assessment of Functioning 
disability scale; CGI, Clinical Global Impression Scale; CGI-SCH, Clinical Global Impression-Schizophrenia scale; BPRS, Brief Psychiatric 
Rating Scale; SADS-C, Schedule for Affective Disorders and Schizophrenia a version for measuring the change in symptomology; PANSS, 
Positive and Negative Syndrome Scale; QLS, Quality of Life Scale; SAPS, Scale for Assessment of Positive Symptoms; SANS, Scale for 
Assessment of Negative Symptoms; GSDS, Groningen Social Disabilities Schedule; SCAN, Schedules for Clinical Assessment in 
Neuropsychiatry; SCLFS, Strauss Carpenter Level of Functioning Scale; SSRG, Scottish Surgical Research Group; UK, United Kingdom; USA, 
United States of America 
The Remission in Schizophrenia Working Group (RSWG) 2005 criteria for remission: Patients were defined as remitters if they demonstrated 
either a complete absence of psychotic symptoms, or if symptoms were present they were of such low intensity that they no longer significantly 
interfered with patients’ day-to-day functioning. The threshold of symptom severity was as follows: 1) the Positive and Negative Syndrome 
Scale (PANSS) item scores of ≤3; 2) the Brief Psychiatric Rating Scale (BPRS) item scores of ≤3; or 3) the Scale for the Assessment of 
Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms scores of ≤2. As for duration of the remission, a period of 
6 months was suggested as a minimum time threshold during which the aforementioned threshold of the symptom severity must be maintained 
to achieve remission.  
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There are currently 42 studies that reported on remission rates and 23 reported on recovery 
rates, with 18 studies reporting on both remission and recovery, for an overall of 
83independent samples. The final sample for all of these studies comprised 19,897 FEP 
patients (range of sample sizes: 20-2,842), with 9,180 (range sample sizes 25-776) with 
remission data and 10,287 (range of sample sizes 20-2842) with recovery data2. I will give 
an overview of the main findings here.  
1.10.4.1. Remission 
Remission is an important treatment end point and was previously defined as a complete 
elimination of the core psychotic symptoms154, 155. However, this definition eventually 
became perceived to be too imprecise without clearly outlined criteria of what constituted 
“complete elimination of the core psychotic symptoms”. Ultimately, it did not recognise the 
multifactorial nature of SZ, leading to variable or even inaccurate reported rate of remission. 
In 2005, the Remission in Schizophrenia Working Group (RSWG) derived a consensus 
definition of remission in SZ 154. In order to summarise the main criteria for the new definition 
of remission in a concise and comprehensive manner, I have outlined the detailed proposed 
criteria for remission as outlined by the RSWG in Table 2. 
 
                                                          
2
 These findings are based on the meta-analyses of remission and recovery rates in FEP, including 
diagnostic subgrouping, and moderators of remission and recovery that is currently in preparation for 
submission by John Lally,* Olesya Ajnakina,* Brendon Stubbs, Robin M Murray (in preparation). 
Remission and recovery from first-episode psychosis in adults: A systematic review and meta-
analysis of long term outcome studies.  
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Table 2 outlines the newly proposed criteria for remission; specifically the proposed items for Remission criteria with cross-scale 
correspondence and relationship to historical constructs of psychopathology dimensions and DSM-IV criteria for Schizophrenia. This table is 
adopted from Andreasen et al 154and is provided here for illustrative purposes only.  
   Proposed Remission Criteria Items 
   Scale for Assessment of Positive Symptoms 
(SAPS) and Scale for Assessment of 
Negative Symptoms (SANS) Items 
 
 
Positive and Negative Syndrome Scale 
Items 
 Brief Psychiatric Rating Scale (BPRS) Items 
Dimension of 
Psychopathology 


















 Hallucinations  
Hallucinations  7  Unusual thought content G9  Unusual thought content 15 
Disorganisation Disorganised speech  Positive formal thought 
disorder  
34  Hallucinatory behaviour P3  Hallucinatory behaviour 12 
 Grossly disorganised or 
catatonic behaviour 
 
Bizarre behaviour  25  Conceptual disorganisation P2  Conceptual disorganisation 4 
Negative symptoms 
(psychomotor poverty) 
Negative symptoms  
Affective flattening  7  Mannerisms/posturing G5  Mannerisms/posturing 7 
   
Avolition-apathy 17  Blunted affect N1  Blunted affect 16 
   
Anhedonia-asociality  22  Social withdrawal N4  
No clearly related 
symptoms 
 
   
Alogia 13  Lack of spontaneity N6  
No clearly related 
symptoms 
 
* Global Rating Item Number refers to the number used to describe the types of psychotic symptoms in each measure (such as Scale for Assessment of 
Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS) Items; Positive and Negative Syndrome Scale Items; and Brief 
Psychiatric Rating Scale (BPRS) Items).  
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As for duration of the remission, a period of 6 months was suggested as a minimum time 
period during which the aforementioned threshold of the symptom severity is expected to be 
maintained for a patient to be classified as a remitter. It was hoped that having clear 
guidelines for what constituted remission would enable comparison between studies and 
importantly would help identify why some patients achieve remission while others do not 156. 
The rates of remission appear to be very stable despite the different methodologies (i.e., 
structural face-to-face interviews (on average 55% remitted) or clinical records (on average 
57% remitted). The rates of remission did not depend on the use of more stringent criteria 
such as the RSWG (on average 57% remitted) or the use other criteria for remission (on 
average 59%).  
Nonetheless, despite the consensus criteria of remission as proposed by Andreasen et al 
154, the rates of reported remission vary considerably from 30% to 80% 74, 157, 158. Although 
these differences may reflect the genuine differences in rate of remission, it also may be the 
case that such a substantial variability may be due to inconsistencies in the criteria for 
remission applied across studies, such as shortening the period of remission or modifying 
the threshold of symptoms severity. For example, Larsen et al 159 categorised their patients 
as remitters if they scored ≤4 on specific PANSS items for 2 months demonstrating that 71-
76% of their sample were in remission at the end of a 5-year follow up. Wiersma et al 50 
defined remission as a complete absence of symptoms and return of usual premorbid 
personality for at least 30 days. Accordingly, only 26.7% of FEP cases were in remission at 
the end of a 15-year follow up. Malla et al 54 defined patients as remitters if they met 
symptomatic threshold proposed by the RSWG for a duration of one month only, showing 
that 83% of patents reached remission at the end of a 2-year follow up.  
It becomes evident that the operationalised definition of remission has not consistently been 
applied across a number of studies, making the comparisons of the results very difficult. 
Recently, in a well-designed longitudinal study, the AESOP (Aetiology and Ethnicity in 
Schizophrenia and Other Psychoses)-10 study 74, conducted in the UK, the authors defined 
remission as absence of overt psychotic symptoms (based on SCAN rating criteria) for a 
period of at least 6 months or longer. Considering that this definition is easier to implement 
when assessing clinical outcomes and that this study was conducted in the overlapping 
geographical area as the sample used in my thesis, I will apply the same operationalised 
criteria for remission. This in turn will facilitate the cross-study comparisons and thus provide 
a better understanding of the longitudinal course of the illness.  
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1.10.4.2. Recovery 
Recovery is conceptualised as a more demanding phenomenon than remission. Complete 
recovery implies the ability to function in the community, return of social and vocational 
functioning and being relatively free of main psychosis symptoms 154. There are different 
definitions of recovery available in the literature with consequent variations in the rates of 
recovery reported among patients with FEP. Some studies focused on absence of psychotic 
symptoms for a substantial duration as the primary criteria for recovery. For example, in 
Morgan’s et al 74 longitudinal study symptom recovery was defined as an absolute absence 
of any psychotic symptoms for the preceding 2 years or more. It was shown that 46% of FEP 
patients met criteria for symptomatic recovery during a 10-year follow up. Others utilised 
Bleuler’s (1975) definition for recovery 160. Accordingly, recovery was characterised with full 
employment, reassumed social roles and no psychotic symptoms except for some 
eccentricity or residual symptom. Harrison et al 53 showed that 56% of n=885 FEP cases met 
criteria for recovery based on the Bleuler’s scale during a 15-year follow up period. In a 
longitudinal study of 37 years, Ciompi (1980) 42 demonstrated that 27% of all cases met the 
Bleuler’s definition for recovery. More recently, full recovery was operationalised as the 
absence of major symptoms, plus evidence for adequate psychosocial functioning, including 
employment (half-time or full-time) and no psychiatric re-hospitalisations. Applying this 
definition of recovery, Harrow et al 161 showed that at the end of a 15-year follow up 41% 
cases experienced 1 or more periods of recovery. In Robinson’s et al 162 patients required to 
fulfil criteria for both symptomatic remission and adequate social/vocational functioning to be 
considered as recovered. The authors showed that 38.6% met criteria for recovery within a 
5-year follow up. Cumulatively, it becomes evident that the rate of reported recovery are 
varied as are the definition of recovery utilised across studies making it difficult to compare 
the results and generalise the findings to a winder general patient population.  
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Table 3. A review of all longitudinal studies that have examined social outcomes and services use in a sample of patients with first episode 
psychosis 
Author 















































FES 23.5   20 100 0 26 85 30 90 
mean=71 
months 













 30  
Bottlender et al 
2010 
UK 
SZ 15 61 
  
41 59 32.2 
  
   20 79 





FES 7 76 57.9 44 100 0 22.2 
  






FES 37 1642 18 289 31.8 68.2 >65.0 
  
  38 43 49 





FE SZ & 
SZA 
2 155 96.1 149 66.5 33.5 26 
 
20.6 53.5     










 50  





FES  2 50 58 29 64 36 26.2    
mean=4.2 
months 
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Author 









































FES 7 51 84.3 43 51.2 48.8 27.3 
  






FEM 4 101 38.6 39 47.5 52.5 22.3 27.4 6.4    33.3 5.1 







88.7 502 50.6 49.4 41.4 
  






FES 7.4 74 
 
71 36 64 23.1 
  























FEP 7 723 66.9 484 67.4 32.6 21.9      39.2 18 





FEP 12 171 71.9 123 57.9 42.1 29 
  






FES 2 50 100 50 64 36 23.9      60  














































FES  13   77 43 57 38.4    
48.2 
weeks 





















 EPET 10   278 100 0 17.1      62.9 25.2 





FEP 3.6 182 88.5 161 74 26 22.4 
  
   27  





FES 20 402 53.7 216 60.7 39.3 23.3 40 
 
   32.4  





FES 2 2960 74.7 
 
49.4 50.6 42.3 42.6 
 
     










24 91.7 8.3 23.3 
 
95.8 64     


















































28.9  28 37  





FES 2 49 77.6 38 
   
79 
 






FES 15 184 41.3 76 36.8 63.2     
mean=8.3 
months 
   



































FES 10 70 
  
64 36 
   
   13  
 
53 | P a g e  
 
Author 








































FES 25 90 52.2 47 50 50 24.5      63.8 63.8 
Rupp and Fletcher 
1940 
USA 





United Arab Emirates 












FES 8 175 88.6 155 46.9 53.1   70.9  mean=283
.8 days 


















FES 5 121 88.4 107 65 35 34.4 48 76 55 mean=53.
3 weeks 
 48 84 





FES 10 200 55 101 73.3 26.7 28.2 25.7     25  
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Author 









































FES 2 254   55.1 44.9 28.8 12.2 14.2  
mean=27 
days 
   






























FES 5 49 85.7 42    65   
mean=8.2 
months 
 19 88 





FEP 10 112 62.5 70 56.3 43.7 26.3 
  








































FEP 13 153 62.7 96 46 44 31.7 59 25   9 32 32 













































FES 10 90 84 76 52.6 47.4 24 
  























FES 4 94 46.8 44 52.1 47.9 21.1 43.7   
mean=47.
8 days 
   





FEP 10 109 63.3 69 59 41 27.4 19 18 82   16  










 36 6 





FEP 15 82 76.8 63 52 48 25 37 
 








15 496 70.4 349 49 51 42 26 30   25 20.4 22.4 














































FES 5 120 84.2 101 72 28 27.1 37  85 
total 16.5 
months 
 26  





FEP 5 176 71 123 45.5 54.5 23.3     56.6 40.2  
FU, follow up period; BL, baseline; n, number; FES, first episode schizophrenia; FEP, first episode psychosis; SZ, schizophrenia; SZA, 
schizoaffective disorder; RSWG, Remission in Schizophrenia Working Group; DSM, Diagnostic and Statistical Manual of Mental Disorders 
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1.10.4.3. Service utilisation 
In the AESOP-10 study 74 it was highlighted that 12% of n=388 FEP patients were never 
admitted to hospital at any point, 18% were admitted at initial presentation only and 70% 
were admitted at least once during the 10 year follow-up. The authors further showed that 
the median length of admission was 48 days, and the proportion of the follow-up spent in 
hospital was around 14 weeks over an average of 520 weeks (10 years) of follow-up. 
Helgason 43 in a 20-year follow up of n=107 first time admitted SZ patients showed that 80% 
of the sample was admitted at least once during the follow up period. Similar findings were 
reported by Harrison et al 53 in a 15-year follow up of n=1,171 FEP cases. White et al 48 
reported that 18% of n=109 FEP patients had no further admissions after first contact with 
mental health services but a minority had more than 10. Cumulatively, these findings show 
that the treatment for psychosis places a substantial burden on services with consumption of 
resources for many years after first onset of illness.  
1.10.4.4. Social outcomes  
Social outcomes encompass functioning in everyday situations, capacity for independent 
living and social interactions 189, maintaining employment and stable relationships during a 
follow up period. Kua et al 44 showed that of n=277 FEP cases 53.2% were unemployed at 
the end of a 20-year follow up period. In a similar 20-year follow up study, Helgason 43 
demonstrated that only 17% of SZ cases were employed full-time, 41% did not have close 
friends and 51% remained single or unmarried. In White et al’s 48 study it was shown that 
48% of all patients never worked during a 10-year follow up. In Mason et al’s 51, 52 research 
spanning over 13 years, 28% of all patients lived alone and 44% lived on disability benefit for 
a mental condition at the end of follow up period. Ciompi 42 showed that at the end of a 37-
year follow up 83% were either single, separated or divorced. In Crumlish’s et al 56 study, 
65.7% were living with parents or other family and 9% lived in either hostels, supported 
accommodation or were homeless. In the more recent AESOP-10 study, Morgan et al 74 
demonstrated that only 12% of patients were employed for 75% of follow up time; in terms of 
relationships, 71% remained single during the follow up period and 68% were single at the 
end of a 10-year follow up period. Cumulatively, these studies provide compelling evidence 
that psychosis is often associated with deterioration in social and occupational functioning in 
the decades after first onset.  
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1.11. Treatment resistance (TR) as an important outcome 
Response to treatment or lack of thereof is one of the most important clinical outcomes of 
psychosis that needs to be considered. Although ‘response to treatment’ has no universally 
accepted research definition, it is recognised clinically as a substantial reduction of 
symptoms, usually accompanied by functional improvement following a treatment with 
antipsychotic medications. Around 30% of patients diagnosed with SZ 190 191 fail to respond 
to two antipsychotics after adequate trials. These patients are defined as having treatment 
resistance (TR). Clozapine is the only evidence-based effective medication for TR. In the 
UK, it is recommended that clozapine be offered to people with SZ whose illness has not 
responded adequately to treatment despite the sequential use of adequate doses of at least 
two different antipsychotic medications192.  
1.12. Limitations and gaps in available follow up studies of outcomes in FEP 
There are a few important gaps in current research on longitudinal outcomes in patients with 
first episode psychosis. I will review the main gaps here.  
1.12.1. Methodological heterogeneity 
Current studies that set out to explore longitudinal outcomes in patients with FEP are 
marked by methodological heterogeneity making the comparisons of the results and drawing 
inferences of the nature and progression of psychosis over time challenging. 
1.12.2. Studies of longitudinal outcomes and Ethnicity are sparse 
The potential reasons for the higher rate of incidence of psychosis observed among Black 
African and Black Caribbean populations residing in the UK than in their White 
counterparts59-61 are still the subject of debate and controversy, especially when it was 
shown that it was not an artefact of misdiagnosis 193 nor differences in genetic predisposition 
to this disorder 66, 69. Although the precise mechanisms of this disparity are not known, this 
heterogeneity is further reflected in the the patterns of treatment delivered to the patients 
from different ethnic backgrounds. There is evidence to suggest that on first contact with 
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mental health services patients of Black ethnicity are more likely to be admitted to a hospital 
under the Mental Health Act (MHA) 1983 62, have police present either during or shortly 
before an admission to a psychiatric unit 69, 194, or to be admitted to high-security psychiatric 
hospitals 195 compared to patients of White ethnicity.  
The evidence is also accumulating that this pattern of care in Black ethnic group persists 
over time. It has been shown that patients of Black Caribbean and Black African ethnicity 
have higher rates of detentions under the MHA over a 2-year follow up period 196. Patients of 
Black ethnicity were more likely to have been re-admitted at least once 197, and to have 
experienced longer hospitalisations over a 18-year follow up compared to patients of White 
ethnicity. Cumulatively, these results may portray an illness trajectory characterised by a 
more degenerating course in patients of Black ethnicity compared to patients of White 
ethnicity. However, the current research into the clinical illness course across different ethnic 
groups is sparse to allow us to make any inferences about the clinical course and outcomes 
in different ethnic groups in the UK. While it is well-established that one-third of the patients 
with severe psychotic disorders recover, it is not known what proportion of these constitutes 
Black ethnic minorities. Reports are also mixed in relation to remission in Black populations 
with some reporting that remission is more common in Black ethnic groups 198, while others 
argue an opposite view 199. In general, research into the ethnic differences in longitudinal 
clinical outcomes in different ethnic groups in the UK is marked with the methodological 
differences. Many studies were limited by small sample sizes 196, and there was a tendency 
to neglect the diversity in culture, religious beliefs and life experience between Black African 
and Black Caribbean populations by combining these ethnic groups in analyses 185, 196-198. 
Some limited their sample to those with diagnosis of schizophrenia 69, 197; such designs bias 
samples towards those with poorer outcomes 49. Ultimately, previous research has not 
provided us with a comprehensive picture of the true course of psychotic disorders after the 
first onset across ethnic groups resident in the UK.  
1.12.3. Length of follow up 
Among the identified studies that I presented in Table 1 and 3, the duration of follow up 
varied from study to study. Some studies focused on 1-2 years 35, 54, 200, others on 3-5 years 
55, 76, 159, 162, 201-203, 10-15 years 46, 48, 50-53, 57, 161, 177, 204, 205, others up to 20 years 44, 45, 185 or 40 
years 42. Ultra-long-term studies are more likely to be limited by high levels of  drop-outs that 
may occur not completely  at random 49 leading to attrition bias. Indeed, some have argued 
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that the first 3-5 years after first onset of illness constitute a critical period in determining 
long-term outcomes 202 56 beyond of which the level of sustained disability endures into the 
long term 206. Therefore, in this thesis I will focus on the first 4-5 years of the illness after first 
contact with metal health services for psychosis.  
1.12.4. Dearth in understanding the risks for TR 
At present it is not possible to predict those who will or will not respond to first line of 
antipsychotic treatments. Early identification of patients who require clozapine has the 
potential to improve clinical outcomes and minimise the social and functional disability that 
results from prolonged psychotic illness 207-209. Although a few potential risk factors for TR, 
such as poor premorbid functioning, longer DUP, increased negative symptoms and a 
younger age of illness onset, have been suggested 191, 210-212, the predictive value of specific 
clinical and demographic factors on TR has not yet been widely investigated 213. While there 
is a large literature investigating predictors of treatment response and remission from illness 
onset 191, TR has not been examined longitudinally as an outcome measure in FEP. 
Additionally, there is a considerable dearth of information on whether those patients who 
subsequently developed TR were resistant from the start of the illness or gradually 
progressed to it. Knowing the exact rates of early resistance or late resistance of those with 
TR may be an important finding with important implications in relation to the delay in 
clozapine use which exists in clinical practice 214, and aetiology of such complex 
phenomenon as treatment resistance. 
1.12.5. Prediction of time to remission  
Remission is one of the best indicators of treatment efficacy and response 156. However, 
predicting who will remit still remains challenging. In examining the potential predictors of 
remission, earlier studies tended to focus either on rates or odds of remission occurring 215, 
216, and as such they are limited in their ability to tell us how long it would take for the 
patients to achieve clinically-viable remission after first contact with mental health services. 
Knowing which groups of patients will take longer to regain their pre-morbid functioning 
could direct clinicians to seek more effective treatment strategies from the start. Previously, it 
has been shown that time to remission was influenced by age of illness onset and duration 
of untreated psychosis 217. However, the influence of symptom dimensions expressed at 
baseline on time to first remission has not yet been investigated. Although it has been 
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argued that combining the traditional operationalised diagnostic categories with the 
psychosis dimensions will lead to a number of benefits no studies to-date have tested 
whether combining symptom dimensions with categorical diagnoses led to a more robust 
model for predicating time to first remission. 
1.13. Conclusion  
The wide variability in treatment response, clinical and social outcomes in patients with FEP 
can be understood by viewing psychotic disorders as a heterogeneous collection of illnesses 
with diverse clinical presentations and response to pharmacotherapeutic interventions. 
However, our current understanding of the outcomes in FEP is limited, especially when it 
comes to patients of Black ethnicity, which may at least partially be related to methodological 
heterogeneity, lack of consistency in inclusion criteria or length of follow-up, definitions of 
outcome and a paucity of epidemiologically robust studies of FEP cohorts. Therefore, 
detailed and hypotheses-driven research is required to establish the basis for improving our 
understating of the longitudinal trajectory of psychotic disorders.  
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AIMS AND HYPOTHESES  
1.14. The aims of the thesis are: 
1.1. To identify the proportion of patients with FEP who had first presented to the ‘at risk’ 
services with the ARMS and who, by definition, subsequently transitioned to first episode 
psychosis.  
1.2. To investigate whether there were significant differences in pathways to care, clinical 
presentations and social circumstances between FEP patients with and without prior 
contact with the ARMS services at the time of first contact with mental health services for 
psychosis.  
1.3. To investigate whether pathways to care, clinical presentations and social 
circumstances significantly differed between two groups of patients with FEP, those who 
did not have prior contact with the ARMS services and those patients who were already 
experiencing a full psychotic episode at the time of first contact with the prodromal 
services.  
2.1. To identify to what extent the psychosis symptom dimensions in FEP patients 
influence the time to first remission after first contact with mental health services with 
psychosis.  
2.2. To investigate whether combining symptom dimensions with categorical diagnoses 
rather than using these predictors separately would lead to a more robust model for 
predicating time to first remission during the first four years after first contact with mental 
health services for FEP. 
3. To establish whether the clinical outcomes and service utilisation differed in Black 
African and Black Caribbean ethnic groups compared to White British patients during 
first five years after first contact with mental health services. 
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4.1. To identify baseline clinical risk factors predictive of treatment resistance (TR) during 
the first five years of illness in first-episode schizophrenia spectrum patients. 
4.2. To identify a proportion of TR patients who showed “early-resistance” (E-TR) and 
those with “late-resistance” (L-TR). 
4.3. To investigate the differences in socio-demographic and clinical presentations 
between patients subgroups with E-TR and without treatment resistance (non-TR), and 
those with L-TR and those who were non-TR.  
4.4. To compare sociodemographic and clinical characteristics at the time of first contact 
with mental health services between the TR patients treated with clozapine and those 
FEP patients who met the criteria for the TR but had not received clozapine.  
1.15. The hypotheses of the thesis are:  
1.1. The prodromal services in South-East London established close links with primary 
care providers and non-health related community services, such as schools, counsellors, 
and emergency and criminal justice agencies, thus creating an accessible and 
acceptable service for help-seeking young people who are at risk of psychosis 28, 38, I 
therefore hypothesise that the proportion of FEP patients who had prior contact with the 
prodromal services before subsequently transitioning to first episode psychosis will be 
high.  
1.2. Because the prodromal services in South-East London are dedicated to reducing the 
length of DUP by detecting the ‘high-risk’ of transition individuals28, 34, 35 I hypothesise 
that at the time of first contact with early intervention services for first episode psychosis, 
DUP will be significantly shorter in those patients who had first presented to the ‘at risk’ 
services with the ARMS and who subsequently transitioned to first episode psychosis 
compared to the FEP patients who did not have a prior contact with the ARMS team. 
1.3. Because of the close links between the prodromal services in South-East London 
and primary care providers I hypothesise that a greater proportion of patients with FEP 
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who had first presented with the prodromal services with the ARMS before making the 
transition to first episode psychosis will be referred to the standard services for FEP by 
health professionals rather than via emergency and forensic teams 
2.1. There is a growing consensus that psychosis symptom dimensions may be more 
useful in providing information about need for care and prognosis218-220; therefore, I 
hypothesise that psychosis symptom dimensions in patients with FEP as measured at 
the time of study entry will predict speed of remission during the early course of illness 
2.2. Similarly to 2.1., because psychosis symptom dimensions may be more accurate in 
providing information about need for care and prognosis compared to the traditional 
diagnostic categories 218-220; I hypothesise that psychosis symptom dimensions 
measured at baseline will provide a more accurate prediction of time to first remission 
than traditional diagnostic categories during the follow up period.  
2.3. As it has been shown that combining dimensional measures with categorical 
diagnoses is more informative than considering them separately 218 my hypothesis is that 
combining dimensional with traditional diagnostic approaches in predicting time to first 
remission will provide more robust and sensitive predictors of time to first remission than 
using these predictors separately during the follow up period than either used separately.  
3. There is some evidence in the literature that individuals of Black ethnicity are more 
likely to make contact with mental health services via admissions under Mental Health 
Act (MHA) legislation62 , in many cases with police present on an admission 69, 194, or 
admission to high-security psychiatric hospitals 195 , compared to White British patients. 
However, attempts have been in recent years to address these issues. Therefore, I 
hypothesise that the clinical course and pattern of care in patients of Black ethnicity 
would not be different from patients of White British ethnicity during the first five years 
after first contact with mental health services for psychosis. 
4. In the current literature, a few potential risk factors such as poor premorbid 
functioning, longer DUP, greater severity of negative symptoms, and a younger age of 
illness onset, have been suggested as important contributing factors for onset of for 
treatment resistance 191, 210-212. Therefore, my hypothesis is that baseline clinical and 
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social risk factors including type and severity of symptoms, gender, age at illness onset, 
ethnicity, DUP will be important predictors of treatment resistance defined at the end of 
the first five years of illness in first-episode schizophrenia spectrum patients. 
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CHAPTER 2 METHODOLOGY 
2.1. Introduction 
The data presented in this thesis is drawn from two independent studies of first episode 
psychosis: 1) EUropean network of national schizophrenia networks studying Gene-
Environment Interaction (EU-GEI) study which was initiated as part of the National Institute 
of Health Research (NIHR); and 2) Genetics and Psychosis (GAP) study which was, 
similarly to the EU-GEI study, part of the NIHR Biomedical Research Centre (BRC) 
conducted in South London, UK. In this chapter I will provide a detailed description of each 
of these two studies beginning with the data collection and assessments and finishing with 
an outline of my personal contributions to both studies. In the first part of this chapter 
(section 2.2) I focus on the EU-GEI study. I have utilised the data collected as part of the 
EU-GEI study in the Study 1 (Chapter 3, page 81-92). All subsections related to 2.3 section 
are dedicated to the GAP study.  
2.2. Overview of the EU-GEI study 
2.2.1. Study design. I compared sociodemographic clinical characteristics including DUP and 
pathways to care in patients attending the Outreach and Support in South London Service 
(OASIS), a specialised community mental health service for people with the ARMS for 
psychosis 28, 37 (i.e., PROD group) with FEP patients without a prior contact with the OASIS 
service before their first contact with mental health services for FEP (i.e., FEP-C group). I 
additionally derived a third group which included patients who were found to be already 
experiencing their FEP at the time of first contact with the OASIS (i.e., FEP-P group).  
2.2.2. Sample. The total sample comprised of n=338 patients with FEP. Participants aged up 
18 to 65 were recruited as part of the NIHR EU-GEI study and who presented to mental 
health services in the South London and Maudsley National Health Service (NHS) 
Foundation Mental Health Trust between 1 May 2010 to 1 May 2012 with a FEP 
(International Classification of Diseases [ICD-10] codes F20-F29 and F30-F33) (World 
Health Organisation [WHO], 1992). However, in my analyses I only included patients aged 
up to 35 years plus 2 years allowing them to develop FEP as only they had had the 
opportunity to attend the ARMS centre. The patients were included in the study if they were 
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current residents of Lambeth (population 303,086) or Southwark (population 288,238) 
boroughs served by the Trust. Exclusion criteria were: 1) evidence of psychotic symptoms 
precipitated by an organic cause; 2) transient psychotic symptoms resulting from acute 
intoxication as defined by ICD-10; 3) head injury causing clinically significant loss of 
consciousness; and 4) learning disability (IQ<70).  
2.2.3. Data sources. The patients were identified from electronic records obtained from the 
South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM 
BRC) Case Register Interactive Search (CRIS) system 221 222. Using specific search terms, 
the CRIS system allows researchers to search the SLaM Patient Journey System which is a 
comprehensive record of all clinical information recorded throughout patients' journeys 
through the Trust services. It includes information on demographic characteristics and 
clinical presentation on first contact and onwards, dates and other details of referrals, 
detailed clinical assessments, care plans and medication, clinical activity and reviews221, 222. 
The CRIS application was developed in 2007–2008 and consists of a series of data-
processing pipelines which both structure and condense effectively anonymised data from 
the full available clinical records 222. Using the CRIS system, I and members of the team who 
worked on identification of first episode psychosis patients as part of the EUGEI study under 
supervision of Prof Craig Morgan identified all patients who came in contact with SLaM for 
FEP over 2 year period (i.e., 2010-2012). We applied search terms such as “hallucinations”, 
“psychotic”, “delusions”, “voices”, “delusions”, etc. We read through the notes for all records 
that these search terms extracted on one-to-one basis in order to ensure that all patients 
included in the study met the inclusion criteria for FEP. Where there was ambiguity about the 
FEP status of a patient, a consensus decision was made; this always included those with 
long-standing expertise in the study of first episode psychosis (C.M.).  
Once a cohort of FEP patients has been identified, I then proceeded to extract information 
on their socio-demographic characteristics, clinical presentation and pathways to care on the 
first presentation to mental health services from electronic records using the BRC CRIS 
system 221. I further utilised the BRC-CRIS to identify those patients from my cohort of FEP 
cases who were referred to the Outreach and Support in South London Service (OASIS), a 
specialised community mental health service for people aged 14-35 years old with the 
ARMS for psychosis 28, 37 services and who, having met criteria for the ARMS, were 
accepted for treatment prior to making the transition to FEP. CRIS was approved as a data 
resource for secondary analysis by the Oxfordshire Research Ethics Committee (reference 
08/H0606/71). 
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2.2.4. Assessments 
An exact copy of the measure that I used to collect information on all the variables listed in 
this section is presented in Appendices (page 187). 
2.2.4.1. Socio-demographic characteristics. The Medical Research Council (MRC) Socio-
demographic Schedule (modified version) was utilised to collect data on socio-demographic 
characteristics and cannabis use 223.  
2.2.4.2. Ethnicity. Ethnicity was self-ascribed as was recorded in the clinical notes by the 
treating clinicians and was further classified using the 16 categories employed by the 2011 
UK Census (http://www.ons.gov.uk/ons/guide-method/census/census-2011/index.html). In 
the present study I combined these into three broad ethnic groups: White (all white groups), 
Black (all black groups), and Other (encompassing Asian, mixed and other ethnicities).  
2.2.4.3. Duration of untreated psychosis (DUP) was defined as the difference between the 
date of an appearance of first symptoms of psychosis, such as positive symptoms and date 
of a start of first treatment with antipsychotic medications 224. Age at first contact was defined 
as the age at which a patient was in contact with mental health services for the first time due 
to their psychotic symptoms 198.  
2.2.4.4. Mode of onset. Similarly to previous studies 225, 226, mode of onset of psychotic 
symptoms was operationalised using definitions developed in the World Health Organisation 
International Pilot Study of Schizophrenia, and was categorised into three main groups: 1) 
acute (psychotic symptoms appeared within hours, 1 week or 1 month of first noticeable 
behavioural change); 2) gradual (psychotic symptoms appeared within period of 1 to 6 
months of first noticeable behavioural change); and 3) insidious (psychotic symptoms 
appeared incrementally over a period of 6 months or greater since first noticeable 
behavioural change). 
2.2.4.5. Pathways to Care. In the present study, four most commonly used pathways were 
examined: 1) general practitioner (GP); 2) emergency medical services (primarily accident 
and emergency departments, walk-in centres); 3) criminal justice agencies (police, prison or 
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probation services and courts); and 4) health workers (social support workers, nurses or 
other mental health workers). 
2.2.5. Analyses 
The distributions of socio-demographic characteristics, clinical presentation and pathways to 
care were explored with frequencies, percentages, mean and standard deviation, median, 
range and IQR. The comparisons between the groups were made using x2 test and Fisher’s 
exact test for categorical data and t-test for continuous data. DUP was heavily skewed and 
was consequently log-transformed to allow parametric analyses. DUP for each group of 
patients is presented in the original scale, while the analyses were conducted using the 
logarithmic-transformed values.  
2.3. Overview of the GAP study  
The research participants used were recruited as part of the GAP study the aim of which 
was to explore the genetic and environmental basis of liability to psychosis. Patients with first 
episode of psychosis (FEP) and healthy participants were recruited from the boroughs 
covered by the SLaM NHS Foundation Mental Health Trust which encompassed: Croydon 
(population 342,800), Lambeth (population 303,086), and Southwark (population 288,238) 
(UK government national statistic; 
http://data.london.gov.uk/datastorefiles/visualisations/atlas/fol10-pop&mig-2010/atlas.html).  
2.3.1. Ethical approval and consent procedure 
The GAP study was granted ethical approval by the South London and Maudsley and 
Institute of Psychiatry Local Research Ethics Committee (Ethics reference number: 
05/Q0706/158). All participants were presented with a study description and consent form 
which contained the following information: 1) consent for the acquisition of whole blood for 
extraction of DNA, RNA, serum and development of cell lines for molecular and biochemical 
studies; 2) for accessing the clinical records; and 3) consent for further contact. It was 
emphasised that there would be no penalties if the participants decided to withdraw from the 
study at any point. If the participants were happy to participate, they were asked to sign the 
informed consent.  
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2.3.2. Study design at baseline  
Initially, the GAP study had a case-control (or cross-sectional) study design where potential 
participants were selected on the basis of whether they had or did not have the outcome of 
interest (in this instance, first episode psychosis). This in turn allowed hypotheses 
concerning potential risk factors for the illness to be investigated by comparing the 
prevalence of “exposures” in those with and those without the “outcome” of interest. The 
primary benefit of employing this study design was that it is less expensive and more time 
efficient to employ a large pool of such patients compared to the prospective study designs, 
as it was not necessary to wait for the development of the disorder (outcome). Importantly, a 
case-control study only requires large sample sizes when the prevalence of the exposure to 
the risk factor in the controls is very rare (<20%) or very common (>80%)227. Though, a few 
important limitations that are inherent to this study design are noteworthy such as selection 
bias.  
2.3.3. Recruitment of FEP cases 
A team of trained researchers weekly screened all inpatients units and outpatient mental 
health services within the catchment areas to identify the eligible cases. All patients aged 18-
65 years and who presented to inpatient and outpatient psychiatric services of the Trust 
between December 2005 and October 2010 with FEP, as per International Classification of 
Diseases (ICD)-10 (F20-F29 and F30-F33) 228 criteria and further validated by administration 
of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN), were approached by 
researchers and were invited to take part in the GAP study. Potential cases were excluded if 
they exhibited evidence of 1) psychotic symptoms were most likely to have arisen from an 
organic cause; 2) transient psychotic symptoms which resulted from an acute intoxication as 
defined by ICD-10; 3) head injury experienced at any time in their life prior to recruitment to 
the GAP study causing clinically significant loss of consciousness; and 4) learning disability 
(IQ<70).  
Within the study period, 606 patients with FEP were approached. Of these 606 patients, 145 
(24%) refused to participate resulting in total of n=461 patients with FEP cases recruited. 
The two most common reasons for refusal were lack of interest in the research and the 
length of the baseline assessments 229. Patients who refused to participate were more likely 
to be men (p=0.04) and of Black Caribbean and Black African ethnic origin (p=0·001) than 
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were those who consented 229. If patients with FEP were too unwell to cooperate at the time 
of recruitment, they were re-contacted once following initiation of treatment. The full 
information on socio-demographic characteristics at baseline was available for 449 (97.4% 
of 461) consented cases.  
2.3.4. Assessments at baseline 
2.3.4.1. Socio-demographic characteristics. The Medical Research Council (MRC) Socio-
demographic Schedule modified version223 was utilised to collect data on socio-demographic 
characteristics (age, gender, level of education attainment, employment status, etc.) for FEP 
cases and healthy controls.  
2.3.4.2. Age at first contact was defined as age at which a patient was in contact with mental 
health services due to onset of first psychotic symptoms 198.  
2.3.4.3. Ethnicity. Ethnicity was self-ascribed from the 16 categories employed by the UK 
Census in 2001 (www.statistics.gov.uk/census 2001). For the purposes of the present thesis 
I further subcategorised the sample to four broad ethnic groups 230: 1) White British ethnic 
group which included the subcategories of: White English, White Welsh, White Scottish and 
White Northern Irish; 2) White Other ethnic category included all patients of White ethnicity 
that were not of White British ethnicity; 3) Black African category included all Black 
participants born in sub-Saharan Africa or born in the UK with at least one parent of sub-
Saharan African origin; and 4) Black Caribbean category comprised all Black individuals 
born in the Caribbean or born in the UK with at least one parent of Caribbean origin; and 5) 
“Other” ethnic group encompassed Asian, mixed-ethnicity and other ethnicities. 
2.3.4.4. History of substance use. Information was collected on history of alcohol use 
administering the Alcohol Use Disorders Identification Test (AUDIT) 231. From February 2006 
onwards the collection of a detailed history of cannabis use was implemented by adding to 
the study assessment the Cannabis Experience Questionnaire modified version, CEQmv, 
232. 
The CEQmv included several questions covering the use of stimulants or any other non-
prescribed drugs. For those patients with FEP who were inpatients at the time of recruitment 
a period of 4 weeks prior to the hospital admission was considered as the abstinence period.  
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2.3.4.5. Baseline diagnosis. Diagnoses at baseline were made utilising the Operational 
Criteria Checklists (OPCRIT) 233. The OPCRIT system consists of a 90-item checklist and 
uses computerised diagnostic algorithms based on published criteria to provide a diagnostic 
category for each subject employing a number of classification systems 233.  
2.3.4.6. Psychotic symptoms. The Positive and Negative Syndrome Scale (PANSS 234) was 
completed in face-to-face interviews with the patients to assess psychotic symptoms over 
the week preceding the assessment. The 30 items are each rated on a 7-point scale 
(1=absent, 7=extreme) and grouped into three subscales: positive symptoms (7 items), 
negative symptoms (7 items) and general psychopathology (16 items). A higher score 
indicates more severe psychopathology over the last 7 days prior to the interview. The inter-
rater validity for this measure between the researchers was higher as highlighted above than 
the conventionally accepted thresholds for the adequate inter-rater agreement (r=0.814).  
2.3.4.7. Duration of untreated psychosis (DUP). DUP was determined from the assessment 
interview and mental health records and defined as the difference between the date of the 
appearance of the first positive psychotic symptom (hallucination, delusion or thought 
disorder rated as 4 or higher on the PANSS 234 as per Singh et al.235 and date of initiation of 
first treatment with anti-psychotic medications 226. The standard rule of thumb was employed 
when trying to attain information on dates in the most reliable manner 235; specifically, using 
the actual dates when known, or using the middle of the months (i.e., 15th) when only the 
month was known or the middle of the year (i.e., 1st of July) when a given year was known 
only.  
2.3.4.8. Global Assessment of Functioning (GAF). GAF was used to measure both overall 
symptoms severity and disability associated with the illness severity at study entry 236. The 
GAF measure is a widely used observer-rated instrument to rate clinical and functional 
status on a scale ranging from 1 to 100. The scale is hypothetical indicating either 
hypothetically the sickest individuals (≥1) or the healthiest (≤100). Even though, the scale is 
further subdivided into 10 equal parts and provides defining characteristics for each 10-point 
interval, a rater is required to assign the exact number on the continuum. The GAF was 
rated following face to face interview for patients with psychosis to ascertain the severity of 
their psychotic symptoms and level of social functioning over the last 7 days before the 
baseline interview.  
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2.3.5. Tracing collection at follow up  
Approximately 4-5 years after first contact with mental health services for psychosis, I sought 
to trace all cases who had given their consent for follow up and for their clinical records to be 
accessed for research purposes. The following methods were used in the process of tracing 
the patients:  
2.3.5.1. Electronic psychiatric clinical records (EPCRs) 
For those patients who were still in contact with the local mental health services, or who 
were discharged following completion of a treatment program, the primary source of 
information on outcomes over the course of the follow up period was the electronic 
psychiatric clinical records (EPCRs). The EPCRs are the primary clinical recordkeeping 
system in the South London and Maudsley NHS Foundation Trust. The EPCRs contain a 
detailed mental state assessment, success of the treatments and a structured summary of 
care delivered. Progress notes recorded the on-going care with the dates, times, contacts, 
interventions and progress with the treatments explicitly documented. This enabled me to 
examine all records in a chronological order. Moreover, diagnosis are also entered into the 
record describing: 1) the main condition treated or (being) investigated during the relevant 
episode of healthcare, and 2) where there is no definitive diagnosis, the main symptom, 
abnormal findings or presenting problem (i.e. for the main condition being investigated). 
2.3.5.2. General Practitioner (GP) 
To trace those patients who dropped out from the services prematurely or were discharged 
from psychiatric care, I contacted their last known General Practitioners (GPs) via mail. The 
contact details of the last known GPs were obtained from the EPCRs. The letters sent 
included the following information: 1) details of the study, such as the name of the study, 
ethnic approval number and who to contact if more information/clarification was required; 3) 
the purpose of the contact; and 3) a short questionnaire the primary purpose of which was to 
explore the patients general state of health, whether the patient was still registered with the 
practice, and if so, requesting the GP to provide the patient’s the most recent contact details. 
A reply slip and stamped addressed envelope were enclosed with the written request. A 
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copy of the letter sent to the GPs is included in Appendices (page 193); a copy of the short 
questionnaire that I included in the letter to the GPs is provided on page 180 
2.3.5.3. Office for National Statistics (ONS) 
All deaths and emigrations up to and including those that occurred during the final year of 
follow-up were identified by a case-tracing procedure with the Office for National Statistics 
(ONS) for England and Wales and the General Register Office (GRO) for Scotland. The 
Office for National Statistics (ONS) is the UK is largest independent producer of official 
statistics and is the recognised national statistical institute for the UK. It is responsible for 
collecting and publishing statistics related to the economy, population and society at 
national, regional and local levels. It also conducts the census in England and Wales every 
ten years. The patients’ gender, date of birth, and last known address were used as 
identification variables for this case-tracing procedure.  
2.3.6. Assessments at follow up  
At follow-up, extensive information was collated across three course and outcome domains 
(clinical, social, and service use) from clinical records using the WHO Life Chart Schedule 
(LCS) extended version (WHO, 1992) 53, 237, 238. This measure provides standardised 
retrospective assessments of patients’ experience for the entire period of illness. The illness 
period was operationalised as the period from the first contact with mental health services for 
psychosis to the dates of the last assessment recorded in electronic notes. The LCS has 
been shown to be reliable for long-term follow-up assessment and adaptable across 
cultures74, 238, 239. A copy of the WHO LSC is included in the Appendices (page 196).  
2.3.6.1. Social outcomes at follow-up 
Using the LCS, I collected detailed information on sociodemographic characteristics of the 
patients that may be markers for overall social functioning and integration (i.e. housing, 
employment, relationships, education and social networks) for the entire follow up period as 
well as on last assessment at the end of the follow up period. Similarly, employing the LCS 
instrument I gathered information on substance use during the entire period of follow-up. For 
the latter outcome, patients were divided into those who reported ever having used illicit 
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drugs including cannabis (0); those who reported infrequent use (1); and those who had 
developed substance dependence (2). A similar approach was employed to coding history of 
alcohol consumption during the course of follow-up. 
2.3.6.2. Clinical outcomes 
2.3.6.2.1. Symptomatic Remission. Similarly to earlier work conducted in the same 
geographical region as my thesis 74, 240 and in line with the operational criteria proposed by 
Andreasen et al 154 using information extracted from clinical records I defined remission as 
an absence of overt psychotic symptoms (operationalized as a score of 2 or 3 on Rating 
Scale 2 in the SCAN; 0=absence, 1=symptom occurred, but fleeting, 2=symptom definitely 
present, 3=symptom present more or less continuously) for 6 months or longer. This 
measure of remission was not dependent on absence of non-psychotic symptoms (e.g. 
depressed mood, neurotic manifestations), nor if the patients were receiving a treatment with 
antipsychotic medications during remission.  
2.3.6.2.2. Time to symptomatic remission. Time to remission was defined as the period from 
the date of first contact with mental health services for FEP to the date that the first 6-month 
period of remission started 241. That is the date that overt psychotic symptoms were first 
absent and thereafter did not return for at least 6 months. This definition of time to remission 
is the same as that used in another FEP study from an overlapping geographical region 74. 
2.3.6.2.3. Symptomatic Recovery. To be consistent with early study conducted in the same 
geographical region as this thesis 123 I defined symptomatic recovery as sustained 
symptomatic remission for consecutive 2 or more years. 
2.3.6.2.4. Antipsychotic medication. Using patients’ electronic case notes I extracted 
extensive information on antipsychotic medication use throughout patients’ care at the Trust. 
This included the overall number of antipsychotic medication prescribed, names of individual 
antipsychotic medications, initiation/discontinuation dates and dose for each antipsychotic 
medication, and the primary reason for changing or discontinuing each antipsychotic 
medication. The dose for antipsychotic medications was recorded as a dose that proved to 
be therapeutic to the patients. This process of collecting information on antipsychotic 
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medication use was carried out from the first contact with mental health services for 
psychosis throughout the follow up period. 
2.3.6.2.5. Antipsychotic medication adherence. Using the LCS and based on the notes 
recorded by the treating clinicians, I further assessed the patients’ adherence to 
antipsychotic medications over the course of my follow up. This assessment was made on a 
three point scale ranging from 1 to 3 (1 [0=33%], 2 [33-67], and 3 [67-100%]) indicating the 
proportion of follow up period during which a patient regularly took antipsychotic medications 
as prescribed. These codes do not include non-adherence explicitly due to treatment 
intolerance; for example, if a patient did not take medications because of adverse effects, 
but once better tolerated medications were prescribed the compliance improved to 100% 
and remained so for the rest the follow up period , I coded them as “3 [67-100%]”.  
2.3.6.2.6. Definitions of treatment resistance (TR). Patients were defined as having TR if 1) 
they were treated with clozapine over the course of the five year follow up period; and 2) 
during the follow up period they showed little or no symptomatic improvement to two 
consecutive treatments with antipsychotic medications of adequate dose and duration (at 
least 6 weeks), but were not commenced on clozapine 192. The adequate daily dose of 
antipsychotic medication was defined according to a daily dose of at least 400mg 
chlorpromazine equivalents 242. Patients who met either or both of these two criteria for 
treatment resistance were defined as such. I only included as TR cases those patients, who 
failed to respond, and not those who were intolerant to the prescribed antipsychotic 
medications or those who self-discontinued medication.  
2.3.6.2.7. “Early-resistance” (E-TR) and “Late-resistance” (L-TR). Those who met the criteria 
for TR were divided into two subgroups: 1) “early-resistance” (E-TR) group which included 
FEP patients who met criteria for TR and who did not experience a symptomatic remission 
from the time of the first presentation to mental health services; and 2) “late--resistance” (L-
TR) encompassed FEP patients who had experienced a response to antipsychotics and 
attained symptomatic remission (of at least 6 months duration), but at a later stage failed to 
respond to the ongoing use of non-clozapine antipsychotics, ultimately meeting the criteria 
for TR. 
2.3.6.2.8. The Global Assessment of Functioning (GAF) at the end of follow up. Similarly to 
baseline, the GAF assessing both symptoms and functioning was used to measure the 
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overall illness severity at the end of the 5-year follow-up using the clinical notes. There were 
excellent intra-class correlations when rating GAF symptoms (GAF-S) from clinical records 
(intra-class correlation (ICC)>0.90). Further, GAF-S scores collected from clinical records 
compared to GAF-S scored via face to face interview showed high comparability (ICC=0.81). 
Copies of GAF symptoms and disability scales are presented in Appendices (pages 191 and 
192).  
2.3.6.3. Services utilisation  
Utilising the LCS extended version 53, 74, 237, 238 and excluding the admission made on the first 
contact for psychosis, I collected detailed information on circumstances of re-admissions 
including the use of Mental Health Act (MHA) legislation and the involvement of police at the 
time of, or shortly before, hospital re-admission. Excluding the first hospital admission on first 
contact with mental health services for psychosis, the cumulative number of re-admissions 
was obtained by summing hospital admissions throughout the follow up period. To calculate 
a cumulate stay as an inpatient during the entire follow up period for each patient I extracted 
information on the date of admission and date of discharge. The days spent as an inpatient 
during each hospital admission were subsequently calculated and then summed up them 
together. A cumulative number of outpatients (or community) mental health services 
throughout the entire follow up period was derived in a similar manner as it was conducted 
for the hospital re-admissions. The types of outpatient/community services each patient was 
referred to were categorised into two main groups: 1) “regular” community services meaning 
contact with the services at intervals of less or equal to one months for prescription or 
monitoring medications and general well-being; and 2) “intensive” community services 
encompassing all individual requiring contact with the assertive outreach services and/or 
acute home treatment teams/crisis intervention services.  
2.3.7. Statistical analyses 
All analyses in the present thesis were conducted in STATA release 12 or 14 (STATACorp 
LP, USA). All statistical tests were 2-sided, and a p-value ≤0.05 was considered statistically 
significant. 
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2.3.7.1. Descriptive statistics  
I described the primary outcomes using frequencies, percentages, mean and standard 
deviations or median with interquartile ranges (IQR). Cumulative survival curves were 
constructed by using Kaplan–Meier estimates. 
2.3.7.2. Comparative statistics  
Comparisons between the groups were conducted using x2 tests or Fisher’s exact test for 
categorical variables and t-test (or Mann-Whitney U test) and/or ANOVA (or Kruskal–Wallis 
one-way analysis of variance) for continuous variables; and range and rank test χ2 for the 
count data.  
2.3.7.3. Confirmatory factor analysis (CFA)3 
Using psychotic symptoms as measured by PANSS, I conducted CFA to evaluate the 
statistical fit 243 of the Wallwork/Fortgang’s five factor model of psychosis 26 in patients with 
FEP. This model included the positive (i.e., P1, P3, P5, G9), negative (i.e., N1, N2, N3, N4, 
N6 and G7), disorganised/concrete (i.e., P2, N5, G11), excited (i.e., P4, P7, G8 and G14), 
and depressed (i.e., G2, G3 and G6) factors. These factors were entered as latent variables 
in the CFA and the PANSS items were entered as observed variables. The Goodness-of-Fit 
Index (GFI) statistics were used to determine the adequacy of fit of the model. These 
included the comparative fit index (CFI; values greater than 0.90 indicate good model fit), the 
root mean square error of approximation (RMSEA; values less than 0.06 indicate good 
model fit), and the standardised root mean square residual (SRMR; values less than 0.08 
indicate good model fit) 243. To improve the model fit I further incorporated the correlated 
measurement errors into the model based on significantly correlated residuals as indicated 
by modification indices 15. Following CFA, factor scores for each of the five symptom 
dimensions were calculated for each patient using STATA's ‘predict’ post-estimation 
command. 
                                                          
3
 These statistical methods were reported in the paper: Ajnakina O, Trotta A, Oakley-Hannibal E, Di 
Forti M, Stilo SA, Kolliakou A, et al. (2015). Impact of childhood adversities on specific symptom 
dimensions in first-episode psychosis. Psychological Medicine 46, 317-26 
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2.3.7.4. Association analyses  
In this subsection I provide a concise overview of what association analyses I used to test 
my hypotheses (where appropriate). The association analyses in this thesis were specific to 
each hypothesis and thus the rational and method of selecting the appropriate association 
analyses varied from study to study. Therefore, I have provided the detailed description of 
these analyses under methods section in each study.  
 To investigate the impact of psychosis symptom dimensions and baseline diagnostic 
categories on the time to first remission, I utilised an accelerated failure time model for 
right censored data (Chapter 3, Study 2). 
 To examine associations between the outcomes and ethnic groups, for count data I 
applied Poisson regression or Negative binomial regression, depending on the 
distribution of the outcomes (Chapter 4, Study 3).  
 I utilised the Cox proportional-hazards regression to model the binary outcomes 
(Chapter 4, Study 3). 
 I employed Penalised logistic regression to analyse the relationship between the 
baseline predictors for treatment resistance status established by the end of the 5-year 
follow up period (Chapter 6, Study 4).  
2.4. Statement of contribution to the investigations 
This is to confirm that the work presented in the thesis is my own carried out under the 
supervision of Prof Anthony David (Chapter 3, Study 1) and Prof Sir Robin M Murray 
(Chapters 1-8). As part of the Study 1, my main contributions to the EU-GEI study is data 
collection on socio-demographic and clinical characteristics, and pathways to care from the 
CRIS system for n=551 patients using the MRC Socio-demographic Schedule (modified 
version). Although I collected information for n=551 patients, in the Study 1 I report data for 
n=338 patients only.  
As part of Studies 2, 3 and 4, my main contributions to the GAP study involve collecting the 
extensive information on three domains-clinical, social and service uses using electronic 
case notes for n=367 (82% of n=449 original GAP sample) patients over the first five years 
after first contact with mental health services for psychosis. I further established the 
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whereabouts, deaths and emigration status, either through the electric patient notes, 
contacting their general practitioners or the ONS for England and Wales and the GRO for 
Scotland, for 89.7% of the original GAP study at the end of the 5-year follow up. Exceptions 
include: all the baseline data such as PANSS score and socio-demographic characteristics 
that I used in studies 2, 3 and 4 were collected by GAP researchers at the time of the start of 
the GAP study. I have created and organised all variables corresponding to the EU-GEI and 
GAP studies using SPSS v 22 and STATA v12/14. In terms of statistical analyses, I was 
responsible for researching the most appropriate and robust statistical methods to test my 
hypotheses that I reported in this thesis.  
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CHAPTER 3 STUDY 1 
First-Episode Psychosis in South London: looking back at use of prodromal services 
3.1. Introduction 
In this study I set out to identify the proportion of patients with a FEP who had first presented 
to the ‘at risk’ services with the ARMS and who, by definition, subsequently transitioned to 
FEP (i.e., PROD group), and characterise this group in terms of their clinical and socio-
demographic characteristics. Moreover, I sought to test whether there were significant 
differences in clinical presentation, socio-demographic characteristics and pathways to care 
between the PROD and FEP-C groups (the latter group encompassed all those patients 
without prior contact with the prodromal service before their first contact with the early 
intervention services for FEP). I hypothesised that the interval between the first onset of 
psychosis symptoms and initiation of treatment will be shorter in the PROD group compared 
to FEP-C group. To answer the additional question of whether those referred to the ARMS 
services who were already experiencing a FEP at the time of the first contact (i.e., FEP-P 
group) 28, 244 were different from the standard first episode populations (perhaps because of 
factors related to help-seeking behaviours), I further compared the clinical presentation, 
socio-demographic characteristics and pathways to care between FEP-P and FEP-C groups.  
3.2. Methods 
The participants aged ≤37 years old used in this study were recruited as part of the EU-GEI 
study. I compared sociodemographic characteristics, clinical presentation, DUP and 
pathways to care in patients attending the Outreach and Support in South London Service 
(OASIS), a specialised community mental health service for people with the ARMS for 
psychosis 28, 37, (i.e., PROD group) with FEP patients without a prior contact with the OASIS 
services before their first contact with the early intervention services for FEP (FEP-C group). 
I additionally derived a third group of patients who were found to be already experiencing 
their FEP at the time of first contact with the OASIS (i.e., FEP-P group). All patients were 
identified within a tightly defined catchment area catered for by the SLaM Trust. For more 
detailed description of the methods (refer to Chapter 2, section 2.2.2, page 66)  
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3.3. Results  
3.3.1. Sample characteristics 
The information on identification of the groups is illustrated in the Figure 4. Between 2010 
and 2012, there were 338 referrals for first onset psychosis within the Southwark and 
Lambeth boroughs served by the Trust. Of these, 283 (83.7%) were referred to conventional 
mental health services for FEP without prior contact with the prodromal clinic (i.e., FEP-C 
group). The remaining n=55 (16.3% of n=338) FEP patients had been in contact with the 
prodromal clinic before making the transition to FEP. Of these, n=14 (25.5% of n=55 and 
4.1% of n=338 FEP cases) were true ARMS patients and who subsequently transitioned to 
FEP (i.e., PROD group) and n=41 (74.5% of n=55 and 12.1% of n=338) were already 
psychotic at the time of their contact with the ARMS team (i.e., FEP-P group). 
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Figure 4. Information on identification of the FEP-C, FEP-P and PROD groups  
 
FEP-C group, first episode psychosis patients without a prior contact with prodromal teams; FEP-P group, 
patients who were already in a first episode psychosis upon referral to the prodromal services; PROD, first 
episode psychosis patients with (prior contact with the prodomal services  
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3.3.2. Socio-demographic characteristics: FEP-C vs PROD groups 
Comparisons in socio-demographic characteristics between the FEP-C and PROD groups at 
the time of first contact with mental health services are presented in Table 4. At the time of 
first contact, the FEP-C group was older (meanyears=27.9, s.d.=5.5) than the PROD group 
(meanyears =24.2, s.d.=6.0) (t=2.46, df=295, P=0.01). A higher proportion of the PROD group 
(83.3%) was born in the UK compared to the FEP-C group (47% of n=234) (x2=6.14, df=1, 
P=0.01). There were no other statistically significant differences between these groups.  
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Table 4. Comparisons in socio-demographic characteristics between first episode psychosis 
patients with (i.e., PROD group) and without (i.e., FEP-C group) prior contact with the 












      
Age years  27.9 (5.5) 24.2 (6.0) 2.46 295 0.01 
      
Gender      
 Female 124 (43.8) 5 (35.7) 0.36 1 0.60 
 Male 159 (56.2) 9 (64.3)    
       
Ethnicity      
 White  98 (35.1) 7 (53.8) 2.65 2 0.29 
 Black  126 (45.2) 3 (23.1)    
 Other 55 (19.7) 3 (23.1)    
       
Country of birth      
 UK 124 (46.8) 10 (83.3) 6.14 1 0.01 
 Not in the UK 141 (53.2) 2 (16.7)    
      
Education      
 School 111 (55.2) 8 (72.7) 1.30 1 0.35 
 A-Level, or above 90 (44.8) 3 (27.3)    
       
Employment status      
 Unemployed 172 (64.7) 7 (50.0) 1.24 1 0.27 
 Employed 94 (35.3) 7 (50.0)    
       
Marital status      
 Not in stable relationship 207 (75.3) 7 (53.9) 2.98 1 0.10 
 Married/stable relationship 68 (24.7) 6 (46.1)    
       
Living arrangements      
 Alone 74 (27.0) 1 (7.1) 4.08 2 0.15 
 Partner/family 125 (45.6) 10 (71.4)    
 No stable accommodation 75 (27.4) 3 (21.4)    
       
Cannabis use      
 No 118 (50.2) 4 (30.8) 1.86 1 0.26 
 Yes 117 (49.8) 9 (69.2)    
FEP-C-patients who present to conventional FEP services; PROD–prodromal patients who presented to 
prodromal services; IQR, 25th and 75th Percentiles range; s.d, standard deviation; df, degree of freedom 
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3.3.3. Clinical presentation and pathways to care: FEP-C vs PROD groups 
Comparisons in clinical presentation and pathways to care between the FEP-C and PROD 
groups at the time of first contact with mental health services are presented in Table 5. DUP 
was highly skewed; the median length of DUP in the PROD group was 19 days (IQR=6-40); 
whereas for the FEP-C group the median of DUP was 86 days (IQR=13-368). Although this 
looks different, it was not significantly different (analysis after log transformation), 
presumably because of small numbers in the PROD group. Seventy three percent of the 
PROD group (n=8/11) and 36% of the FEP-C group had an insidious mode onset of first 
psychotic symptoms (x2=6.67, df=2, p=0.05). The pathways to care for FEP were 
significantly different between the groups (x2=8.72, df=3, p=0.02): 45% (n=124/274) of the 
FEP-C group made their first contact with mental health services via emergency services 
and 18% of this group were referred by criminal justice system. In contrast, around 77% of 
the PROD group were referred to the prodromal clinic by either GP or other health 
professionals.  
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Table 5. Comparisons in clinical presentation characteristics, and pathways to care between 
first episode psychosis patients with (i.e., PROD group) and without (i.e., FEP-C group) prior 
contact with the prodomal services in South London 











DUP days  86 (13-368) 19 (6-40) 1.35 219 0.18 
      
Source of referral      
 General Practitioner 67 (24.5) 6 (46.2) 8.72
a
 3 0.02 
 Emergency services 124 (45.3) 2 (15.4)    
 Health & social worker 34 (12.4) 4 (30.8)    
 Criminal justice agency 49 (17.9) 1 (7.7)    
       
Mode of onset      
 Acute 121 (43.7) 2 (27.3) 6.67 2 0.05 
 Gradual 56 (20.2) -    
 Insidious  100 (36.1) 8 (72.7)    
FEP-C-patients who present to conventional FEP services; PROD–prodromal patients who presented to 
prodromal services; DUP, duration of untreated psychosis; GP, general practitioner; IQR, 25th and 75th 
Percentiles range; s.d, standard deviation; df, degree of freedom 
a
 The analyses were conducted using the logarithmic-transformed values 
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3.3.4. Socio-demographic characteristics, DUP and pathways to care: FEP-C vs FEP-P 
groups 
Comparisons in socio-demographic and clinical characteristics and pathways to care 
between the FEP-C and FEP-P groups at the time of first contact with mental health services 
are presented in Table 6. At the time of first contact the ARMS team, n=41 (74.5% n=55 
FEP patients who had a prior contact the ARMS services) were already experiencing a full 
psychotic episode (i.e., FEP-P). The FEP-P group was younger (meanyears=24.7, s.d.=4.4) 
than the FEP-C group (meanyear=27.9, s.d.=5.4) (t=3.56, df=322, p<0.001). A higher 
proportion of the FEP-P group lived with members of their family or partners (63% of n=41) 
compared to the FEP-C group (46% of n=274) (x2=6.77, df=2, p=0.03). Further, the 
pathways to care differed between the groups (x2=9.94, df=3, p=0.02); 46% of the FEP-P 
group were referred to mental health services by their local GPs, while 45% of the FEP-C 
group was referred by emergency services; 17.9% of the FEP-C group, compared to 7.7% of 
the FEP-P group, came in contact with mental health services via criminal justice agency 
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Table 6. Comparisons in socio-demographic characteristics, clinical presentation and 
pathways to care between first episode psychosis patients without prior contact the 
prodromal teams (i.e., FEP-C group) and those who were already in a first episode 
psychosis upon referral to the prodromal services (i.e., FEP-P group) in South London 
Presentation at first contact with 










      
Age 27.9 (5.4) 24.7 (4.4) 3.56 322 <0.001 
      
Gender      




159 (56.2) 24 (59.5)    
Ethnicity      
 White 98 (35.1) 15 (36.6) 0.16 2 0.92 




55 (19.7) 7 (17.1)    
Country of birth      
 UK 124 (46.8) 23 (62.2) 3.01 1 0.08 
 
Not in the UK 
 
141 (53.2) 14 (37.8)    
Education      
 School 111 (55.2) 13 (39.4) 2.85 1 0.09 
 
A-Level or above 
 
90 (44.8) 20 (60.6)    
Employment status      
 Unemployed 172 (64.7) 26 (63.4) 0.02 1 0.88 
 Employed 94 (35.3) 15 (36.6)    
       
Marital status      
 Not in stable relationship 205 (75.1) 32 (80.0) 0.46 1 0.56 
 Married/stable relationship 68 (24.9) 8 (20.0)    
       
Living arrangements      
 Alone 74 (27.0) 11 (26.8) 6.77 2 0.03 
 Partner/family 125 (45.6) 26 (63.4)    
 No stable accommodation 75 (27.4) 4 (9.8)    
       
Cannabis use      
 No 118 (50.2) 19 (51.3) 0.02 1 0.90 
 Yes 117 (49.8) 18 (48.7)    
       
DUP days  Median(IQR) 86 (13-368) 104.5 (52-387) -0.77
a
 253 0.44 
      
Source of referral      
 GP 67 (24.5) 18 (46.2) 9.94 3 0.02 
 Emergency services 124  (45.3) 12 (30.8)    
 Health & social worker 34 (12.4) 6 (15.4)    
 Criminal justice agency 49 (17.9) 3 (7.7)    
       
Mode of onset      
 Acute 121 (43.7) 15 (36.6) 1.83 2 0.40 
 Gradual 56 (20.2) 12 (29.3)    
 Insidious 100 (36.1) 14 (34.1)    
FEP-C, who present to conventional FEP services; FEP-P, FEP referrals with prior contact with prodromal 
services; DUP, duration of untreated psychosis; GP, general practitioner; IQR, 25th and 75th Percentiles range; 
s.d, standard deviation; df, degree of freedom; 
a
 The analyses were conducted using the logarithmic-transformed 
values 
 
90 | P a g e  
 
3.4. Discussion 
In this study I showed that 4.1% of patients presenting to mental health services with FEP 
had previously presented to the ARMS services during the prodromal phase of psychosis 
and subsequently transitioned to a full-blown psychotic disorder. Although the ARMS 
services are well-known locally, it may be that recognising pre-psychotic cases is much more 
difficult than might be assumed 245. It is also feasible that a larger proportion of FEP cases 
have an acute onset without a clear prodrome than is commonly appreciated. The task of 
effectively detecting true at risk cases based on referrals and help-seeking rather than 
epidemiological surveys is clearly challenging especially given the lack of sensitive and 
specific biomarkers indicative of the prodromal phase of psychosis 246, 247. If these figures are 
replicated in other similar settings with similar prodromal services, it will suggest that the 
promise of early detection of those at high risk for transition to a psychotic disorder with the 
aim of large scale primary prevention is still some way off. Even if effective, safe, acceptable 
and economical interventions were readily available we are not yet in a position to apply 
them in a way which could make anything but the smallest impact on the incidence of 
psychosis.  
3.4.1. How could we increase the number of patients coming to ARMS services?  
I found that around 77% of all referrals to the ARMS services were made by health 
professionals such as local GPs and other health workers. Clearly this pathway leaves out 
young individuals developing psychosis who do not seek help 248, 249 or are not registered 
with GPs. Similarly, migrants may be less likely to be registered with GPs and may have less 
trusting attitudes toward mental health professionals 250. Indeed, I found that a greater 
proportion of prodromal patients who came in contact with the ARMS services were born in 
the UK. Further, the likelihood of help-seeking is influenced by the mode of onset of 
psychotic symptoms 251. Previous studies showed that patients in less symptomatic states 
were more likely to seek help from their GPs 251. Considering that 44% of all the FEP cases 
had an acute onset of psychotic symptoms, it is not surprising that many would not have 
sought help via GPs and thus accessed the ARMS services. The age of first contact was 
younger in FEP patients who had first presented to the ARMS services and subsequently 
transitioned to psychotic disorder than in the FEP group without prior contact with prodromal 
services. This shows that the ARMS services are successful in reaching out to younger 
clients; though it also may reflect an artefact of the age limit imposed by the services. 
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Moreover, the DUP was not different between the groups. Nevertheless, it is possible that 
treatment delay could have been even longer for these individuals had it not been for the 
presence of the ARMS services.  
Additionally, I found that around 75% of all referrals to the ARMS services were already 
experiencing their first episode psychosis at the time of the contact with the prodromal team. 
Although this supports the notion that the ARMS services are successful in detecting FEP 
patients who are in turn promptly referred to more appropriate early intervention services, 
the results of the study do not suggest that the ARMS services provide additional functions 
by detecting individuals with FEP who otherwise would not have had access to mental health 
services. 
3.4.2. Methodological considerations  
The results of the present study should be interpreted in light of methodological limitations. 
Although the SLaM BRC Case Register, which was the primary source of information for the 
present study, has a near 100% clinical coverage in its boroughs221, it is still feasible that 
some of the patients might have sought or purchased mental healthcare elsewhere for a 
psychotic disorder and thus would not have been registered in the SLaM BRC Case 
Register, nor included in the present study. It may be argued that extracting information from 
clinical records may not always produce reliable data. For example, for the purposes of 
determining DUP from clinical records, treating clinicians might not always have recorded in 
the notes when psychosis symptoms began and their magnitude. The quality and 
completeness of information recorded in the electronic notes for each case inevitably varied 
and this may have introduced some bias. Finally, the data relating to living circumstances, 
relationship status and employment provide crude proxies for social networks and as such 
they can only hint at the potential role of social contexts and networks in influencing the 
pathway to care. 
3.5. Summary and concluding remarks  
Little is known about patients with a FEP who had first presented to prodromal services with 
ARMS and who subsequently transitioned to psychotic disorder. I investigated the 
differences between FEP patients with and without a prior contact with the ARMS services 
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within a tightly defined catchment area in South London. In this study, employing 338 FEP 
patients aged up to 35 plus 2 years who presented to the mental health services between 
2010 and 2012, I found that a small fraction of individuals (4.1%) who present with FEP to 
the main secondary mental health provider had previously been in contact with the ARMS 
services and made a subsequent transition to a psychotic disorder. Although my results 
were suggestive that the ARMS services in South London have been successful in reducing 
the delays from the first onset of psychotic symptoms to the initiation of appropriate 
treatments, the overall difference between the groups did not reach the accepted level of 
statistical significance. The ARMS services indeed performed a useful service in providing 
an extra pathway for patients who were already psychotic; yet the overall findings indicate 
that such services are unlikely to be in a position to prevent all but a few at-risk individuals 
transitioning to a FEP even if effective preventative treatments were available.  
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CHAPTER 4 STUDY 2 
Symptom dimensions versus DSM-IV diagnostic categories as predictors of time to 
first remission in first-episode psychosis  
4.1. Introduction 
In this study, I compared the utility of psychosis symptom dimensions derived using the 
Wallwork/Fortgang five-factor model 26 with conventional diagnostic categories to predict 
time to remission in a sample of patients with FEP. I hypothesised that the symptom 
dimensions would provide a more accurate prediction of time to first remission compared to 
the diagnostic categories. Building on previous research which highlighted that combining 
dimensional measures with categorical diagnoses is more informative in determining the 
causes of psychosis than considering them separately218, I further tested whether combining 
symptoms dimensions with categorical diagnoses would lead to a more robust model for 
predicating time to first remission. 
4.2. Methods 
4.2.1. Sample  
The original GAP sample comprised n=339 FEP cases; of these Positive and Negative 
Syndrome Scale (PANSS 234) scores were available for n=236 cases (69.6% of the original 
GAP sample). This subsample with PANSS ratings did not differ significantly from the full 
GAP sample in terms of gender, age, ethnicity and baseline diagnosis (Table 7). For the 
purposes of this study the baseline diagnoses were grouped using DSM-IV codes into 
schizophrenia (295), schizophreniform disorder (295.40), and affective psychoses (296, 
296.24, 296.44). Because the diagnosis of schizoaffective disorder does not have a clear 
construct, as it is a mixture of schizophrenia and affective symptoms,252 and a relatively 
small sample of patients had this diagnosis, I combined schizoaffective disorder with the 
other psychoses in the analyses and labelled this group as ‘other psychoses’ (295.70, 297.1, 
298.9). 
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 The self-reported ethnicities were categorised into three broad ethnic groups: White (all 
white groups), Black (all black groups) and Other (mixed and all other ethnic groups).  
4.2.2 Data at follow up 
Approximately 4 years after first contact with mental health services for psychosis, 81% of 
this subsample (n=191/236) was successfully traced. Therefore, the data presented here are 
based on these n=191 cases (56.3% of the 339 original GAP cases).  
For detailed description of definitions of remission and time to remission please refer to 
Chapter 2, sections 2.3.6.2.1 and 2.3.6.2.2., page 75. For the detail description of methods 
used to derive the five symptom dimensions used in this study please refer to Chapter 2, 
section 2.3.7.3., page 78.  
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Table 7. Comparisons of demographic and clinical characteristics between patients with and 








  Mean/n sd/% Mean/n sd/% t/x
2
 df p 
Age at first contact 28.9 9.1 30.6 10.2 1.50 325 0.13 
         
Gender        
 Female  45 38.8 77 35.2 0.43 1 0.29 
 Male  71 61.2 142 64.8    
         
Ethnicity         
 White (all categories) 80 43.5 80 44.2 0.02 1 0.89 
 Black (all categories) 104 56.5 101 55.8    
         
Diagnosis         
 Schizophrenia  59 26.1 26 27.4 0.36 3 0.95 
 Schizophreniform 65 28.8 25 26.3    
 Affective Psychoses 52 23.0 24 25.3    
 Other Psychoses 50 22.1 20 21.0    
df, degrees of freedom. GAP, Genetics and Psychosis study. PANSS, Positive and Negative Syndrome Scale. 
sd, standard deviation. 
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The tracing procedure is outlined in Figure 5. During the first four years of follow-up, of all 
FEP cases included in the original GAP study with PANSS ratings available, n=15 (6.3%) 
emigrated, n=5 (2.1%) had died, and n=9 (3.8%) were excluded as these patient did not 
have information on follow up and their contact details were not available at baseline to 
enable to me trace them either via their GP or ONS/GRO tracing procedures. I was unable 
to trace the remaining 16 (6.8%) patients via electronic records. Ultimately, I successfully 
traced 93.2% of my original sample and the full information at follow-up was available for 
80.9% (n=191/236) of patients. Those who had died or were excluded tended to be 
significantly older; there were no differences in gender, ethnicity or diagnosis at baseline by 
administrative outcome (Table 8). 
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Table 8. Baseline demographic characteristics and diagnosis by administrative outcome 





Abroad Died Excluded Test statistic 
 n % n % n % n % n % n % t/x
2
 df p 
Sample with PANSS ratings 236 100 191 81.9 16 6.8 15 6.3 5 2.1 9 3.8    
                 
Gender                
 Female 80 34.8 68 35.6 5 31.2 5 33.3 2 40.0 - - 1.82 4 0.88 
 Male 150 65.2 123 64.4   10 66.7 3 60.0 3 100    
                 
Age years Mean (s.d.) 28.6 9.0 28.2 8.3 30.9 11.6 26.3 6.8 37.6 17.2 38.3 18.8 2.79 227 0.03 
                 
Ethnicity                
 White (all categories) 81 34.9 66  34.2 7 43.7 4 26.7 3 60.0 1 33.3 4.09 8 0.85 
 Black (all categories) 94 40.5 77 39.9 6 37.5 8 53.3 2 40.0 1 33.3    
 Other 57 24.6 50 25.9 3 18.8 3 20.0 - - 1 33.3    
                 
Diagnosis                
 Schizophrenia 59 26.5 53 28.5 3 18.8 1 6.7 2 50.0 - - 9.09 12 0.62 
 Schizophreniform 65 29.2 52 28.0 5 31.2 6 40.0 1 25.0 1 50.0    
 Affective Psychoses 51 22.9 43 23.1 3 18.7 5 33.3 -  -     
 Other Psychoses 48 21.5 38 20.4 5 21.3 3 20.0 1 25.0 1 50.0    
df, degrees of freedom. PANSS, Positive and Negative Syndrome Scale. SD, standard deviation
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Figure 5. Flow chart documenting how n=191 psychosis patients were traced and 
administrative outcomes four years after first contact with mental health services for a first 
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4.2.3. Data Analyses  
Detailed description of the methods employed to conduct the confirmatory factor analyses 
are provided in the Chapter 2, section 2.3.7.3., page 78.  
4.2.3.1. Survival analyses. To better understand the impact of baseline factors on the time to 
first remission, I utilised an accelerated failure time model (AFT) for right censored data. The 
main differences between the AFT and Cox regression analyses is that while Cox regression 
model assumes that the effect of a covariate is to multiply the hazard by some constant, an 
AFT model assumes that the effect of a covariate is to accelerate or decelerate the life 
course of illness by some constant 253. The best-fitting parametric model was identified by 
comparing the Bayesian Information Criterion (BIC) between the exponential, Weibull, 
lognormal and gamma models, not including confounders. The BIC quantifies the overall 
uncertainty associated with the data and the model parameters with the smaller values being 
indicative of a better model fit. The results of these analyses showed that the model with 
Gamma distribution was the most appropriate for my analyses. 
4.2.3.2. Converting parameter coefficients into weeks to remission. The parameter 
coefficients in the AFT model were converted into differences in weeks in time to remission 
through the equation (eβ x median time of follow-up (i.e., 208.4 weeks)) 254. For continuous 
variables, the beta-coefficient indicates the time difference measured in weeks in time to 
remission associated with a 1-unit increment in the explanatory variable. For categorical 
variables, this value indicates the time difference measured in weeks in time to remission by 
comparing 1 level with the reference level. Positive values denote longer time to remission; 
whereas negative values indicate shorter time to remission 254. 
4.2.3.3. Identifying potential confounding variables. I examined variables collected at 
baseline (i.e., age at first contact with mental health services, relationship and employment 
status, living arrangements, educational attainments, DUP, and illicit substance use) and 
during the follow-up (i.e., medication adherence, relationship and employment status, living 
arrangements and illicit substance use) by conducting univariate analysis with time to 
remission as the dependent variable. The covariates with p-values of <0.20 were considered 
for my multivariate model. I eliminated the variables with the largest p-values individually 
until all the remaining variables had a p-value of <0.05. This procedure highlighted age at 
100 | P a g e  
 
first contact, DUP and illicit substance use during the follow-up period as important 
confounding factors. Although the variable that measured the compliance with antipsychotic 
medications over the course of follow-up did not meet this inclusion criteria for the final 
model, based on the evidence indicating that this was an important confounding factors for 
time to remission 217 I included this additional variable in my final analyses.  
4.2.3.4. Testing model fit. I tested different models, each including either symptom 
dimensions or diagnostic categories, or combination of both, as the main predictors of time 
to first remission after first contact with mental health services for psychosis. Similarly to 
selection of the best distribution of the AFT model, I used the BIC to test the model fit. The 
model with the lowest BIC score fits the data best. To compare models, I calculated ΔBIC 
which was defined as the model minus the model with the lowest BIC score 255. Therefore, 
the best model will have a ΔBIC score of 0. Models >4 units away from the best model 
(ΔBIC>4) are considered to be significantly inferior compared to the best model (i.e., the best 
model will have a BIC=0); whereas the models that have more than 10 units away from the 
best fit model (ΔBIC>10) are considered to have little or no support from the data 
255. 
4.3. Results 
4.3.1. Core analytic sample 
Demographic characteristics for the core analytic sample of n=191 cases and remission of 
psychosis over four-year follow-up are presented in Table 9. An average of four years after 
first contact with mental health services for psychosis (meanyears=4.4, s.d.=1.7; 832 person 
years), I successfully traced n=191 (80.9% of n=236) patients using their electronic notes. 
The mean age at first contact was 28.6 years (s.d.=9.0); nearly two-thirds (64.4%) of the 
sample were men and 46.1% were of White ethnicity. Thirty-eight percent of the sample had 
a diagnosis of schizophrenia and 19% were diagnosed with manic psychosis. Further, 67% 
of my sample was recruited from inpatient services and 96% were on antipsychotic 
medication at the time of study entry.  
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Table 9. Baseline demographic characteristics for n=191 first episode psychosis patients 
with PANSS data and who were successfully followed up over four-year follow-up from first 
presentation to mental health services 




 Mean/n  s.d./% 
   
Age years  28.6  9.0 
    
Gender   
 Female 68  35.6 
 Male  123  64.4 
    
Ethnicity    
 White (all groups) 65  46.1 
 Black (all groups) 46  32.6 
 Other 30  21.3 
    
Diagnosis   
 Schizophrenia  53  28.5 
 Schizophreniform 52  28.0 
 Affective Psychoses 43  23.1 
 Other Psychoses 38  20.4 
    
On antipsychotic medication at study entry  184  96.3 
    
DUP days  35.0  118.6 
    
Years of follow-up 4.4  1.8 
 Median (IQR) 4  3-5 
    
Rate of remission 112  60.2 
    
Time to remission weeks 18.3  26.0 
 Median (IQR)  8  5-20 
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4.3.2. Confirmatory factor analysis 4 
CFA was conducted in the current sample with the Wallwork/Fortgang five-factor model of 
PANSS items 26. When the correlated residuals (i.e., measurement errors) were not 
introduced into the model, the results of CFA indicated a poor model fit: CFI=0.767, 
RMSEA=0.101 (90% CI 0.092-0.111) and SRMR=0.111. However, once significantly 
correlated residuals were incorporated into the model, the CFA produced an excellent fit of 
the model: CFI=0.959, RMSEA=0.052 (90% CI 0.037-0.067) and SRMR=0.071. 
The mean symptom dimension scores at entry to mental health services by diagnostic 
categories are illustrated in Figure 6. Although five symptom dimensions are evident across 
all diagnostic categories, patients with the baseline diagnosis of schizophrenia scored more 
highly on the disorganised/concrete symptom dimension compared to those with manic and 
other psychotic disorders (F=4.63, df=185, p=0.004).  
 
                                                          
4
 These results have been published in Ajnakina O, Trotta A, Oakley-Hannibal E, Di Forti M, Stilo SA, 
Kolliakou A, et al. (2015). Impact of childhood adversities on specific symptom dimensions in first-
episode psychosis. Psychological Medicine. 46, 317-26 
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Figure 6. Five psychosis symptom dimension scores by traditional DSM-IV diagnostic 
categories 
 
Graphs display the mean psychosis symptom dimension scores for first episode psychosis patients with a 
diagnosis of schizophrenia, manic psychosis and other psychoses at first presentation to psychiatric services. 
The continuous symptom dimension scores were derived using the ‘predict’ post-estimation command in Stata 
following a confirmatory factor analysis of the Wallwork/Fortgang five-factor model 
26
 of the items from the 
Positive and Negative Syndrome Scale 
234
. The five dimensions capture positive, negative, 
disorganised/concrete, excited, and depressed symptom items at first presentation to psychiatric services.  
*p<0.05, ** p<0.01, ***p<0.001 
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4.3.3. Time to remission 
The rate of remission during the first four years of illness was 60.2% and the average time to 
the start of the first period of remission was 18.3 weeks (s.d.=26.0; median=8 weeks, 
IQR=5-20 weeks). Those who did not remit (n=74) showed more severe symptoms on the 
disorganised/concrete (t=1.99, df=184, p=0.05) symptom dimension compared to remitters 
at the time of study entry. Otherwise, remitters and non-remitters did not differ in severity of 
other symptom dimensions at baseline. Among n=112 patients who met criteria for 
remission, 18% were continually asymptomatic till the end of follow-up period. For these 
patients, the mean of time to remission was 19 weeks (median=5, IQR=4-20). Moreover, 
26% of all remitters remitted within one month, 13% remitted within 12 weeks and 6.5% 
remitted between 68-144 weeks after first contact with mental health services.  
4.3.4. Associations between time to remission and symptom dimensions vs diagnostic 
categories 
Kaplan–Meier (K-M) survival curves of time to the first remission stratified by diagnostic 
categories are shown in Figure 7. This K-M survival curve illustrates that the average time to 
first remission was within 20 weeks; this is highlighted by the RED arrow in the figure 7. 
However, those patients who received a diagnosis of schizophreniform disorder at baseline 
took the longest time to achieve first remission after the first contact with mental health 
services; this is highlighted by the BLUE arrow in the Figure 7.  
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Figure 7. Kaplan–Meier survival curve of the time from the first presentation to psychiatric 
services for psychosis to the start of the first period of remission, by traditional diagnostic 
categories 
 
The y axis illustrate the proportion of FEP out of the total=1 achieving the first remission after first contact with 
mental health services; the axes indicates when in weeks. For the purposes of this study the baseline diagnoses 
were grouped using DSM-IV codes into schizophrenia (295), schizophreniform disorder (295.40), and affective 
psychoses (296, 296.24, 296.44). Because the diagnosis of schizoaffective disorder does not have a clear 
construct, as it is a mixture of schizophrenia and affective symptoms,
252
 and a relatively small sample of patients 
had this diagnosis, I combined schizoaffective disorder with the other psychoses in the analyses and labelled this 
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Multivariate accelerated failure time (AFT) model estimates of time to first remission are 
provided in Table 10. Over the first four years of follow-up, the positive symptom dimension 
measured at baseline was associated with an average of 14.6 weeks (β=0.07, 95% CI=0.01-
0.13), the excited dimension with an average of 35.4 weeks (β=0.17, 95% CI=0.03-0.41) and 
the disorganised/concrete dimension with an average of 20.8 weeks (β=0.10, 95% CI= 0.01-
0.19) longer to first remission after first contact with psychiatric services. The combination of 
all five symptom dimensions led to a significant association with the time to first remission 
with an average increase of 8.3 weeks to remission (β=0.04, 95% CI=0.01-0.07). The 
baseline diagnosis of schizophrenia was significantly associated with an average of 52 
weeks longer to first remission compared to non-schizophrenia diagnoses (β=0.25, 95% 
CI=0.06-0.43). The combination of the baseline diagnosis of schizophrenia with all five 
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Table 10. Multivariate Accelerated Failure Time model estimating difference in time to the 
start of first remission after first contact with mental health services for psychosis 
Clinical characteristics at first contact  β (SE) 95% CI 
Symptom dimensions     
 Positive  0.07 (0.03)** 0.01-0.13 
 Excited  0.17 (0.07)** 0.03-0.31 
 Negative  0.03 (0.04) -0.06-0.11 
 Disorganised/Concrete  0.10 (0.05)** 0.01-0.19 
 Depressed  -0.02 (0.08) -0.17-0.13 
 All 5 psychosis dimensions  0.04 (0.02)*** 0.01-0.07 
     
Diagnostic categories     
 Schizophrenia   0.25 (0.09)*** 0.06-0.43 
 Schizophreniform disorder  -0.18 (0.10) -0.37-0.01 
 Affective Psychoses  -0.05 (0.08) -0.21-0.12 
 Other Psychoses   -0.03 (0.10) -0.22-0.16 
 All four diagnostic categories   -0.03 (0.02) -0.08-0.02 
     
Combination of both approaches     
 Schizophrenia diagnosis and all 5 psychosis 
dimensions  
 
0.05 (0.01)*** 0.02-0.07 
Effect size is indicated by β coefficient and standard error (SE) from the accelerated failure time survival model. 
CI, confidence interval. All analyses adjusted for age at the time of first contact with mental health services for 
psychosis, duration of untreated psychosis and substance use measured during the four-year follow-up period 
and antipsychotic medication adherence over the course of follow-up. 
*p<0.05, ** p<0.01, ***p<0.001 
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4.3.5. Selecting the best model for predicting time to remission  
The results of the BIC and ΔBIC analyses are presented in Table 11. Compared to all four 
categorical diagnoses (Models 7-10, BIC range from 160.71 to 167.45), using symptom 
dimensions individually as predictors of time to remission did not lead to models with better 
predictive powers (Models 1-5, BIC range from 165.48 to 171.30). Using all four categorical 
diagnoses in combination produced a model (Model 11, BIC=165.83) with an equal 
predictive power to the model that combined all five symptom dimensions (Model 6, 
BIC=163.61) in predicting time to first remission. Further analyses showed that 
supplementing the baseline schizophrenia diagnosis with five symptom dimensions 
generated the best model fit (Model 12, BIC=154.50) for predicting time to first remission. 
The ∆BIC analyses highlighted that none of the five symptom dimensions (∆BIC range from 
10.98 to 16.80), nor the diagnostic categories (∆BIC range from 6.21 to 12.95), produced a 
robust model fit compared to Model 12. 
 
109 | P a g e  
 
Table 11. Comparisons of the fit of all significant models using BIC scores and ΔBIC 
 
Models Predictors of time to first remission BIC ∆BIC 
Symptom dimensions   
 Model 1 Positive dimension 165.48 10.98 
 Model 2 Excited dimension 165.54 11.04 
 Model 3 Negative 170.96 16.46 
 Model 4 Disorganised/Concrete 166.45 11.95 
 Model 5 Depressed 171.30 16.80 
 Model 6 All 5 psychosis dimensions 163.61 9.11 
     
Diagnostic categories   
 Model 7 Schizophrenia 160.71 6.21 
 Model 8 Schizophreniform disorder 162.52 8.02 
 Model 9 Affective Psychoses 167.20 12.70 
 Model 10 Other Psychoses 167.45 12.95 
 Model 11 All four diagnostic categories 165.83 11.33 
     
Combination of both approaches   
 Model 12 Schizophrenia diagnosis and all 5 psychosis 
dimensions 
154.50 0 
BIC, Bayesian Information Criterion; ΔBIC is defined as the model minus the model with the lowest BIC score  
All models adjusted for age at the time of first contact with mental health services for psychosis, duration of 
untreated psychosis and substance use measured during the four-year follow-up period and antipsychotic 
medication adherence over the course of follow-up. 
The model in bold provided the best fit (i.e., the lowest BIC score) 
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4.4. Discussion  
In the present study 60% of 191 patients with FEP achieved remission during the first four 
years after first contact with mental health services for psychosis; 18% of this group were 
continually asymptomatic till the end of follow-up period. A quarter of all remitters had 
remitted within one month and a minority (7%) took up to 33 months to achieve remission; 
however, the majority of the patients remitted within 4 months after first contact with mental 
health services. I found that the positive, excited and disorganised/concrete dimensions of 
psychosis were important predictors of time to first remission in this sample.  
4.4.1. Time to remission and symptom dimensions vs diagnostic categories 
Although a previous study showed that negative symptoms of psychosis measured by 
PANSS at baseline differentiated non-remitters from remitters at the end of a 16-year course 
of illness 256, I did not find evidence to suggest that the negative symptom dimension had an 
impact on time to first remission during the 4-year of follow-up in my sample. This may have 
been due to the shorter time-frame of my study. It is also possible that people with 
predominantly negative symptoms may be less likely to be treated as inpatients and thus 
may have been under-represented in my sample which recruited a large proportion of 
patients from psychiatric wards.  
My results highlight that the positive, excited and disorganised/concrete dimensions of 
psychosis are important predictors of longer time to first remission. The psychosis symptoms 
that constituted these three dimensions in my study all expressed at onset have been shown 
to correlate with a poor therapeutic response to antipsychotic medications 257. It therefore 
could be speculated that patients in the present study with these symptom dimensions at 
presentation may take longer to respond to treatments with antipsychotic medications, 
potentially delaying attainment of remission. Demonstrating that specific symptom 
dimensions are predictive of time to remission in FEP is an important first step in mapping 
these putative markers of response onto illness outcome. My results also showed that a 
diagnosis of schizophrenia was associated with a longer time to first remission. This 
observation is consistent with a characterisation of this disorder as one with lower rates of 
remission and a more disabling course than other psychotic disorders 258, 259.  
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In contrast to my hypothesis, the psychosis symptom dimensions were not superior to the 
traditional diagnostic categories in predicting time to first remission. In fact, I found that the 
combination of the diagnosis of schizophrenia with all five symptom dimensions produced 
the best model in predicting a longer time to remission. As there are no specific markers to 
guide the choice of treatment and to stratify patients with FEP by treatment response 260, I 
provide novel findings that may serve as important prognostic markers indicative of those 
subgroups who will take substantially longer to respond to treatment (as indicated by 
remission status) within the first four years after first contact with psychiatric services. 
4.4.2. Methodological considerations  
The five factor model of psychosis symptoms employed in the present study was selected 
for being a consensus model derived from existing studies 26 that has been shown to be 
optimal for use in FEP samples 27. Similarly, I employed the operationalised definition of 
remission and time to remission that has previously been utilised in an earlier study 
conducted in an overlapping geographical region 74, 240 ensuring comparability of the results 
between the studies. The symptom dimensions were founded on the PANSS which has 
previously been shown to be resilient to the effects of age, severity of symptoms, chronicity 
of illness 261 and short-term medication withdrawal 262.  
The findings of the present study should be interpreted in light of methodological limitations. 
It is important to note that nearly 80% of the patients were recruited to the original GAP 
study from inpatient units; this may imply that very early remitters may not have been fully 
represented from the start. Due to relatively small sample size, I was unable to explore 
associations between the depressive psychotic disorders and time to remission. Finally, 
many diagnostic categories assigned to patients on first contact with mental health services 
may either be provisional or likely to change over the illness course 263, as seen in my 
sample with a relatively high number of patients with a diagnosis of schizophreniform 
disorder. Nevertheless, in the present study I focused on the baseline diagnosis, rather than 
the diagnosis obtained at the end of the follow-up period, to emulate the naturalistic setting 
for all patients with FEP when predicting time to remission depending on the diagnosis 
received on the very first contact with the psychiatric services. 
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4.5. Summary and concluding remarks 
There has been much recent debate concerning the relative clinical utility of symptom 
dimensions versus conventional diagnostic categories in psychosis patients. In this study I 
investigated whether symptom dimensions at presentation for FEP better predicted time to 
remission than diagnostic categories over a four-year follow-up. My sample comprised 191 
FEP patients aged 18-65 years presenting for the first time to psychiatric services in South 
London, UK. Psychopathology was assessed at baseline with the Positive and Negative 
Syndrome Scale and five symptom dimensions were derived using Wallwork/Fortgang’s 
model; baseline diagnoses were grouped using DSM-IV codes. Time to start of first 
remission was ascertained from clinical records. The Bayesian Information Criterion (BIC) 
was used to find the best fitting accelerated failure time model of dimensions, diagnoses and 
time to remission. My results showed that 60% of patients remitted over the four years since 
first presentation to psychiatric services, and the average time to start of first remission was 
18.3 weeks (s.d.=26.0). The positive, excited and disorganised/concrete symptom 
dimensions as well as baseline categorical diagnosis of schizophrenia predicted time to 
remission. However, a combination of the DSM-IV diagnosis of schizophrenia with all five 
symptom dimensions led to the best model for predicting a longer time to first remission. 
These results indicate that the use of a combination of five symptom dimensions and the 
traditional diagnostic category of schizophrenia provides a more robust prediction of the 
length of time that it would take for patients to respond to treatment after the first contact with 
mental health services for FEP.  
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CHAPTER 5 STUDY 3 
Patterns of illness and care over the 5 years following onset of psychosis in Black 
African, Black Caribbean and White British patients  
5.1. Introduction 
Psychiatric epidemiology has consistently demonstrated that the incidence rates of psychotic 
disorders are considerably elevated among those of Black ethnicity residing in the UK 
compared to the host population59-61. The evidence further suggests that individuals of Black 
ethnicity are more likely to make contact with mental health services via admissions under 
Mental Health Act (MHA) legislation62 , in many cases with police present on an admission 69, 
194, or admission to high-security psychiatric hospitals 195 compared to White British patients. 
These findings were echoed in the ÆSOP (Aetiology and Ethnicity in Schizophrenia and 
Other Psychoses) study, which was one of the first studies of people with first onset 
psychosis (FEP) in England 61. There are some indications that this pattern of more 
compulsory care persists over the course of their illness 185, 196, 199.  
Over the past 20 years there has been an increased focus on specialist early intervention 
services for first episode psychosis (FEP) 264, 265 which ignited recognition that individuals 
with psychotic disorders still can experience symptomatic improvements and regain a 
degree of social and occupational functioning 266. The evidence is consistent that one-third of 
patients with psychosis recover 74, 267. Yet, it is still unclear whether this figure applies to 
Black ethnic groups. Reports are mixed in relation to the symptomatic remission in Black 
populations with some reporting that remission is more common in Black ethnic groups 198, 
while others argue an opposite view 199. Importantly, earlier research into longitudinal illness 
trajectory across ethnic groups is marked by methodological limitations, such as small 
sample sizes 196, and a tendency to neglect the diversity in culture, religious beliefs and life 
experience between Black African and Black Caribbean populations by combining these 
ethnic groups in analyses 185, 196-198. Furthermore, some investigators have limited their 
sample to those with diagnosis of schizophrenia only 69, 197; or who had been re-admitted 
during a follow up period, and as such bias results towards poorer outcomes 49.  
114 | P a g e  
 
Cumulatively, previous research has not provided us with a comprehensive picture of the 
true course of psychotic disorders in Black African and Black Caribbean ethnic groups, and 
whether the intensity of care delivered to Black ethnic groups reflects the severity of their 
psychopathology. Therefore, using a quasi-prospective cohort design and utilising the data 
from a large and well-characterised sample of patients with FEP, I sought to investigate 
clinical and social outcomes in Black African and Black Caribbean ethnic groups compared 
with White British patients. I further tested whether the intensity of care delivered to Black 
ethnic groups was reflected in their overall functional disability and illness severity in the due 
illness course after first contact with mental health services for psychosis. My null hypothesis 
was that the clinical course and pattern of care in patients of Black ethnicity would not be 
different from patients of White British ethnicity.  
5.2. Methods 
Detailed description of the methods behind the baseline assessment and follow up as well 
as for tracing the patients over the first five years of illness after he first contact with mental 
health services are provided in Sections 2.3-2.3.6.3., pages 69-77  
5.2.2. Statistical analysis  
5.2.1. Statistical Analyses 
I described primary outcomes using frequencies, percentages, mean and standard 
deviations, median and interquartile ranges (IQR). Between groups comparisons were made 
using x2 tests for categorical variables; ANOVA tests, or Kruskal-Wallis tests, for continuous 
variables; rank x2 tests for count data. All analyses were two-tailed, and a P-value≤0.05 was 
considered statistically significant. All analyses were conducted in STATA release 14 
(STATA Corp LP, USA).  
5.3. Results 
5.3.1. Sample at baseline  
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The baseline sample in this study comprised 297 FEP patients. Of these, 111 (37.4%) were 
of White British, 110 (37.0%) were of Black African and 76 (25.6%) were of Black Caribbean 
ethnicity. At the time of first contact with mental health for psychosis, a higher proportion of 
Black Caribbean patients lived alone (x2=6.98, df=2, p=0.03) and were unemployed 
(x2=7.24, df=2, p=0.03) compared to White British and Black African ethnic groups. There 
were no other differences between the ethnic groups at the time of first contact with mental 
health services for psychosis (Table 12) 
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Table 12. Baseline diagnosis, socio-demographic and clinical characteristics, by ethnicity  
Baseline socio-










Statistics df p-value 
         
Age years , Mean (s.d.) 28.3 (8.8) 29.5 (9.9) 26.8 (7.5) 28.6 (8.6) F=2.51 284 0.08 
         
DUP days , Mean (s.d.) 39.2 (126.3) 41.6 (148.4) 36.8 (103.7) 40.2 (131.8) F=0.02
a
 173 0.98 
         
Gender, n (%)        
 Women 100 (34.6) 34 (31.5) 34 (31.8) 32 (43.2) chi
2
=3.28 2 0.19 
 Men 189 (65.4) 74 (68.5) 73 (68.2) 42 (56.8)    
         
Diagnosis, n (%)        
 Non-affective psychosis 185 (75.2) 63 (71.6) 71 (75.5) 51 (79.7) chi
2
=1.31 2 0.52 
 Affective psychosis 61 (24.8) 25 (28.4) 23 (24.5) 13 (20.3)    
         
Living arrangements, n (%)        
 Alone  69 (39.4) 26 (37.1) 23 (32.4) 20 (58.8) chi
2
=6.98 2 0.03 
 With partner or parents 106 (60.6) 44 (62.9) 48 (67.6) 14 (41.2)    
         
Relationship status, n (%)        
 Single  130 (74.3) 52 (74.3) 52 (73.2) 26 (76.5) chi
2
=0.13 2 0.94 
 Stable relationship  45 (25.7) 18 (25.7) 19 (26.8) 8 (23.5)    
         
Employment, n (%)        
 Unemployed 114 (66.3) 46 (68.7) 40 (56.3) 28 (82.4) chi
2
=7.24 2 0.03 
 Employed 58 (33.7) 21 (31.3) 31 (43.7) 6 (17.6)    
         
GAF symptoms, Mean 
(s.d.) 
46.7 (20.1) 47.1 (21.0) 47.6 (18.9) 43.6 (21.2) F=0.31 119 0.73 
         
GAF disability, Mean (s.d.) 55.1 (18.3) 56.1 (19.9) 57.0 (16.2) 48.1 (18.2) F=1.91 119 0.15 
s.d., standard deviations; DUP, duration of untreated psychosis; d.f., degrees of freedom; GAF, global assessment of functioning 
a the results are presented after log-transformation 
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A flow chart depicting how the cases were traced and administrative outcomes is presented 
in Figure 8. Approximately 5 years (meanyears=5.1, s.d.=2.4; 1,251 person years) after first 
contact with mental health services, a total of 11 (3.7%) patients had died; but information on 
longitudinal outcomes was available for 7 of these, thus these 7 patients were included in all 
analyses. Twelve (4.1%) patients had migrated, and 6 (2.1%) patients moved out from the 
catchment area. Additional 7 (2.4%) patients were excluded as I did not have information on 
follow up and their details were not available at baseline to enable me to trace them via 
ONS/GRO tracing procedures. I was unable to trace the whereabouts for 23 (7.9%) patients. 
Those patients who had died during the follow up period without any information on the 
course of their illness (n=4 (1.4%)) were older (meanyears=44.5, sd=18.4) (F=4.05, df=282, 
p=0.003); and those who emigrated tended to be of Black African ethnicity (x2=18.36, df=8, 
p=0.02) (Table 13). Cumulatively, I successfully traced 92.1% of my original sample and the 
full information at follow up was available for 84.5% (n=245/290) patients. FEP patients who 
were lost to follow-up were not significantly different in the baseline characteristics from 
patients who had full follow up data (Table 14).  
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Figure 8. Flow chart documenting how patients were traced and administrative outcomes 
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Statistics df p-value 
          
Gender, n (%)         
 Female 82 (34.2) 7 (30.4) 7 (58.3) 2 (50.0) 1 (16.7) Ch
2
=4.44 4 0.35 
 Male 158 (65.8) 16 (69.6) 5 (41.7) 2 (50.0) 5 (83.3)    
          
Age at first contact, n (%) 27.9 (8.1) 29.1 (11.7) 26.3 (5.9) 44.5 (18.9) 29.8 (4.7) F=4.05 282 0.003 
          
Ethnicity, n (%)         
 White British 93 (38.0) 9 (39.1) 1 (8.3) 2 (50.0) 3 (50.0) Chi
2
=18.36 8 0.02 
 Black African 84 (34.7) 10 (43.5) 11 (91.7) 1 (25.0) 1 (16.7)    
 Black Caribbean 67 (27.3) 4 (17.4) - 1 (25.0) 2 (33.3)    
          
Living arrangements, n (%)         
 Alone  61 (41.5) 2 (15.4) 3 (37.5) 1 (33.3) 2 (50.0) Chi
2
=3.66 4 0.45 
 With partner or parents 86 (58.5) 11 (84.6) 5 (62.5) 2 (66.7) 2 (50.0)    
          
Relationship status, n (%)         
 Single  107 (72.8) 9 (69.2) 8 (100.0) 2 (66.7) 4 (100.0) Chi
2
=4.59 4 0.33 
 Stable relationship  40 (27.2) 4 (30.8) - 1 (33.3) -    
s.d., standard deviations; d.f., degrees of freedom  
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Table 14. Baseline demographic characteristics for those who were lost to follow up 
compared to individuals with full follow up data   
Baseline sample 
characteristics  




Statistics df p-value 
       
Age years, Mean (s.d.) 30.1 (11.5) 27.9 (8.1) t=-1.46 281 0.15 
       
Gender, n (%)      
 Women 17 (37.8) 82 (34.2) chi
2
=0.22 1 0.64 
 Men 28 (62.2) 158 (65.8)    
       
Ethnicity, n (%)      
 White British 15 (33.3) 93 (38.0) chi
2
=5.04 2 0.08 
 Black African 23 (51.1) 85 (34.7)    
 Black Caribbean 7 (15.6) 67 (27.3)    
       
Living arrangements, n (%)      
 Alone  8 (28.6) 61 (41.5) chi
2
=1.65 1 0.20 
 With partner or parents 20 (71.4) 86 (58.5)    
       
Relationship status, n (%)       
 Single  23 (82.1) 107 (72.8) chi
2
=1.08 1 0.30 
 Stable relationship  5 (17.9) 40 (27.2)    
       
GAF symptoms, Mean (s.d.) 41.5 (17.0) 47.7 (20.6) t=1.24 118 0.22 
       
GAF disability, Mean (s.d.) 54.7 (18.4) 55.1 (18.4) t=0.09 118 0.93 
s.d., standard deviations; d.f., degrees of freedom; GAF, global assessment of functioning 
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5.3.2. Core analytic sample 
My core analytic sample comprised 245 (82.5% of n=297) FEP patients with an average 
follow-up length of 5 years after first contact with mental health services for psychosis. This 
sample encompassed 93 (38.0%) patients of White British, 85 (34.7%) patients of Black 
African and 67 (27.3%) patients of Black Caribbean ethnicity. Patients of Black Caribbean 
ethnicity had the longest length of follow up (meanyears=5.6, sd=2.6) compared to White 
British (meanyears=4.9, sd=2.4) and Black African (meanyears=4.9, sd=2.2) ethnic groups; 
though this difference did not meet the standard level for statistical significance (F=2.12, 
df=243, p=0.12). Sixty six percent (158/240 cases) of the total sample were of male gender 
with Black African patients being particularly likely to be male (x2=5.39, df=2, p=0.07) (Table 
15). 
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Follow up, 
Mean (s.d.) 
5.1 (2.4) 4.9 (2.4) 4.9 (2.2) 5.6 (2.6) F=2.12 243 0.12 
         
Gender, n (%)        
 Women 82 (34.2) 29 (31.5) 23 (28.1) 30 (45.5) x
2
=5.39 2 0.07 
 Men 158 (65.8) 63 (68.5) 59 (71.9) 36 (54.5)    





123 | P a g e  
 
5.3.3. Clinical presentation over the follow up period  
Clinical illness course for the entire follow up period after first contact with mental health 
services for psychosis by ethnicity is presented in Table 16. Over the 5-year follow up 
period, 63.1% (n=149/236) of the overall sample reported remission and 28.4% (n=63/222) 
met criteria for recovery at least once, with a median duration of the baseline episode of 8 
weeks (IQR=6-20). White British, Black African and Black Caribbean ethnic groups did not 
differ in these outcomes. During the follow up period, no ethnic group showed a more rapid 
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Table 16. Clinical outcomes over the first five years after first contact with mental health services for psychosis, by ethnicity 












Duration of baseline episode, w        
 Median (IQR) 8 (6-20) 8 (4-20) 8 (4-16) 8 (8-20) 2.77
a
 2 0.25 
         
Symptomatic remission, ever        
 n (%) 149 (63.1) 53 (60.9) 55 (64.7) 41 (64.1) 0.30
b
 2 0.86 
         
Symptomatic recovered, ever        
 n (%) 63 (28.4) 25 (31.3) 21 (25.3) 17 (28.8) 0.64
b
 2 0.73 
         
GAF symptoms change        
 Mean (sd) 13.3 (26.8) 14.9 (27.1) 12.1 (25.1) 11.8 (30.6) 0.14
c
 95 0.87 
         
GAF disability change        
 Mean (sd) 9.4 (23.9) 8.6 (25.6) 6.7 (21.9) 16.8 (23.6) 1.12
c
 96 0.33 
w, weeks; sd, standard deviation; df, degrees of freedom, GAF, global assessment of functioning  
a
 rank test x
2 




tests for categorical variables 
c
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5.3.4. Pattern of care over the follow up period  
Patterns of care during the follow up period after first contact with mental health services for 
psychosis by ethnicity are presented in Table 17. Excluding admissions on first contact with 
mental health services, 70% of my sample was re-admitted at least once, and 30% of the 
sample had ≥3 hospital re-admission during the follow up period. Patients of Black 
Caribbean ethnicity had a shorter time to first re-admission after first contact 
(medianweeks=46.2, IQR=23.6-114.0) compared with Black African and White British ethnic 
groups (rank test x2=5.32, df=2, p=0.07). Black Caribbean ethnic group had the longest 
(mediandays=141.0, IQR=42.0-362.0) and patients of White British ethnicity had the shortest 
(mediandays=69.0, IQR=38.0-173.0) overall length of time spent in psychiatric units; however, 
neither of these differences met the standard threshold for statistical significance. Further, a 
higher proportion of Black African and Black Caribbean ethnicity had compulsory re-
admissions (x2=17.34, p=0.002) and instances of police involvement during an admission to 
a psychiatric unit (x2=22.82, p<0.001) compared with White British ethnic group.   
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Table 17. Service utilisation over the first five years after first contact with mental health services for psychosis, by ethnicity 














         
Time to first readmission, w        
 Median (IQR) 50.1 (15.1-107.6) 51.4 (13.3-111.4) 52.1 (16.1-93.6) 46.2 (23.6-114.0) 5.32
a
 2 0.07 
         
Admissions, n (%)        
 None 71 (30.7) 30 (35.7) 21 (25.3) 20 (31.3) 4.89
b
 4 0.30 
 1-2 93 (40.3) 33 (39.3) 39 (47.0) 21 (32.8)    
 >3 67 (29.0) 21 (25.0) 23 (27.7) 23 (35.9)    
         
Length of inpatient stay, d        
 Median (IQR) 107.0 (38.5-275.5) 69.0 (38.0-173.0) 122.5 (37.0-300.0) 141.0 (42.0-362.2) 4.93
a
 2 0.09 
         
Compulsory, n (%)        
 None 60 (34.3) 29 (46.8) 12 (19.1) 19 (38.0) 17.34
b
 4 0.002 
 1-2 80 (45.7) 26 (41.9) 38 (60.3) 16 (32.0)    
 >3 35 (20.0) 7 (11.3) 13 (20.6) 15 (30.0)    
         
Police involved, n (%)        
 None 74 (42.5) 35 (56.5) 14 (22.6) 25 (50.0) 22.82
b
 4 <0.001 
 1-2 79 (45.4) 24 (38.7) 40 (64.5) 15 (30.0)    
 >3 21 (12.1) 3 (4.8) 8 (12.9) 10 (20.0)    
         
Community services        
 Median (IQR) 3 (2-5) 3 (2-4) 3 (2-5) 3 (2-5.5) 3.19
a
 2 0.20 
w, weeks, d, days, IQR, inter-quartile range; sd, standard deviation; df, degrees of freedom 
a rank test x2 for the count data  
b x2 tests for categorical variables 
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5.3.4.1. Does ethnicity predict the pattern of treatment provided over the first five years of 
illness? 
Longitudinal service use outcomes in Black African and Black Caribbean ethnic groups 
compared to White British ethnicity independent of confounding factors such as age at first 
contact with mental health services, gender, and baseline diagnoses are presented in Table 
18. During the 5-year follow up, patients of Black African ethnicity were at a greater risk to be 
re-admitted at least once (HR=1.57, 95% CI=1.06-2.36), to be admitted under MHA 
(HR=2.07, 95% CI=1.28-3.33) or have police involved prior to or during a re-admission 
(HR=2.49, 95% CI=1.47-4.19) compared to their White British counterparts. Further, patients 
of Black African ethnicity were at a greater risk for multiple compulsory re-admissions 
(IRR=1.73, 95% C=1.17-2.56) and police involvement during re-admissions (IRR=2.17, 95% 
CI 1.32-3.56) over the follow up period than patients of White British ethnicity. Both Black 
African (IRR=1.48, 95% CI=1.06-2.10) and Black Caribbean (IRR=1.48, 95% CI=1.03-2.11) 
ethnic groups were at a greater risk to have a high number of re-admission than their White 
British counterparts.  
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Table 18. Longitudinal service use outcomes in Black African and Black Caribbean ethnic 
groups compared to White British ethnicity independent of confounding factors such as age 









Re-admitted, ever    
 HR (95% CI)  - 1.57** (1.06-2.34) 1.06 (0.69-1.63) 
     
Admissions, number    
 IRR (95% CI)  - 1.48** (1.06-2.10) 1.48 ** (1.03-2.11) 
     
Length of inpatient stay    
 IRR (95% CI)  - 1.72 (0.87-3.42) 1.24 (0.59-2.60) 
     
Compulsory, number    
 IRR (95% CI)  - 1.73*** (1.17-2.56) 1.44 (0.95-2.19) 
     
Compulsory, ever    
 HR (95% CI)  - 2.07*** (1.28-3.33) 1.17 (069-1.99) 
     
Police involved, number    
 IRR (95% CI)  - 2.17*** (1.32-3.56) 1.61 (0.95-2.74) 
     
Police involvement, ever    
 HR (95% CI)  - 2.49*** (1.47-4.19) 1.28 (0.71-2.31) 
     
Regular community 
services, number 
   
 IRR (95% CI)  - 1.25** (1.04-1.51) 1.17 (0.96-1.43) 
     
Intensive community 
services, number 
   
 IRR (95% CI)  - 1.23 (0.95-1.59) 1.08 (0.83-1.42) 
 
IRR, incidence rate ratio; CI, confidence intervals; HR, hazard ration;  
Adjusted for age at first contact with mental health services, gender and baseline diagnosis 
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Next I adjusted the models which produced significant results in the above set of analyses 
for additional variables: living arrangements, relationship status and substance use over the 
follow up period. The aim of these analyses was to investigate whether the significant results 
were explained by these factors (Table 19). The risk for Black Africa patients being re-
admitted at least once (HR=1.77, 95% CI=1.25-2.72), to be admitted under MHA (HR=2.17, 
95% CI=1.29-3.63) or have police involved prior to or during a re-admission (HR=2.75, 95% 
CI=1.56-4.86), though slightly attenuated, remained significant, compared to their White 
British counterparts. Similarly, patients of Black African ethnicity were still at a greater risk for 
multiple compulsory re-admissions (IRR=1.64, 95% CI=1.07-2.51) and even more so for 
police being involved during re-admissions (IRR=2.42, 95% CI=1.41-4.13) over the follow up 
period than patients of White British ethnicity. The risk for a higher number of re-
hospitalisations to the psychiatric wards in patients of Black African and Black Caribbean 
ethnicity remained significant after adjusted analysis for living arrangements, relationship 
status and substance use over the follow up period; though it was considerably reduced for 
Black Caribbean ethnic group.  
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Table 19. Longitudinal service use outcomes in Black African and Black Caribbean ethnic 
groups compared to White British ethnicity independent of confounding factors such as age 
at first contact with mental health services, gender, and baseline diagnoses and follow up 
variables (i.e., living arrangements, relationship status and substance use over the follow up 
period) 






Re-admitted, ever    
 HR (95% CI)  - 1.77** (1.25-2.72) 1.13 (0.70-1.81) 
     
Admissions, number    
 IRR (95% CI)  - 1.58** (1.08-2.33) 1.49* (1.00-2.24) 
     
Compulsory, number    
 IRR (95% CI)  - 1.64** (1.07-2.51) 1.42 (0.90-2.23) 
     
Compulsory, ever    
 HR (95% CI)  - 2.17*** (1.29-3.63) 1.19 (0.66-2.13) 
     
Police involved, number    
 IRR (95% CI)  - 2.42*** (1.41-4.13) 1.77 (0.99-3.14) 
     
Police involvement, ever    
 HR (95% CI)  - 2.75 *** (1.56-4.86) 1.39 (0.73-2.64) 
     
Regular community 
services, number 
   
 IRR (95% CI)  - 1.30 (0.98-1.72) 1.05 (0.77-1.41) 
 
IRR, incidence rate ratio; CI, confidence intervals; HR, hazard ration;  
Adjusted for age at first contact with mental health services, gender, living arrangement, substance use during 
and relationship status during the follow up period and the duration of the follow up period 
*p<0.05, ** p<0.01, *** p<0.001 
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5.3.5. Socio-demographic characteristics over the follow up period 
By the end of the follow up period, a higher proportion of Black Caribbean patients lived 
alone (61.2% of n=67); while a substantial proportion of Black African ethnic group (25.3% of 
n=93) lived in a supported accommodation (x2=10.88, df=2, p=0.03) as shown in Table 20. A 
lower proportion of White British patients were single (67% of n=91) compared to Black 
African (83.3% of n=84) and Black Caribbean (81.8% of n=66) ethnic groups (x2=7.81, df=2, 
p=0.02). Moreover, 26% (n=17/66) of White British (compared to 8% (n=6/72) of Black 
African and 5% (n=3/56) of Black Caribbean ethnic groups) lived in privately rented 
accommodations; whereas, 93% (n=52/56) of Black Caribbean ethnic group were housed by 
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Table 20. Socio-demographic characteristics by the follow up period, by ethnicity  
* 












         
Living arrangement, n (%)        
 Alone 116 (47.9) 39 (42.4) 36 (43.4) 41 (61.2) 10.88
a
 4 0.03 
 Not alone 80 (33.1) 39 (42.4) 26 (31.3) 15 (22.4)    
 Supported accommodation 46 (19.0) 14 (15.2) 21 (25.3) 11 (16.4)    
         
Relationship status, n (%)         
 Single  185 (76.8) 61 (67.0) 70 (83.3) 54 (81.8) 7.81
a
 2 0.02 
 Stable relationship  56 (23.2) 30 (33.0) 14 (16.7) 12 (18.2)    
         
Employment, n (%)        
 Unemployed 191 (81.6) 73 (86.9) 65 (76.5) 53 (81.5) 3.07
a
 2 0.22 
 Employed 43 (18.4) 11 (13.1) 20 (23.5) 12 (18.5)    
         
Type of accommodation, n (%)        
 Owned 11 (5.7) 5 (7.6) 6 (8.3) - 25.05
a
 6 <0.001 
 Housing association/Local 
authority rented 
142 (73.2) 38 (57.6) 52 (72.2) 52 (92.9)    
 Privately rented 26 (13.4) 17 (25.8) 6 (8.3) 3 (5.4)    
 Homeless 15 (7.7) 6 (9.1) 8 (11.1) 1 (1.8)    
         
df, degrees of freedom 
a x2 tests for categorical variables 
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5.4. Discussion 
In this study I investigated the differences in the illness trajectories and pattern of care 
between White British, Black African and Black Caribbean ethnic groups during the 5-year of 
follow up period. My findings highlight that during the first five years of illness after first 
contact with mental health services, the longitudinal trajectory of psychosis in patients of 
Black ethnicity is characterised by longer inpatient stays, higher rates of compulsory 
admissions and increased instances of police involvement during or shortly before a re-
admission to a psychiatric hospital compared with patients of White British ethnicity. This 
pattern of care in Black ethnic groups was not reflected in their overall functional disability 
and illness severity in the due illness course or likelihood to report either remission or 
recovery during the follow up period. 
5.4.1. Longitudinal course and outcome of first episode psychosis 
In contrast to a previous 18-yearlong study conducted in the overlapping geographical region 
as our study 185, I did not observe that patients of Black ethnicity had significantly elevated 
rate of hospital re-admissions over the 5-year period of follow up compared with White 
British patients. Consistently with this early work though185, my results highlighted that both 
Black African and Black Caribbean ethic groups had a longer total inpatient stay than their 
White British counterparts. While it may be argued that a longer time spent at psychiatric 
hospitals over the illness course may be an indicator of a more severe illness course in 
patients of Black ethnicity, it is equally plausible that patients’ living arrangements were 
important contributing factors to these findings268. Indeed, a higher proportion of patients of 
Black ethnicity lived alone, was single or was housed by local authorities compared with their 
White British counterparts. This may suggest that longer inpatient stays may have been due 
to a lack of suitable accommodations after hospital discharges. Further, some have raised a 
cause for concern that ethnic minority patients underutilise psychiatric community services 
after contact with mental health services 196, my results showed nonetheless that this was 
not the case for Black African and Black Caribbean ethnic groups when compared to White 
British counterparts during my follow up period.  
Previously, it has been reported that people of Black ethnicity were more likely to be 
compulsorily detained compared with patients of White ethnicity during one year 269, and two 
years of follow up 196. My results showed that this still remains the case during first 5-years of 
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illness after first contact with mental health services for psychosis. It has been suggested 
that the risk for compulsory detentions is amplified by a reluctance to seek help during a 
mental health crisis among those of Black ethnicity 269, 270. The alleged unwillingness to 
utilise the available services at the time of mental health crisis has been linked to a variety of 
factors including distrust of psychiatric services 271, lack of insight into mental health 
difficulties 272 and language barriers 270. Cumulatively my findings suggest that the factors 
which led to a higher rate of compulsory admissions among Black individuals in the past 
have not yet diminished. Further, the results highlighted that the patients of Black African 
ethnicity tended to have multiple instances of police involvements during hospital re-
admissions. It has previously been shown that family members of those of Black ethnicity 
contact the police more frequently at times of clinical deterioration in their relative 63; though I 
was unable to test if this was a factor in the increased rates of compulsory admissions in 
Black cases.  
Additionally, I found that the proportion of unemployed increased in White British and Black 
African ethnic group by the end of the follow up period. While it is common for individuals 
with psychosis to struggle to develop or maintain stable relationships 273, there was an 
increased proportion of single individuals in the Black African and Black Caribbean ethnic 
group compared with White British group. Cumulatively these findings suggest that patients 
of Black ethnicity become increasingly socially excluded as their illness progresses. 
5.4.2. Methodological considerations  
Generally, longitudinal studies tend to suffer from systematic bias due to non-random loss of 
information during the follow up period. Nonetheless, in the present study considerable 
efforts have been made to minimise this potential bias by establishing the whereabouts, 
deaths and emigration status for impressive 92% of my sample. The quality and 
completeness of information reported in the clinical notes for each case inevitably varied, 
which in turn may have introduced bias. It is possible that clinicians might not have always 
recorded in the electronic clinical notes when symptoms were present and thus in some 
instances patients may have been classified inaccurately as remitted or recovered. Having 
said that, the rates of remission and recovery identified in this study are consistent with 
earlier studies which collected data either from face-to-face interviews only 123 or extracted it 
retrospectively 102. It is also feasible that some of patients might have sought or purchased 
mental healthcare for a psychotic disorder elsewhere, or sought alternative means to 
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manage their symptoms, and thus would not have been registered in the SLaM electronic 
notes or included in the present study. Similarly, those patients who were reluctant to seek 
help would not be included in our sample; this in turn may reduce generalisability of my 
results. Further, I was unable to investigate whether the longitudinal outcomes differed 
depending on the generation of immigrants my ethnic groups belong to. Since the female 
patients tend to have a less severe illness course 49, the small population of women in in 
sample may have steered the results to more severe end of the illness course. Finally, 
although the compared ethnic groups were not matched by age and sex considerable effects 
have been made to ascertain a sample of patients who were representative of the general 
population in age, gender, ethnicity, educational qualifications, and employment status at the 
time of the study entry. 
5.5. Summary and concluding remarks 
Previous research has not provided us with a comprehensive picture of the longitudinal 
course of psychotic disorders in Black people living in Europe. I sought to investigate clinical 
outcomes and pattern of care in Black African and Black Caribbean groups compared with 
White British patients during the first five years after first contact with mental health services 
for psychosis. In the present study I utilised 245 FEP cases aged 18-65 who presented to 
psychiatric services in 2005-2010 in South London (UK). Using the electronic psychiatric 
clinical notes in the South London and Maudsley NHS Foundation Trust (SLaM), I extracted 
extensive information on three domains - clinical, social, and service use. My results showed 
that differences remain in patterns of care among those of Black African, Black Caribbean 
and White British patients resident in London during the first five years after first contact with 
mental health services for psychosis. The longitudinal trajectory of psychosis in patients of 
Black ethnicity is characterised by longer inpatient stays, higher rates of compulsory 
admissions and increased instances of police involvement during or shortly before a re-
admission to a psychiatric hospital compared with patients of White British ethnicity. The 
observed pattern of care in Black ethnic groups was not reflected in their overall functional 
disability and illness severity in the due illness course or likelihood to report either remission 
or recovery during the follow up period. The prognosis is also still poor in terms of social 
functioning and isolation among Black ethnic groups during their illness. Further study is 
required to establish whether these differences reflect social or clinical differences between 
ethnic groups. Nonetheless, my findings reiterate a greater need for action in health systems 
and social policy to challenge and reduce these disparities. 
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CHAPTER 6 STUDY 4 
Clinical predictors of treatment resistance in first episode schizophrenia  
6.1. Introduction  
Treatment resistant schizophrenia (TRS) is a major cause of disability and functional 
impairment; it affects up to 30% of patients diagnosed with SZ 191. In the UK, it is 
recommended that clozapine, which is the only evidence-based effective medication for 
TRS, be offered to people with SZ whose illness has not responded to treatment despite the 
sequential use of adequate doses of at least two different antipsychotic medications 192. 
Early identification of patients who require clozapine has the potential to improve clinical 
outcomes and minimise the social and functional disability that results from prolonged 
psychosis 207-209.  
The aim of this study was to identify baseline clinical and demographic risk factors, which 
were predictive of treatment resistance (TR) defined at the end of the first five years of 
illness. To achieve this, I tested associations between TR status and a number of risk 
predictors, including type and severity of symptoms, gender, age, ethnicity, duration of 
untreated psychosis (DUP) and premorbid level of functioning. Further, in this study I aimed 
to look for differential clinical and social factors between those who showed “early- 
resistance” TR (E-TR) and those with “late- resistance” TR (L-TR). I aimed to assess the 
differences between patients in the E-TR group and those who were not treatment resistant 
(non-TR), and patients with L-TR and those who were non-TR. I additionally compared the 
TR patients treated with clozapine with those who met the criteria for the TR but had not 
commenced clozapine, in terms of their baseline sociodemographic and clinical 
characteristics. 
6.2. Methods 
6.2.1. Sample  
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For this study, only those FEP cases who met criteria for the following ICD-10 diagnoses: 
F20.0, F25.0, F28.0, F29.0, (for this study I refer to these patients as schizophrenia 
spectrum psychosis; no cases of schizotypal disorder were included in this group) 274 were 
included at baseline. Age at first contact was further categorised into four groups based on 
the results of interquartile analyses (18-20, 21-25, 26-30, and >31 years). 
6.2.2. Association Analysis 
Rigde regression, which is a form of Penalised logistic regression (PLR), was used to 
analyse the relationship between the predictors for TR status. In order to accommodate 
potential confounders when there may be relatively few observed outcome events, Rigde 
regression penalises large, imprecise coefficient estimates by shrinking them towards zero, 
thereby reducing the overall variability in the model, and minimises the emergence of 
excessively wide confidence intervals for odds ratios. Therefore, the Rigde regression may 
be considered a more robust approach to elucidating risk more accurately than logistic 
regression analysis in small to medium-sized data sets with few confounding factors275.  
To explore the moderating effects of gender and ethnicity in predicting the risk for TR, I 
examined whether there were significant interactions between these variables and the 
independent predictors used to predict TR status at follow up.  
Confounding factors were identified through correlation analyses between the primary 
outcome (i.e. TR vs non-TR at five years) and a number of clinical and sociodemographic 
factors measured at baseline and during the follow up period. All variables with p<0.05 were 
included in the final model as confounding factors. Consequently, I adjusted the PLR 
analyses for the following variables: age at first contact for psychosis, and living 
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6.3. Results 
6.3.1. Sample characteristics  
At baseline, the sample comprised n=282 cases with a diagnosis of a schizophrenia 
spectrum psychosis with the average age of 27.6 (sd=8.6) years. A flow chart depicting how 
the cases were traced and administrative outcomes is presented in Figure 9. Approximately 
5 years (meanyear=5.4, SD=2.5; 1,310 persons years) after first contact for psychosis, n=10 
(3.6%) emigrated, n=2 (0.7%) were excluded as these patient did not have information on 
follow up and their contact details were not available at baseline to enable to me trace them 
either via their GP or ONS/GRO tracing procedures, and n=4 (1.4%) had died. I was unable 
to trace a further n=21 (7.5%) cases. Those who died were significantly older than those 
who were followed up (Table 21). 
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Table 21. Baseline demographic characteristics for those who were lost to follow up. These data are limited to first-episode schizophrenia 
spectrum patients and exclude cases of schizotypal disorder  
  Total  Followed up  
Contact made, 
unsuccessful  
Abroad Died Excluded Statistics  
 n(%) 282  245 (86.9) 21 (7.5) 10 (3.6) 4 (1.4) 2 (0.7)  
         
Gender, n(%)        
 Female  80 (32.6) 7 (33.3) 2 (20) 2 (50) - x
2
=2.24 df=4 p=0.79 
 Male  165 (67.4) 14 (66.7) 8 (80) 2 (50) 2 (100)  
         
Age at first contact (mean (s.d.)) 27.6 (8.6) 27.1 (7.9) 31.4 (12.3) 26.4 (7.8) 42.5 (15.2) 27.5 (0.7) F (4, 276) =4.48 p=0.002 
         
Ethnicity, n(%)        
 White  90 (38.8) 9 (45.0) 1 (10.0) 3 (75.0) 1 (50.0) x
2
=6.13 df=4 p=0.14 
 Black  142 (61.2) 11 (55.0) 9 (90.0) 1 (25.0) 1 (50.0)  
s.d., standard deviation; df, degrees of freedom 
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Figure 9. Flow chart documenting how cases were traced and administrative outcomes five 
years after first contact with mental health services for schizophrenia spectrum psychosis 
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6.3.2. Core analytic cohort 
I successfully traced n=245 (86.9%) of the original GAP cohort. Of these, 67.3% were male 
and 61.1% were of Black ethnicity. There were 239 cases with sufficient information on 
treatment over the follow up period to determine TR or non-TR status. Eighty (33.5%) of the 
cases met the criteria for TR and n=159 (66.5%) were non-TR. The other 6 (2.4% of the core 
analytic cohort) cases had not received an adequate trial of antipsychotic medications to 
allow it to be determined if criteria for TR or non-TR was met. 
6.3.3. Predictors of treatment-resistance (TR) 
Comparisons in baseline sociodemographic and clinical characteristics between the TR and 
non-TR groups are presented in Table 22. Patients in the TR group were significantly 
younger on the first presentation to mental health services for first psychotic symptoms 
(meanyears=25.0, sd=6.1) when compared to the non-TR group (meanyears=27.9, sd=8.3) 
(t=2.79, df=148, p=0.01). The median length of DUP for the TR group was 72 days (IQR=15-
368) which was longer but not significantly from the non-TR group (median=40, IQR=5-127) 
(Mann Whitney U test=-1.56, p=0.12). There was no significant difference between the mean 
IQ in the TR group (mean=92.6, sd=13.0) compared with the non-TR group (mean=87.5, 
sd=16.2) (Mann Whitney U test=-1.25, p=0.22). The mean premorbid IQ was higher in the 
TR group (mean=92.8, sd=9.6) compared to those in the non-TR group (mean=88.5, 
sd=11.0), but this did not reach statistical significance (Mann Whitney U test=-1.58, p=0.11).   
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Table 22. Comparisons in baseline characteristics between the non-treatment resistance 
(i.e., TR) non- and treatment resistance (i.e., TR) groups. These analyses are limited to first-








 Mean (SD)/n(%) Mean (SD)/n(%) t/U/x
2
 df p 
      
DUP days       
Median (IQR) 40 (5-127) 72 (15-368) -1.56  0.12 
      
Age years   27.9 (8.3) 25.0 (6.4) 2.79 237 0.01 
      
Gender       
 Female  52 (32.7) 27 (33.7) 0.03 1 0.49 
 Male  107 (67.3) 53 (66.3)    
       
Ethnicity       
 White ethnic groups 57 (37.7) 30 (39.5) 0.06 1 0.46 
 Black ethnic groups 94 (62.3) 46 (60.5)    
       
Living arrangements       
 Alone 41 (42.3) 15 (38.5) 0.17 1 0.42 
 Not alone  56 (57.7) 24 (61.5)    
       
Relationship status      
 Single/separated  78 (80.4) 32 (80.0) 0.003 1 0.56 
 Stable relationship  19 (19.6) 8 (20.0)    
       
Education       
 no/basic 79 (82.3) 32 (82.1) 0.001 1 0.58 
 higher 17 (17.7) 7 (17.9)    
       
Cannabis use       
 none/infrequent 75 (67.6) 32 (68.1) 0.004 1 0.55 
 every day 36 (32.4) 15 (31.9)    
       
Alcohol intake      
 0-14 units week 83 (86.5) 51 (89.5) 0.30 1 0.39 
 >15 units week 13 (13.5) 6 (10.5)    
       
Current IQ minus 
estimated premorbid IQ 
1.01 (1.5) 0.1 (2.81) 0.30 67 0.76 
SD, standard deviation; df, degrees of freedom; IQR, interquartile range; DUP, Duration of untreated psychosis 
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Baseline clinical predictors of TR at five-year follow up for the whole sample and stratified by 
ethnicity and gender are presented in Table 23. The severity of psychotic symptoms as 
measured by PANSS at the time of first contact for psychosis did not predict the risk for TR 
during the first five years of follow up. Those patients who were defined as TR were more 
likely to have an early illness onset (<20 years) compared to the non-TR group (OR=2.66, 
95% CI=1.31-5.40). Further, there were significant interactions between age at first contact 
for psychosis with ethnicity (p=0.02) and gender (p=0.002). Therefore, in addition to 
exploring the impact of age at first contact in predicting TR in the cohort, I further stratified 
the analyses by gender and ethnicity. I observed that this relationship between an early age 
of first contact (<20 year) and TR was significant in cases of Black ethnicity (OR=3.71, 95% 
CI=1.44-9.56) and in males (OR=3.13, 95% CI=1.35-7.23) independent of confounding 
factors (Table 24). 
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Table 23. Baseline clinical predictors of treatment resistance (TR) in a sample with 
schizophrenia spectrum disorder  
 
Baseline clinical predictors 
Total sample (n=245) 
Non-TR TR 
  OR (95% CI) OR (95% CI) 
a Age categories    
 >31 years  - 0.58 (0.28-1.20) 
 26-30 years  - 1.09 (0.54-2.20) 
 21-25 years  - 0.66 (0.35-1.26) 
 <20 years  - 2.66*** (1.31-5.40) 
    
b Psychopathology    
 PANSS total  - 1.01 (0.98-1.04) 
 PANSS Positive  - 1.02 (0.96-1.09) 
 PANSS Negative  - 1.01 (0.94-1.10) 
    
 GAF Disability  - 0.98 (0.95-1.01) 
 GAF Symptoms   0.97 (0.93-1.00) 
    
 PANSS Lack of 









OR, odds ratio; CI, confidence interval; PANSS, Positive and Negative Syndrome Scale, GAF, Global 
Assessment of Functioning Scale; DUP, duration of untreated psychosis  
a 
Adjusted for alcohol use, illicit substance use and living arrangements at follow up  
b
 Adjusted for age at first contact, alcohol use, illicit substance use and living arrangements at follow up  
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Table 24. Age at first contact as a baseline predictor of treatment resistance (TR) in a sample with schizophrenia spectrum disorder stratified 
by gender and ethnicity  
OR, odds ratio; CI, confidence interval; PANSS, Positive and Negative Syndrome Scale, GAF, Global Assessment of Functioning Scale; DUP, duration of untreated psychosis  
a 
Adjusted for alcohol use, illicit substance use and living arrangements at follow up  








 by Ethnicity  by Gender 
 White ethnic group (n=90) Black ethnic group (n=142)  Female (n=80) Male (n=165) 
           
  Non-TRS TRS Non-TRS TRS  Non-TRS TRS Non-TRS TRS 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
a 
Age categories           
>31 years  - 1.01 (0.31-3.25) - 0.47 (0.18-1.27)  - 0.63 (0.22-1.80) - 0.38 (0.12-1.18) 
26-30 years  - 1.69 (0.60-4.79) - 0.82 (0.29-2.29)  - 0.86 (0.23-3.27) - 1.33 (0.57-3.10) 
21-25 years  - 0.43 (0.14-1.30) - 0.70 (0.29-1.65)  - 1.32 (0.44-3.96) - 0.49 (0.21-1.11) 
<20 years  - 1.60 (0.43-5.87) - 3.71*** (1.44-9.56)  - 1.92 (0.43-8.60) - 3.13*** (1.35-7.23) 
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6.3.4. “Clozapine” group vs “met criteria” group  
Comparisons in baseline sociodemographic and clinical characteristics between the 
“Clozapine” group vs “met criteria” group are presented in Table 25. Among those patients 
who were defined as TR, n=38 TR cases (47.5% of n=80 TR group and 15.5% of n=245 
cases with a diagnosis of schizophrenia spectrum psychosis at study entry) commenced 
treatment with clozapine; whereas n=42 TR cases (52.5% of n=80 TR group) met criteria for 
clozapine (for more details please refer to Chapter 2, section 2.3.6.2.6.- 2.3.6.2.7., ., page 
76) but did not commence it. A significantly higher proportion of patients in the clozapine 
group (91%) lived with family members or friends compared to the “met criteria” group (50%) 
(x2=5.58, p=0.02). At first contact for psychosis, the clozapine group had exhibited more 
severe psychopathology (Mann Whitney U test=2.05, p=0.04) and negative symptoms 
(Mann Whitney U test =2.01, p=0.04) than the “met criteria” group. Similarly, the clozapine 
group also had increased negative symptoms (mean=21.7, sd=9.1) compared to the non-TR 
group (mean=15.4, sd=6.0) (Mann Whitney U test=-2.22, p=0.02)  
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Table 25. Comparison in baseline socio-demographic and clinical characteristics between 
“clozapine” group and those who met criteria for clozapine (“met criteria”) but did not 
commence the clozapine during the course of illness. These analyses are limited to first-
episode schizophrenia spectrum patients and exclude cases of schizotypal disorder  
 
Baseline socio-demographic 






  Mean (sd)/n(%) Mean (sd)/n(%) t/U/x
2
 df p-value 
       
Age years  24.7 (5.1) 25.3 (7.4) -0.41 78 0.68 
       
Gender       
 Female 10 (26.3) 17 (40.5) 1.79 1 0.13 
 Male  28 (73.7) 25 (59.5)    
       
Ethnicity       
 White (all categories) 16 (44.4) 14 (35.0) 0.71 1 0.27 
 Black (all categories) 20 (55.6) 26 (65.0)    
       
Living arrangements      
 Alone 1 (9.1) 14 (50.0) 5.58 1 0.02 
 Not alone  10 (90.9) 14 (50.0)    
       
Relationship status      
 Single/separated  9 (81.8) 23 (79.3) 0.03 1 0.62 
 Stable relationship  2 (18.2) 6 (20.7)    
       
Cannabis use      
 none/infrequent 15 (71.4) 17 (65.4) 0.19 1 0.45 
 every day 6 (28.6) 9 (34.6)    
       
Alcohol intake      
 0-14 units week 24 (96.0) 27 (84.4) 2.01 1 0.16 
 >15 units week 1 (4.0) 5 (15.6)    
       
DUP days      
 Median (IQR) 33 (14-102) 171 (19-439) -1.17  0.24 
       
PANSS total  79.1 (16.3) 63.6 (17.7) 2.05  0.04 
PANSS Positive  17.8 (6.6) 16.0 (8.2) 0.92  0.36 
PANSS Negative  21.7 (9.1) 14.9 (6.2) 2.01  0.04 
       
GAF Disability  51.7 (11.0) 49.3 (16.6) 0.86  0.39 
GAF Symptoms  40.0 (13.3) 39.9 (18.4) 0.33  0.74 
       
PANSS Lack of judgement & 
insight 




2.7 (1.1) 2.2 (1.4) 1.43  0.15 
sd, standard deviation; df, degrees of freedom; PANSS, Positive and Negative Syndrome Scale, GAF, Global 
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6.3.5. “Early-resistance” TR (E-TR) vs “Late-resistance” TR (L-TR) with the non-TR groups 
Among those with TR, n=55 (69.6% of n=79 with TR) were E-TR and n=24 (30.4% of n=79 
with TR) were L-TR. at the time of first contact for psychosis, there were no significant 
differences in sociodemographic characteristics between the E-TR and non-TR groups, and 
between the L-TR and non-TR cases (Tables 26-27). The E-TR group expressed more 
severe psychopathology at baseline (mean total PANSS score=72.7, sd=20.6) than the non-
TR group (mean total PANSS score=62.7, sd=16.8) (Mann Whitney U test=-2.07, p=0.04) 
(Table 26). Additionally, patients in the L-TR group were significantly younger at the time of 
first contact for psychosis (meanyears=23.7 years, sd=5.1) compared to the non-TR group 
(meanyears=27.4 years, sd=8.0), (t=2.44, df=81, p=0.03) (Table 27). 
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Table 26. Comparison in baseline socio-demographic and clinical characteristics between 
non-treatment resistance (i.e. non-TR)  group and “early resistance” E-TR. These analyses 
are limited to first-episode schizophrenia spectrum patients and exclude cases of schizotypal 
disorder  
Baseline socio-demographic 






 Mean (sd)/n(%) Mean (sd)/n(%) t/U/x2 df p 
      
Age years 27.9 (8.3) 25.6 (6.9) 1.87 212 0.06 
      
Gender       
 Female  52 (32.7) 14 (25.4) 101 1 0.40 
 Male  107 (67.3) 41 (74.6)    
       
Ethnicity       
 White  57 (37.8) 20 (37.7) 0.00 1 0.99 
 Black  94 (62.2) 33 (62.3)    
       
Living arrangements      
 Alone 41 (42.3) 11 (39.3) 0.08 1 0.83 
 Not alone  56 (57.7) 17 (60.7)    
       
Relationship status      
 Single/separated  78 (80.4) 23 (79.3) 0.02 1 0.90 
 Stable relationship  19 (19.6) 6 (20.7)    
       
Cannabis use       
 none/infrequent 75 (67.6) 23 (74.2) 0.05 1 0.52 
 every day 36 (32.4) 8 (25.8)    
       
Alcohol intake      
 0-14 units week 83 (86.5) 33 (84.6) 0.08 1 0.79 
 >15 units week 13 (13.5) 6 (15.4)    
      
DUP days      
Median (IQR) 40 (5-127) 59 (10-368) -0.85  0.40 
      
PANSS total  62.7 (16.8) 72.7 (20.6) -2.07  0.04 
PANSS Positive  15.3 (6.7) 17.9 (8.2) -1.36  0.17 
PANSS Negative  15.4 (6.0) 17.4 (8.5) -0.71  0.48 
      
GAF Disability 54.4 (20.6) 48.7 (14.8) 1.11 77 0.27 
GAF Symptoms 49.0 (27.8) 40.5 (17.3) 1.45  0.15 
      
PANSS Lack of judgement & 
insight  




2.1(1.4) 2.6 (1.4) -1.82  0.07 
TR, treatment resistance; sd, standard deviation; df, degrees of freedom; PANSS, Positive and Negative 
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Table 27. Comparison in baseline socio-demographic and clinical characteristics between 
non-treatment resistance (i.e., non-TR) group and “late resistance” L-TR. These analyses 










 Mean (sd)/n(%) Mean (sd)/n(%) t/U/x2 df p 
      
Age years 27.9 (8.3) 23.7 (5.1) 2.44 181 0.02 
      
Gender       
 Female  52 (32.7) 13 (54.2) 4.19 1 0.07 
 Male  107 (67.3) 11 (45.8)    
       
Ethnicity       
 White  57 (37.8) 9 (40.9) 0.08 1 0.82 
 Black  94 (62.2) 13 (59.1)    
       
Living arrangements      
 Alone 41 (42.3) 4 (40.0) 0.02 1 0.89 
 Not alone  56 (57.7) 6 (60.0)    
       
Relationship status      
 Single/separated  78 (80.4) 8 (80.0) 0.001 1 0.98 
 Stable relationship  19 (19.6) 2 (20.0)    
       
Cannabis use       
 none/infrequent 75 (67.6) 9 (60.0) 0.34 1 0.57 
 every day 36 (32.4) 6 (40.0)    
       
Alcohol intake      
 0-14 units week 83 (86.5) 17 (100.0) 2.60 1 0.21 
 >15 units week 13 (13.5) -    
      
DUP days      
Median (IQR)      
      
PANSS total  62.7 (16.9) 63.5 (13.6) -0.26  0.80 
PANSS Positive  15.3 (6.7) 13.9 (5.9) 0.54  0.59 
PANSS Negative  15.4 (6.0) 17.2 (7.2) -0.73  0.47 
      
GAF Disability 54.4 (20.6) 55.0 (15.3) -0.08 65 0.94 
GAF Symptoms 49.0 (21.8) 37.9 (16.3) 1.27  0.20 
      
PANSS Lack of judgement & 
insight 




2.1 (1.4) 1.9 (1.1) 0.23  0.82 
TR, treatment resistance; sd, standard deviation; df, degrees of freedom; PANSS, Positive and Negative 
Syndrome Scale, GAF, Global Assessment of Functioning Scale; DUP, duration of untreated psychosis  
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6.4. Discussion 
My main findings are that TR illness was seen in 34% of patients by the end of the 5-year 
follow-up period after first contact with mental health services, and 70% of the TR patients 
did not respond to treatment with antipsychotic medications from illness onset. Further, an 
earlier age of illness onset was strongly associated with TR status by the end of the follow 
up period. This is consistent with the results of previously published studies indicating that 
an earlier age of onset is associated with poorer outcomes and lower rates of complete 
remission in patients with FEP 74, 276. Although a younger age of illness onset has been 
previously associated with the emergence of treatment resistance in patients with 
schizophrenia 277, 278, my study highlights this in a longitudinal study of first episode 
schizophrenia spectrum psychoses. Cumulatively, these results show that clinicians may 
need to be more vigilant when treating individuals with a first episode of schizophrenia 
spectrum psychosis in late adolescence (ages<20) in terms of their response, or lack of it, to 
initial trials of antipsychotic medications and to be prepared to use clozapine more promptly 
when a lack of response is evident.  
The significant association between the illness onset before the age of 20 and TR was most 
marked for males and for those of Black ethnicity. The finding that males had an earlier 
onset of illness in the non-TR group in combination with the younger age of SZ onset in 
those who eventually develop TR may be indicative of the neurodevelopmental model of the 
TRS. However, there was no evidence to suggest that the estimated deterioration in IQ 
scores was greater in the TR group compared to the non-TR group. Similarly, my results did 
not indicate that environmental risk factors were more prevalent in the TR group. Thus my 
findings do not provide support for a neurodevelopmental pre-eminence in the TR group. 
It is noteworthy that there are a number of other factors that have been shown to play an 
important role in risk for treatment resistance and in general lack of response to treatment 
with antipsychotic medications in patients with schizophrenia, such as urbanicity 279 and 
genetic risk factors 280 281 282 that have not been examined in this study. Further, it has been 
suggested that major depressive disorder in comorbidity with schizophrenia was a predictor 
for TRS283. Cognitive symptoms have also been suggested to be associated with poor 
response to antipsychotics283. However, I did not examine these risk factors in my sample in 
association with TRS and its possible two types as it was beyond of the aims of my PhD. I 
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hope future research on treatment resistance and its possible subtypes can expand to 
include all of these additional potential risk factors. 
6.4.1. Early resistance TR (E-TR) & Late resistance (L-TR) 
Of the TR group, 70% displayed unremitting symptoms from the time of first antipsychotic 
treatment. This finding is mirrored in the AESOP-10 year follow up study of FEP cases 
where it was shown that 84% of those with TR were resistant from illness onset284, even 
though the sample employed in the AESOP-10 study was not specific to schizophrenia 
spectrum psychoses. Cumulatively, these findings indicate that this course of illness is not 
associated with prior antipsychotic use but rather raises the possibility that it may be a 
distinctive schizophrenia subgroup. This assumption is further supported by evidence 
indicating the biological differences between treatment resistant and treatment responsive 
schizophrenia285, 286. Further, in this study, 30% of those with TR initially responded to 
antipsychotic medications before developing late treatment resistance. One feasible 
explanation for this finding is that the loss of antipsychotic response may be due to the 
emergence of dopamine super-sensitivity in these patients. 
6.4.2. Access to clozapine 
Clozapine was commenced in less than half of those who met criteria for TR over the course 
of the 5-year follow up. Those who were commenced on clozapine were more likely to 
exhibit more severe psychotic symptoms and increased negative symptomatology at 
baseline when compared to those who ‘met-criteria’ for clozapine use but had not 
commenced it. These results may indicate that a more florid psychosis may be a likely factor 
in decision-making for the earlier use of clozapine in TR. Further, my results showed that 
those patients who were started on clozapine were significantly more likely to be living at 
home with family, compared to those who ’met criteria’ for TR potentially. This in turn may be 
indicative of reluctance to initiate treatment with clozapine in patients who are perceived to 
have lack of family support or have unstable living arrangements. 
6.4.3. Methodological considerations 
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The main limitations of the present study include the relatively small population of female 
patients and the lack of a robust measure of medication adherence, which may have 
affected the association with meeting the criteria for TR 287. The rate of TR reported by the 
end of the 5-year follow up is relatively high. This may be due to the fact that a higher 
proportion of the original patients employed in this study were recruited from inpatient rather 
than community settings. Specifically, a higher proportion recruited from inpatient settings 
might indicate a greater clinical need for more intensive treatments than those who were 
managed in the community setting (though who were not recruited to this study). This is 
particularly relevant as the threshold for psychiatric hospital admission in London (UK) is 
higher than many other settings. 
6.5. Summary and concluding remarks 
Clozapine remains the only evidence based antipsychotic for TR in patients with SZ. The 
ability to predict which patients with first onset of schizophrenia would subsequently meet 
criteria for TR could help to reduce or diminish the severe functional disability which in turn 
may ensue if TR is not recognised and treated correctly. In this study I utilised n=245 first-
episode schizophrenia spectrum patients and tested the relationship between baseline 
demographic and clinical characteristics and the emergence of TR by the end of the 5-year 
follow up period. Additionally, I assessed associations with early- and late- onset TR and 
non-TR, and differences between those TR patients treated with clozapine and those who 
met NICE criteria for clozapine but had not commenced.  
The results indicate that an early age (i.e., >20) is associated with an increased risk for 
onset of TR during the first five years, particularly in male patients and patients of Black 
ethnicity. Over 70% of the TR group presented with a treatment resistant picture at illness 
onset. I did not find evidence suggesting that social factors and premorbid functioning were 
associated with the emergence of TR during the course of illness. These findings reinforce 
the case for early assessment of treatment resistance in first episode schizophrenia 
spectrum patients so that clozapine may be considered and introduced promptly as a third 
line treatment in first episode schizophrenia. Future studies with larger samples are required 
to replicate and progress this important area of clinical prediction.  
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CHAPTER 7 GENERAL DISCUSSION 
7.1. Overview of the findings and their implications  
In this thesis I set out to investigate pathways to care, and longitudinal clinical and social 
outcomes in patients with first episode psychosis (FEP) who were recruited as part of the 
National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) Genetics 
and Psychosis (GAP) study as well as EUropean network of national schizophrenia networks 
studying Gene-Environment interaction (EU-GEI) study and presented to the psychiatric 
services of the South London and Maudsley (SLaM) National Health Service (NHS) 
Foundation Mental Health Trust. In this chapter I will outline my main findings and their 
implications for the wider clinical or research practices in the light of methodological 
limitations.  
7.1.1. Study 1: Pathways to care in first episode psychosis patients: Looking back at use of 
prodromal services 
7.1.1.1. Overview of main results 
This is the first study to have examined the differences in pathways to care and clinical 
presentation between heterogeneous groups of patients with FEP resident in inner city 
deprived areas of South London. The results showed that 4.1% of patients presenting to 
mental health services with FEP had previously presented to the ARMS services during the 
prodromal phase of psychosis and subsequently transitioned to clinical psychosis. This sub-
group of patients was significantly younger at the time of first contact with mental health 
services compared to the FEP patients without prior contact with the ARMS services. This 
finding may be indicative of the ability of the ARMS services to detect at risk patients earlier 
compared to the standard early intervention services for FEP. However, as the ARMS 
services have established a cut-off point in age for accessing the services to be 35 year old 
or lower, individual with a later age of onset would not have been in contact with the 
prodromal teams. This in turn would ensure that the prodromal teams always deal with 
patients who are younger at the age of first contact compared to the standard services for 
psychosis.  
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Although the interval between the first onset of symptoms and initiation of treatment was 
shorter in those attending the ARMS services compared to those referred to conventional 
services, the overall difference in DUP between these two groups did not meet the standard 
threshold for statistical significance. DUP is dependent on a number of factors that need to 
be examined in order to understand this result: 1) sources of referral to mental health 
services 41, 245, 249 41; 2) help-seeking behaviours 248, 249; 3) mode of onset of first psychotic 
symptoms 225, 226, 288., and 4) absence of a consensus definition of DUP. I will examine each 
of these points in light of my findings. 
7.1.1.2. DUP and Sources of referral to mental health services 
I found that 77% of all referrals to the ARMS services were made by health professionals 
such as local GPs and other health workers. In contrast, 45% of the FEP without a prior 
contact with the ARMS teams came under care of mental health services via emergency 
services and 18% were referred by criminal justice agencies, such as police and courts. 
These results show that a substantial proportion of young individuals with an early onset of 
psychosis do not seek help 248, 249, and may not even be registered with a GP. Therefore, 
they will not be detected by the prodromal services or other services until the involvement of 
police or emergency services becomes inevitable. Moreover, considering that GP 
attendance is associated with prolonged DUP 41, 245, 249, while the emergency medical 
services and criminal justice agency are associated with substantially shorter DUP 41, it may 
be that the DUP would have remained significantly different were the pathways to care the 
same between the groups. 
7.1.1.3. DUP and Help-seeking behaviours 
Identification of individuals with subclinical psychotic experiences is heavily reliant on help-
seeking behaviours. The likelihood of help-seeking is dependent on the awareness and 
insight into the earliest manifestations of psychotic symptoms, and even more so on the 
availability of supportive families and strong social networks around young individuals who 
are at high risk 226. Indeed, in my sample at the time of first contact with mental health 
services a higher proportion of the FEP patients without prior contact with the ARMS 
services did not have a stable accommodation and lived alone compared to those FEP 
patients who had prior contact with prodromal teams. The age of illness onset is another 
important factor that may have an impact on whether the patients would seek help or not. 
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For example, it has been shown that young individuals with onset of psychosis between 16-
29 years of age are less likely to engage in help-seeking behaviours compared to those 
individuals who had onset of first psychotic symptoms within 30-65 years age category 226. 
Therefore, many young individuals who qualify for care of prodromal services would not 
have been under their radar straight away causing a longer DUP than expected. It has been 
previously suggested that individuals of non-white British ethnicity were reluctance to seek 
help during a mental health crisis 269, 270, which might have been linked to distrust of 
psychiatric services 271, lack of insight into mental health difficulties 272 and language barriers 
270. In this study I have shown that a significant proportion of FEP patients who did not have 
prior contact with the prodromal teams were non-UK born individuals. This is an important 
factor to consider when trying to shed some light on the unexpectedly longer DUP observed 
in this study.  
7.1.1.4. DUP and Mode of onset 
The vast majority of the prodromal group had an insidious mode of onset, which is 
characterised by a lack of clear differentiation between premorbid personality and onset of 
psychosis289. Not surprising therefore, this type of symptoms onset has been shown to be 
associated with considerable delays in initiation of treatment after first onset of psychotic 
symptoms 226. With slower onset of first symptoms it may be difficult to distinguish the first 
indicators of the illness from other motivational or developmental difficulties 245, prompting 
the individuals to re-adjust their lifestyle in attempts to minimise the disruption or distress 
associated with the illness rather than seek help 226. Similarly, members of their families or 
close friends may be less likely to encourage these individuals to help-seek when the onset 
of symptoms is spread over a long period 226. My results indicate that some people have an 
onset that is rapid and severe while in others have onset that is so insidious that they escape 
the notice of the prodromal services  
7.1.1.5. No consensus definition of DUP 5 
Currently there is no consensus definition of DUP. This, at least partially,  may be due to still 
existing challenges of differentiating between what constitutes onset of psychotic symptoms, 
                                                          
5
 This section was published in David, AS and Ajnakina, O (2016). Psychosis as a continuous 
phenotype in the general population: The thin line between normality and pathology. World 
Psychiatry, 15(2):129-30. doi: 10.1002/wps.20327. 
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which can then be used as a marker for onset of the period of untreated psychosis and the 
onset of the actual psychotic disorder. The claim that ARMS services reduce the DUP in 
comparison to standard clinical services for psychosis 244 is critically dependent on whether 
the time between the earliest report of symptoms and the early intervention services is taken 
as the DUP or, whether the beginning of DUP is ‘reset’ after such an intervention unless or 
until the individual develops their first episode of full-blown psychosis. Another approach that 
would help shed some light on what constitutes DUP is to clearly differentiate between the 
duration of prodromal period which is defined as the period from the first unspecific 
symptoms related to psychosis to the first continuous (present most of the time) psychotic 
symptom 290 and the actual DUP. This method would enable one to highlight whether and 
how much the prodromal services benefit the patients before they make the transition to the 
FEP and how lasting these benefits are over the subsequent course of illness. Unfortunately 
I was unable to examine this in the present study. 
7.1.1.6. Do prodromal services provide care to those who might not have access to care 
otherwise? 
My results highlighted that ~75% of those patients who had prior contact with the prodromal 
services before coming to the standard services for FEP were already fully psychotic at the 
time of the contact with the ARMS services. As this group of patients did not significantly 
differ from the FEP who did not have prior contact with the prodromal team, I concluded that 
the prodromal services do not appear to be providing additional functions by detecting 
individuals with FEP who otherwise would not have had access to mental health services.  
7.1.1.7. Conclusion 
This preliminary work suggests that when we look back on the journey that first episode 
psychosis patients took before arriving at the standard clinical services we find that very few 
come via prodromal services. This suggests that the scope for reducing or postposing the 
onset of psychosis may still be limited. Much of the work of the ARMS services, and by 
implication similar prodromal programmes, appears to be spent dealing with people who 
either will not develop psychosis, or are already experience a first episode of psychosis. 
While the latter signifies an appetite for a variety of flexible services to care for people with 
early psychosis, it highlights the greater challenge of providing care for people before they 
develop psychosis and to therefore prevent it or catch it early. These findings also imply that 
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research based on the view that high-risk participants recruited through the ARMS services 
captures a process or phase in the illness that affects the majority of FEP patients may 
possibly be questioned.  
7.1.2. Study 2: Symptom dimensions versus DSM-IV diagnostic categories as predictors of 
time to first remission in first-episode psychosis during a 4-year follow-up 
7.1.2.1. Overview of main results 
In this study I showed that the positive, excited and disorganised/concrete dimensions of 
psychosis are important predictors of time to first remission in patients with FEP. In terms of 
diagnostic categories, I found that the diagnosis of schizophrenia was associated with a 
longer time to first remission. I did not find evidence to support my hypothesis that the 
psychosis symptom dimensions were superior to traditional diagnostic categories in 
predicting time to first remission. Instead, the results highlighted that the combination of 
baseline categorical diagnosis of schizophrenia with these five symptom dimensions 
produced the best model fit. These are novel findings that may serve as markers indicative 
of those subgroups of patients with FEP who will take substantially longer to remit within four 
years after first contact with psychiatric services. 
7.1.2.2. Implications for classification  
The significance of these results is two-fold. First, they may have important implications for 
clinical practice by laying a foundation for integrating symptom profiles into treatment 
planning in a manner that is generalisable, but sensitive to differences among individual 
patients. Secondly, they demonstrate that in considering the categorical and dimensional 
approaches together would provide greater insights into patients’ need for care and 
treatment response. With additional evidence this may influence future classification 
systems. My findings also suggest that it was unfortunate that symptom dimensions were 
relegated to an Annexe within the DSM-5. 
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7.1.2.3. Conclusion  
There is currently a greater focus on meaningful and practically applicable outcomes of 
psychotic disorders with symptomatic remission being accepted as one of the best indicators 
of treatment efficiency and response. There has recently been a move towards dimensional 
approaches to psychosis and I was keen to build on previous research which highlighted that 
combining dimensional measures with categorical diagnoses is more informative in 
determining the causes of psychosis than considering them separately 218. I was also keen 
to build on previous research which highlighted that combining dimensional measures with 
categorical diagnoses is more informative in determining the causes of psychosis than 
considering them separately218. 
These results indicate that the use of a combination of the positive, excited and 
disorganised/concrete dimensions of psychosis with the traditional diagnostic category of 
schizophrenia provides a more robust prediction of the length of time that it takes for patients 
to respond to treatment after the first contact with mental health services for psychosis, 
rather than applying either of these two approaches separately. Therefore, the clinical care 
for patients with FEP would be best served by supplementing the schizophrenia diagnosis 
with symptom dimension scores when predicting delayed treatment response as measured 
by time to first remission. The results of this study need, of course, to be replicated in other 
prospective cohorts. 
7.1.3. Study 3: Patterns of illness and care over the 5 years following onset of psychosis in 
Black African, Black Caribbean and White British patients 
7.1.3.1. Overview of main results 
Over the first five years of follow up after first contact with mental health services, 63.1% of 
my overall sample reported symptomatic remission and 28.4% met criteria for symptomatic 
recovery at least once. The rates of remission and recovery that I identified in my research 
are confident with the studies that have investigated clinical longitudinal outcomes in FEP 
patients. Specifically, as outlined in the Table 1 (page 29) there are 57 studies published to 
date reporting on remission rates and 39 studies reported on recovery rates, with 18 studies 
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reporting on both remission and recovery, with a pooled rate of remission is 59.3% and for 
recovery is 39.4%.  
The overall clinical illness course was quite homogenous across White British, Black African 
and Black Caribbean ethnic groups. This stands in contrast to the pattern of care that 
patients from Black African and Black Caribbean ethnic backgrounds received compared to 
their White British counterparts during the follow up period. Patients of Black African ethnic 
group were at a greater risk to be re-admitted, to be admitted under MHA or have police 
involved prior to or during a re-admission at least once during the 5-year follow up compared 
to their White British counterparts. Further, patients of Black African ethnicity were at a 
greater risk of multiple compulsory admissions and police involvement during admissions 
over the follow up period than patients of White British ethnicity. Similarly, patients of Black 
African and Black Caribbean ethnicity were at an elevated risk to have a higher number of 
re-admissions to a psychiatric ward than their White British counterparts. All of these results 
were independent of differences in living arrangements, relationship status and substance 
use during the course of follow up between these ethnic groups.  
Additionally, I found that the proportion of unemployed increased in White British and Black 
African ethnic group by the end of the follow up period. While it is common for individuals 
with psychosis to struggle to develop or maintain stable relationships 273, there was an 
increased proportion of single individuals in the Black African and Black Caribbean ethnic 
group compared with White British group. Cumulatively these findings suggest that patients 
of Black ethnicity become increasingly socially excluded as their illness progress. 
7.1.3.2. Conclusion 
Ethnic disparities in mental health outcomes have become an area of concern. In this study I 
examined the longitudinal clinical outcomes and patterns of treatment in patients with FEP of 
White British, Black African and Black Caribbean ethnicity over a 5-year course of illness. 
The results of this study demonstrate that differences remain in patterns of care among 
those of Black African, Black Caribbean and White British patients who are resident in 
London during the first five years after first contact with mental health services for psychosis. 
The longitudinal trajectory of psychosis in patients of Black ethnicity is characterised by 
longer inpatient stays, higher rates of compulsory admissions and increased instances of 
police involvement during or shortly before a re-admission to a psychiatric hospital compared 
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with patients of White British ethnicity. The observed pattern of care in Black ethnic groups 
was not reflected in their overall functional disability and illness severity in the due illness 
course or likelihood to report either remission or recovery during the follow up period. The 
prognosis is also still poor in terms of social functioning and isolation among Black ethnic 
groups during their illness. Further study is required to establish whether these differences 
reflect social or clinical differences between ethnic groups. Nonetheless, our findings 
reiterate a greater need for action in health systems and social policy to challenge and 
reduce these disparities. 
7.1.4. Study 4: Clinical predictors of treatment resistance in first episode schizophrenia & 
Two distinct patterns of treatment resistance 
7.1.4.1. Overview of main results 
Treatment resistance (TR) was seen in 35% of patients with first episode schizophrenia 
spectrum disorders by five years follow-up; an earlier age of onset of psychosis (<20 years 
old) was strongly associated with TR. This association was specific to patients of male 
gender and for those of Black ethnicity. These findings reinforce the case for early 
assessment of treatment resistance in first episode patients so that clozapine may be 
considered and introduced promptly as a third line treatment in first episode schizophrenia. 
7.1.4.2. Two types of TR: Early-resistant and Late-resistant TR  
The finding that 23% of the total population met the criteria for TR from illness onset 
indicates that this course of illness may not be associated with prior antipsychotic use and 
raises the possibility that it may be a distinctive and homogenous schizophrenia subgroup. 
This is in line with evidence that there may be biological differences between treatment 
resistant and treatment responsive schizophrenia285, 286. This finding also mirrors the rate of 
20% who displayed ‘chronicity’ from illness outset in a FEP population 50, though is higher 
than a previous finding of 10% of FEP cases found to have shown not to respond to 
antipsychotic medications at the end of the first year of treatment 291.  
Further, my finding that 70% of the TR group displayed early treatment resistance is similar 
to an earlier study in established schizophrenia, which identified that over half of patients 
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with ‘poor outcomes’, remained psychotic from illness onset 292. The high rates of early 
resistance of those with TR in this population is an important finding and should be viewed in 
relation to the delay in clozapine use which still exists in clinical practice 214. The remaining 
30% of the treatment resistant group gradually transitioned to TR having responded to 
treatment at the start of the illness. One possibility is that the loss of antipsychotic response 
could be due to the emergence of dopamine receptor super-sensitivity in these patients. 
Dopamine super-sensitivity is postulated to occur due to upregulation of dopamine receptors 
and neural adaptation293, 294. Cumulatively, these findings indicate that two distinct patterns 
of TR may exist in patients, with the majority displaying TR from the onset and a smaller 
subset of patients developing TR after periods of relapse.  
7.1.4.3. Implications for clinical practice 
Increasingly, cases of first episode schizophrenia spectrum disorders in higher-income 
countries are managed within dedicated early intervention and first episode psychosis 
services. However, delays remain in the initiation of clozapine 214. In this study of a first 
episode schizophrenia spectrum psychosis cohort, I found that 70% of those with TR would 
have been most appropriately treated with clozapine at an early stage of their presentation. 
This suggestion is further strengthened by evidence that early treatment with clozapine is 
effective 295 and that worse outcomes are seen with a delayed use of clozapine 296, 297. Thus, 
there is a need for a greater awareness and appreciation within FEP services that early 
resistance to antipsychotic medication is a not uncommon phenomenon.  
7.1.4.3. Accessing Clozapine: Current practice and future directions  
Clozapine was commenced in less than half of those with TR over the course of the 5 years 
follow up. Those who were commenced on clozapine in this study were more likely to exhibit 
more severe psychotic symptoms and increased negative symptomatology at baseline when 
compared to those who ‘met-criteria’ for clozapine use but had not commenced it during the 
period of the follow up. These findings in turn indicate that a more florid psychosis may be a 
likely factor in a clinician’s decision for the earlier initiation of clozapine in TR. Another 
significant finding in relation to practice and clozapine initiation was that those started on 
clozapine were significantly more likely to be living at home with family compared to those 
who ’met criteria’ for clozapine in patients with TR. This may be indicative of a possibility that 
clozapine treatment is restricted for some who meet criteria for TR due to a perceived lack of 
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family support or unstable living arrangements. An alternative explanation may be that 
patients living with family are more likely to take their clozapine, whereas those living alone 
are often given a depot instead. These factors should prompt a consideration for the 
provision of more dedicated hospital and community facilities to allow for the successful 
completion of the early stages of clozapine use with adequate supervised accommodation 
provided as required. There is some evidence that such an approach is effective in 
increasing access to clozapine298.  
7.1.4.4. Conclusion  
Cumulatively, these findings of this study reinforce the case for early assessment of 
treatment resistance in patients with first episode schizophrenia so that clozapine may be 
considered and introduced promptly as a third line treatment. The identification of the two 
types of TRS may imply that there may be two distinct mechanisms responsible for onset of 
treatment resistant in patients with schizophrenia. Future studies with larger samples are 
required to replicate and progress this important area of clinical prediction.  
7.2. Methodological considerations 
7.2.1. Strengths 
7.2.1.1. Sample  
The sample utilised in this thesis was a well-characterised sample of first onset patients 
presenting for the first time with psychosis. Therefore, the findings reported here are not 
likely to be confounded by chronicity of illness or prolonged medication use 25, 49.  
7.2.1.2. Comparability of the results.  
The results reported in this PhD thesis have produced findings, which are directly 
comparable with other research conducted in this field. Specifically, WHO Life Chart 
measure for retrospective data collection that, in addition to having been shown to be a 
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reliable scale, has been used across a number of studies conducted either in the same 
geographical region74 as my thesis or in other countries in Europe 109. Similarly, I employed 
the operationalised definition of remission (Study 2 and 3) that has previously been utilised 
in earlier studies conducted in the same geographical region74, 240. Further, the five factor 
model of psychosis symptoms employed in the Study 2 was selected for being a consensus 
model derived from existing studies 26 that has been shown to be optimal for use in FEP 
samples 27. Cumulatively, this will facilitate the comparability of my results with those 
obtained in future studies.  
7.2.1.3. Duration of follow up.  
Current the evidence suggests that the first 3 to 5 years of illness course constitutes the 
‘critical period’ of treatment efficacy56, beyond this period, the level of sustained disability 
endures into the long term 206. Accordingly, in this thesis I focused on the first four (Study 2) 
and five (Study 3, 4, 5) years of illness after first contact with mental health services for 
psychosis. Therefore, the results reported in this thesis may have captured the most 
informative outcomes of illness progression across three major ethnic groups resident in the 
UK. 
7.2.1.4. Drop-out rate  
According to the earlier studies that I have presented in Table 1 and 3, the current average 
drop-out rate is 28% across all identified longitudinal studies with an average length of follow 
up of 5 years17, 84, 116, 120, 122, 131, 134, 299. However, the drop-out rate in my theses is 18%, which 
is considerably lower compared to previous research. Additionally, of this 18% who dropped 
out from the study during the 5-year follow up period, I established the whereabouts, deaths 
and emigration status of 7.7% patients. Thus, the cumulative drop-out rate in my sample was 
10.3%. This in turn ensures that any potential bias that might have risen due to the non-
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7.2.2. Limitations 
7.2.2.1. Longitudinal study design 
Generally, longitudinal study design tends to suffer from selection bias due to the non-
random loss to follow-up. I have made considerable efforts to minimise any potential bias by 
establishing the whereabouts, deaths and emigration status for 89.7% of the original GAP 
sample. I have also conducted comparative statistical analyses comparing patients with the 
information available at followed up and those patients who were lost to follow up. I did not 
find evidence to suggest attrition bias present in my sample.  
7.2.2.2. Using clinical notes for data collection.  
It may be argued that collecting information on outcome from clinical records may not 
produce reliable data. For example, for the purposes of determining the rate and duration of 
remission from clinical records, treating clinicians might not always have recorded in the 
notes when symptoms were present and thus in some cases patients may have been 
classified inaccurately as remitters. Nonetheless, there is evidence suggesting that 
remission is remarkably stable and does not differ depending on the use of more stringent 
criteria such as the RSWG, the use of broader criteria (e.g., if defined as patients being 
asymptomatic & attaining pre-morbid functioning sustained for ≥6 months), nor whether it 
was based on face-to-face interviews or clinical records6. Besides, a similar argument can 
be applied to prospective study designs. Indeed, the validity and reliability of information 
obtained from face-to-face interviews after years of exposure to treatments with 
antipsychotic medications and distress that are all associated with the prolonged course of 
the illness may also be questioned. It is noteworthy that the electronic clinical notes are the 
primary clinical recordkeeping system in the South London and Maudsley NHS Foundation 
Trust which complies with national frameworks such as the Care Programme Approach with 
the dates, times, contacts and interventions and progress with the treatments explicitly 
documented. It may therefore be argued that the method for obtaining information on 
                                                          
6
 These findings are based on the meta-analyses of remission and recovery rates in FEP, including 
diagnostic subgrouping, and moderators of remission and recovery that is currently in preparation for 
submission by John Lally,* Olesya Ajnakina,* Brendon Stubbs, Robin M Murray (in preparation). 
Remission and recovery from first-episode psychosis in adults: A systematic review and meta-
analysis of long term outcome studies 
166 | P a g e  
 
outcomes may be at least as accurate, or perhaps even more so, as the face-to-face 
interviews.  
Further, following up patients based on their electronic records may imply that those patients 
who were successfully traced tended to have poorer outcomes or at least a greater need for 
care as they were still in contact with mental health services at the end of the follow up 
period compared to those patients who dropped out from the study during the follow-up 
period. However, this criticism may be not applicable to my study as the vast majority of the 
patients (~82%) were still under care of mental health services at the end of the follow up 
period; though it is important to acknowledge that I do not know the nature and severity 
outcomes of those ~18% patients who were lost to follow up.  
7.2.2.3. Underestimated rate of followed up true FEP cases?  
Because young individuals and ethnic minorities with an early onset of psychosis may be 
less likely to be registered with GPs and thus come under the radar of mental health 
services 173, 174,250, the rate of FEP cases that I have followed up during my PhD may be 
underestimated. 
7.2.2.4. Utilisation of ethnic categories 
Another limitation to this thesis centres around the utilisation of ethnic categories which are 
often not very precise 300. The use of broad ethnic categories can obscure more subtle 
variations within the groups.  
7.2.2.5. Generalisability of the results.  
It is important to note that around 85% of the patients were recruited to the original GAP 
study from inpatient units; while a substantially smaller proportion of patients was recruited 
from community based mental health settings. This may imply that the sample represented 
more severe FEP cases from the start. Therefore, the results reported in this thesis could not 
be generalised to the general patient population. However, there were no significant 
differences in mean total PANSS scores (inpatients: 64.1 (sd=16.4) vs outpatients: 61.9 
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(sd=18.9) (Mann Whitney U test=0.934, p=0.35) and negative PANSS scores (inpatients: 
15.5 (sd=6.6) vs outpatients: 16.1 (sd=5.8) (t=-0.39, p=0.70) between those recruited from 
an inpatient setting and those from a community setting. Though inpatients had significantly 
increased mean positive PANSS scores (mean=16.2, sd=6.6) compared to those recruited 
from community settings (mean=13.2, sd=5.8; t=2.34, p=0.02). Nonetheless, the increased 
proportion of patients who were inpatients at the study entry, and the recruitment from 
clinical services rather than by population screening or other methods may imply that some 
of the clinical outcomes examined in this thesis, such as the rate of treatment resistance 
identified, may be overestimated. 
7.3. Future directions  
There are two approaches that can be taken in order shed some light on why psychotic 
disorders are marked by heterogeneity in terms of clinical presentation 4 and outcomes and 
how best to predict longitudinal outcomes that in turn would provide guidance to the 
clinicians on the best intervention strategies to pursue based on an individual’s profile across 
a set of risk factors301. 
7.3.1. Polygenic underpinning of longitudinal outcomes  
When trying to disentangle the reasons for the diversity in outcomes and treatment response 
in patients with first episode psychosis a special consideration should be given to the genetic 
nature of psychotic disorders, especially schizophrenia. Although many schizophrenia cases 
are sporadic, around 80% of the variance in liability to this disorder can be attributed to the 
additive genetic factors 302. It has now been recognised and acknowledged that 
schizophrenia is a polygenic illness 303. Accordingly, a combination of hundreds of thousands 
of common variants with an effect that would not have any predictive power individually 
simultaneously contributes to an overall risk to this illness 304. It has been shown that up to 
~35% of genetic liability to schizophrenia was captured by summed common variants (this 
approach has become known as polygenic risk score for schizophrenia (PRS-SZ) 305)306. The 
ultimate goal of PRS-SZ approach is to identify an individual genetic risk for specific 
outcomes, such as onset of FEP, or likelihood to respond to a specific treatment. To-date, 
the PRS-SZ approach has been applied to only a narrow range of disciplines within aetiology 
of this complex illness, focusing primarily on cognition307 308 309  and baseline symptom 
dimensions310 311 312 313 . There are tree studies which investigated whether PRS-SZ was a good 
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prognostic tool to use for prediction of response to antipsychotic medications; thigh the 
results to support this were mixed282 281 . More importantly, no studies have tested potential 
associations between the PRS-SZ and longitudinal outcomes such as response to treatment 
after first contact with mental health services.  
Knowing what groups of patients will have a genetic predisposition for poorer outcomes over 
the course of illness will lay a strong foundation for the developing of preventive strategies 
based on an individual genetic loading for the illness. Therefore, future research should aim 
to examine whether there is significant associations between the PRS-SZ and some of the 
outcomes that I tested in this thesis over the illness course.  
7.3.2. Machine Learning (ML) to predict outcomes on individual levels 
While in the present thesis I have outlined an illness trajectory of psychosis starting from the 
at-risk-mental health to transition to first episode psychosis and finishing with onset of 
treatment resistance after the first five years of the illness, I did not examine the predictors 
for these outcomes on an individual level. Thus, if a person came seeking help for first 
episode psychosis on the basis of my findings all I could tell would have been that on 
average they may remit within 4 months and never have another episode, or they have 34% 
of chance to develop chronic and treatment-resistant illness, but there was no way to predict 
which category they belong to. In the future, I would like to do just that employing machine 
learning and statistical learning techniques.  
Machine learning (ML) methods are designed to provide the best estimate of an outcome in 
an individual from multiple predictors. These methods use a training dataset to learn from 
relationships between predictors and outcomes which are then validated in a test dataset to 
establish how well they predict an outcome in an independent sample314. Although ML 
methods were criticised for being a “black box” as these methods do not provide 
explanations for why particular variables were selected as predictors of the outcomes, they 
are power tools for risk prediction at an individual level314. Therefore, I propose that the 
outcomes that I focused on this this thesis, such as remission and services use, should be 
examined with ML techniques. These results of these potential studies may lay a foundation 
for a risk calculator that may provide guidance to the clinicians to pursue more appropriate 
intervention strategies based on an individual’s profile across a set of risk factors.  
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7.4. Concluding remarks  
In this thesis I looked back pathways to care to see how patients came under attention of 
mental health services, and I looked forwards to investigate the trajectory and different 
outcomes of the illness over the first 4 to 5 years after patients came in contact with mental 
health services for psychosis. The main conclusion that I can draw when looking back is that 
it is still challenging to identify individuals who are at high risk for onset of first episode 
psychosis and to therefore prevent it or catch it early. When looking forwards, it becomes 
evident that it was unfortunate that symptom dimensions were relegated to an Annexe within 
DSM-5 as I showed that the use of a combination of five symptom dimensions and the 
traditional diagnostic category of schizophrenia provides a more robust prediction of the 
length of time it takes for patients to respond to treatment as was measured by time to first 
remission. I also showed that the differences still remain in longitudinal service utilisation for 
those FEP patients of Black ethnicity resident in London. Finally, my findings reinforce the 
need for earlier assessment of treatment resistance in first episode patients so that 
clozapine may be considered and introduced promptly as a third line treatment in first 
episode schizophrenia. I hope this PhD thesis will service as an encouragement to conduct 
more detailed and hypotheses-driven research in the field of longitudinal outcomes and FEP 
to establish the basis for risk prediction, improving the available services and promoting 
equality of care throughout the illness course.   
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Subject number:  2EU02. |__|__|__|__|  
Date of Birth  |__|__|-|_|_|-| 1 | 9 |__|_ | 
Date    |__|__|-|_|_|-| 2 | 0 |__|_ | 
 
Social (1) Socio-demographics (at first contact) 
 
1. Gender  [O -77 Not Recorded]  O1 Male  O2 Female 
 
2. Age  [O -77 Not Recorded]  |__|__|     
 
3. Postcode  [O -77 Not Recorded]  |__|__|__|__|-|__|__|__|__|   
 
4. Ethnicity   [O -77 Not Recorded] 
 
O11White British O12 White Irish O13 White gypsy, traveller O14 Other White 
O15 Mixed (w, bc) O16 Mixed (w, ba) O17 Mixed (w, as)  O18 Other Mixed 
O19 Indian O20 Pakistani O21 Bangladeshi O22 Chinese 
O23 Other Asian O24 Black Caribbean O25 Black African  O26 Other Black  
O27 Arab  O28 Other, specify: _________________________  
 
5. Place of Birth [O -77 Not Recorded] 
  
O1 Austria O2 Belgium O3 France O4 Germany 
O5 Ireland O6 Italy O7 Spain  O8 Suisse 
O9 The Netherlands  O10 Turkey O11 United Kingdom O12 Brazil 




6. Age of migration (if applicable) [O -77 Not Recorded]  |__|__| 
 
7. Ever employed (paid work) [O -77 Not Recorded]    O0 No 
 O1 Yes 
 
8. Registered with a GP  [O -77 Not Recorded]    O0 No 
 O1 Yes 
 












Friends Other: specify 
(e.g.  hostel, halls of residence) 
Not 
Recorded 
O1 O2 O3 O4 O5 O6 O7 O8_______________________ O -77 
 
10. Housing tenure 
 






Rented (Private) Rented (government) Other, specify: Not 
Recorded 
O1 O2 O3 O4 O5________________________ O -77 
 
11. Ever had a long-term relationship (one year or more)  [O -77 Not Recorded]     O0 No
          O1 Yes 
 
12. Number of children ...?     [O -77 Not Recorded] 
 |__|__| 
 
13. Relationship status …? 
 
Single Married, living with 
someone 
In a steady relationship Divorced, separated Widowed Not Recorded 
O1 O2 O3 O4 O5 O -77 
 
14. Highest level of education achieved ...? [O -77 Not Recorded]  
 
O1  School, no qualifications   (to end of compulsory education; passed no exams, tests, etc.) 
O2  School, with qualifications  (to end of compulsory education; passed one or more exams, tests, etc.) 
O3  Tertiary, Further   (first level of non-compulsory education; e.g. A-levels, Baccalaureate) 
O4 Vocational    (job related education, e.g. teacher training, plumber, electrician, etc.) 
O5  Higher (undergraduate)   (University; first degree) 
O6  Higher (postgraduate)   (University: higher than first degree level, e.g. Masters, PhD) 
 




house person, physical 









O1 O2 O3 O4 O5 O6 O -77 
 
16. Weekly + contact with family [O -77 Not Recorded]    O0 No 
 O1 Yes 
 
17. Weekly + contact with friends [O -77 Not Recorded]    O0 No 
 O1 Yes 
 
18. Any report of socially isolation [O -77 Not Recorded]    O0 No 
 O1 Yes 
  
DUP 
Please note the most accurate date!  
 
 In case only information about the year of onset is available, please note the 1st of July of that year as 
date of onset   
 In case only information about the month of onset is available, please note the 15th of that month as 
date of onset 
 
Date of onset psychosis:  
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First day of onset of psychotic symptoms  
 
Onset of psychotic symptoms is defined as: Clear evidence of delusions, hallucinations, first rank symptoms, 
catatonic symptoms (i.e. A score of 2 for a psychotic symptom in Part II of the SCAN OR a score ≥ 4 on 
PANSS items P1, ‘delusions’, P3 ‘hallucinatory behaviour’, P5 ‘Grandiosity’, P6 ‘Suspiciousness’ or A9 
‘Unusual thought content’).  
 
Date of contact with mental health services (for FEP) 
(day/month/year):      [O -77 Not 
Recorded]  
 
Date of onset psychosis:    [O -77 Not 
Recorded]  
 
Mode of Onset 
O1  Abrupt onset definable to within hours or days 
O2  Acute onset definable to within 1 week 
O3  Moderately acute onset definable within 1 month 
O4 Gradual onset over period up to 6 months 
O5  Insidious onset over period greater than 6 months 
 
Pathway to Care 
1 Mode of Contact 
(Secondary Mental Health 
Service) 
  0 = Community; 1 = Home treatment; 2 = In-patient (voluntary);  
3 = In-patient (compulsory); -77 = Not recorded 
    
2 MHA Section (if applicable)   1 = Section 2  6 = Section 37  -77 = Not 
recorded 
2 = Section 3  7 = Section 37/41 
3 = Section 4  8 = Section 47 
4 = Section 5(2)  9 = Section 48 
5 = Section 5(4)   
  
2a. MHA Sec 136/135   
 
 0= No                     1= Yes                    -77= Not recorded 
3 Source of Referral   1 = General practitioner; 2 = Nurse, other health worker, or social 
worker; 
3 = Accident and Emergency; 4  = Police; 5 = Courts; 6 = Prison; 
7 = Other, specify; -77 = Not recorded 
    
4 Contact out of hours 
 
  0 = No   1 = Yes  -77 = Not recorded 
    
5 Family Involvement 
 
  0 = No   1 = Yes  -77 = Not recorded 
    
6 Police or CJA Involvement 
 
  0 = No   1 = Yes  -77 = Not recorded 
  _   _     
          





[O -77 Not Recorded]  
 









O1 Probable O2 Definite 





1 Ever smoked/used cannabis?   [O -77 Not Recorded]  O1 Yes O0 No 
 
No. Relative 
(1 Father; 2 Mother; 
3 Sibling; 4 Child) 
Age Treatment 









(1 Good; 2 Fair; 3 Poor) 
Type of Disorder 
1.       
2.       
3.       
4.       
5.       
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Global Assessment of Functioning (GAF) Scale - SYMPTOMS 
 




Consider psychological functioning on a hypothetical continuum of mental health-illness. 
Rate symptoms over the last week before interview. Use intermediate codes where appropriate e.g. 45, 68, 72. 
 
100-91 No symptoms. 
90-81 Absent or minimal symptoms (e.g. mild anxiety before an exam). 
80-71 If symptoms are present they are transient and expectable reactions to psychosocial stresses 
(e.g. difficulty concentrating after family argument). 
70-61 Some mild symptoms (e.g. depressed mood and mild insomnia). 
60-51 Moderate symptoms (e.g. flat affect and circumstantial speech, occasional panic 
attacks). 
50-41 Serious symptoms (e.g. suicide ideation, severe obsessional rituals, frequent 
shoplifting). 
40-31 Some impairment in reality testing or communication (e.g. speech is at times 
illogical, obscure or irrelevant). 
30-21 Behaviour is considered influenced by delusions or hallucinations OR serious 
impairment in communications or judgment (e.g. sometimes incoherent, acts 
grossly inappropriately, suicidal preoccupation). 
20-11 Some danger or hurting self or others (e.g. suicide attempts without clear 
expectation of death, frequently violent, manic excitement) OR gross 
impairment in communication (e.g. largely incoherent or mute). 
10-1 Persistent danger of severely hurting self or others (e.g. recurrent violence) 
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Global Assessment of Functioning (GAF) Scale - DISABILITY 
 




Consider psychological, social and occupational functioning on a hypothetical continuum of mental health-illness. 
Do not include impairment of function due to physical or environmental limitations.  
Rate functioning over the last week before interview. Use intermediate codes where appropriate e.g. 45, 68, 72. 
 
100-91 
Superior functioning in a wide range of activities; life’s problems never get out 
of hand; is sought out by others because of his/her positive qualities. 
90-81 
Good functioning in all areas, interested and involved in a wide range or 
activities, socially effective, generally satisfied with life, no more than everyday 
problems or concerns (e.g. an occasional argument with family members). 
80-71 
No more than slight impairment in social, occupational, or school functioning 
(e.g. temporarily falling behind in school work). 
70-61 
Some difficulty in social, occupational, or school functioning (e.g. occasional 
truancy, or theft within the household), but generally functioning pretty well, has some 
meaningful interpersonal relationships. 
60-51 
Moderate difficulty in social, occupational, or school functioning (e.g. few 
friends, conflicts with co-workers). 
50-41 
Any serious impairment in social, occupational, or school functioning (e.g. no 
friends, unable to keep a job). 
40-31 
Major impairment in several areas, such as work or school, family relations, 
judgment, thinking, or mood (e.g. depressed man avoids friends, neglects family, and is unable to 
work; child frequently beats up younger children, is defiant at home, and is failing at school). 
30-21 Inability to function in almost all areas (e.g. stays in bed all day; no job, home or friends). 
20-11 
Occasionally fails to maintain minimal personal hygiene (e.g. smears faeces) OR gross 
impairment in communication (e.g. largely incoherent or mute). 
10-1 Persistent inability to maintain minimum personal hygiene. 












Dear [GP PRACTICE], 
 
Re:  [First Name] [Second Name] [DOB]  
  
 I am writing to you with regard to the above patient, who to my knowledge, is currently on 
your caseload. This patient participated in a study on First-Episode Psychosis, the Genetics and 
Psychosis (GAP) Study in our centre-Institute of Psychiatry, King’s College London-and agreed that 
he could be followed-up (Ethics reference number: 05/Q0706/158; the patient consent form is 
attached). 
 
We are now trying to contact all those who participated in the study. Unfortunately, we have 
been unable to get in touch with the patient. We think that this may be due to change in the patient’s 
contact details since our previous contact. We would be very grateful if you were able to provide us 
with the relevant contact information, i.e. current mobile phone number and/or home number of 
patient. This would allow us to re-assess a larger cohort of patients with a pre-existing psychotic 
disorder and would be of immense benefit for the scientific and clinical community.  
 
Although we do realise that you must be very busy with your clinical commitments, we 
would really appreciate if you could respond to the questions I have enclosed to this letter and either 
fax this form back to me on Fax: 020 7848 0287 or by post in the envelop provided. 
 
Should you have further queries, please contact my colleague Olesya Ajnakina on 020 7848 







Professor Robin M Murray  
MD DSc FRCP FRCPsych FMedSci FRS 
Professor of Psychiatric Research 
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Short Questionnaire for GPs: First-Episode Psychosis, the Genetics and Psychosis (GAP) 
Name/DOB/First contact 
 
Is the above patient still in contact with you?                                                         Y/N 
 















Currently, is the patient under the care of the local Community Mental Health Team 
(CMHT)?                                                                                                                   Y/N 
 
















Are you aware of the presence of suicidal behaviour, i.e. the patient required medical 
attention (A&E or hospitalization) following a deliberate self-harm act? If so, could you 








Has the patient ever been admitted to hospital with mental health issues since the patient 
has been on your caseload?                                                                      Y/N 
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Name of the Participant: ……………………………………………………………………..... 
ID: ………………………………………………………………………………………………. 
Date of birth: …………………………………………………………………………………… 
Date of the assessment: ………………………………………………………………………. . 
Name of the Assessor: …………………………………………………………………………. 
Date of First Contact: …………………………………………………………………………. 
 
SECTION 1: CLINICAL COURSE AND SYMPTOMS 
 
NOTE: COMLETE TIME LINE SHEET, PLOTTING EACH PSYCHOTIC EPISODE 
 
2.1 CURRENT MENTAL STATE 
Is the patient now (last 30 days) in a psychotic episode? 
0 = No 
1 = Yes 
2 = Yes, but not continuous with episode in inclusion 
 




a) What is longest period (in weeks) during which the patient has had a remission of psychotic symptoms? 
(Use definition of remission in Appendix 1, without the 6 month requirement) 
 
b) Has the patient had a remission of psychotic symptoms for a period of at least 6 months since the initial evaluation? 
(See Appendix 1 for definition of remission) 
 
0 = No 1 = Yes 
 
If impossible to assess, specify reason 
 
b) If YES above, for how many weeks was the patient in the episode of inclusion (i.e. baseline episode) 
(888 = patient still in episode of inclusion)  
 
2.3 USUAL SYMPTOM SEVERITY (during psychotic episodes only) 
0 = No further episodes 
1 = Mild 
2 = Moderate 
3 = Severe 
 
Note: Use SCAN rating criteria 
‘The severity of a symptom can be assessed in terms of duration, persistence, degree of interference with other mental functions, 
distress, impairment of everyday activities, effect on other people, and contact with services of various kinds.’ 
 
SCAN Rating Scales 
0  Symptom(s) did not occur during period 
1  Symptom(s) definitely occurred during period, but probably uncommon or transitory 
OR of such a minor degree it is not appropriate for use in classification 
2  Symptom(s) definitely present, on multiple occasions or for part of time, during period 
AND at a level sufficient to use in classification  
3  Symptom was more or less continuously present throughout the period/episode AND present in severe form 
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2.4 PRESENCE OF NEGATIVE SYMPTOMS 
(Over follow-up period) 
 
0 = No 
1 = Yes, for less than 6 months 
2 = Yes, for more than 6 months 
 
i.e. 
a) Marked reduction or loss of interests, initiative and drive, leading to serious deterioration of the performance of usual 
activities and tasks 
b) Emergence or marked exacerbation of social withdrawal (active avoidance of communication with other people) 
c) Gross and persistent self-neglect 
 
2.5. COURSE TYPE 
 
1 = Episodic, no episode lasted over 6 months 
2 = Continuous, no remission lasted over 6 months (Primarily symptoms A) 
3 = Continuous, no remission lasted over 6 months (Primarily symptoms B) 
4 = Continuous, no remission lasted over 6 months (Primarily symptoms A & B) 
5 = Neither episodic nor continuous, at least 1 episode & 1 remission lasted over 6 months 
 
IF EPISODIC OR NEITHER EPISODIC NOR CONTINUOUS, RATE ITEM 2.6. – 2.7. 
IF NEVER PSYCHOTIC OR CONTINUOUS GO TO ITEM 2.6. 
 
2.6. NUMBER OF PSYCHOTIC EPISODES (Do NOT include first episode) 
 
(See Appendix 1 for definition of psychotic episode. Each “psychotic episode” must be separated by at least 6 months 
spent in remission). 
 
0.0 = Patient presently in remission from episode of inclusion 
 




2.8 SUICIDE ATTEMPT(S) 
a) Rate the number of suicide attempts by the patient since the index episode  
of evaluation (if in any doubt re: intention, rate as deliberate self-harm) 
0 = None 
 
2.9 DELIBERATE SELF-HARM 
a) Rate the number of episodes of deliberate self-harm by the patient since the index 
episode of evaluation (if in any doubt re: intention, rate as deliberate self-harm) 
0 = None 
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SECTION 2: SERVICE USE AND TREATMENT 
3.1 HAS THE PATIENT BEEN IN CONTACT WITH SERVICES AT ANY POINT  
DURING THE FOLLOW-UP PERIOD? 
 
0 = No 
1 = Yes 
 
If YES, continue 
If NO, is this because: 
 
0 = None were offered 
1 = Patient did not attend 
 


















Note: ALL RECORDED CONTACTS MUST BE FOR ANY MENTAL ILLNESS. NOTE WHETHER CONTACT 
WAS FOR PSYCHOSIS OR NEUROSIS ON TIME LINE SHEET. 
 
NOTE: COMPLETE TIME LINE SHEET, PLOTTING EACH HOSPITAL ADMISSION, EACH PERIOD OF 
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HOSPITAL ADMISSIONS (1) 
 
3.2 COMPLETE FOR EACH HOSPITAL ADMISSIONS DURING THE FOLLOW-UP 
PERIOD (inc. first admission), USING CODES PROVIDED BELOW 




3.2.1 Date of Admission  …………/…………/……….. 
 
3.2.2 Date of Discharge                                                                      …………/…………/……….. 
 
 
3.2.3 Ward Type 
 
 
3.2.4a MHA Status on Admission 
 
 
3.2.4.b MHA Status during Admission 
 
 
3.2.5. MHA Section(s)  
(Specify section from the list below) 
 
3.2.6 Source of Referral 
 
 
3.2.7 Reason for Admission  
(nb: there can be more than 1 reason 
for admission) 
 
3.2.8. Family Involvement  
 
3.2.9. Police or CJA Involvement  
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CODES FOR HOSPITAL ADMISSIONS 
 
3.2.3 Ward type 
What type of ward was the patient admitted to? 
0 = Acute  
1 = Rehabilitation 
2 = Secure/Forensic 
3 = Other, specify 
 
3.2.4 MHA Status 
What was the mode of admission? 
0 = Voluntary  
1 = Compulsory 
 
3.2.5. MHA Section (s)  
Section of Mental Health Act used, if applicable 
1-Section 2 6=Section 37 
2=Section 3 7=Section 37/41 
3=Section 4 8=Section 47 
4=Section 5(2) 9=Section 48 
5=Section 5(4) 10-Section 136 
 
3.2.6 Source of Referral 
What was the source of referral resulting in hospital admission? 
1 = Psychiatrist or  6 = Police 
other mental health professional  7 = Courts/Prison 
2 = General practitioner  8 = Other, specify 
3 = Nurse, other health worker, or social worker   
4 = Accident and Emergency 
5 = Emergency Clinic 
 
3.2.7 Reason for Admission 
What were the main reasons for admission? 
0 = Patient attempted suicide or bodily harm 
1 = Patient’s behaviour perceived as potential danger to himself (e.g., talked of killing 
      or harming himself; refusal of food, etc.). 
2 = Patient committed an assault, or other violent or hazardous act (e.g., setting fire or 
      destroying property) 
3 = Patient’s behaviour perceived by others as threatening or grossly annoying. 
4 = Deterioration in mental health 
5 = Other reason (specify) 
 
3.2.8. Family involvement  
Were the patient’s family or friends involved in seeking help that resulted in hospital; admission? 
0=No 1=Yes 
 
3.2.9. Police or CJA Involvement 
Were the police or any other criminal justice agency involved in bringing about hospital admission? 
0=No 1=Yes 
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USE OF OUTPATIENT/COMMUNITY SERVICE (1) 
 
3.3 COMPLETE FOR EACH PERIOD OF CONTACT WITH OUTPATIENT/COMMUNITY SERVICES DURING THE 
FOLLOW-UP PERIOD (inc. first contact), USING CODES PROVIDED BELOW (use further sheets if necessary)  
   
3.3.1. Date of Referral 
 
3.3.2.a Date Last Seen 
 
3.3.2.b Date of Discharge or Hospital admission 
 
3.3.3. Source of Referral 
 
3.3.4. Type of Contact 
(Specify details below for all changes in type of contact) 
 
3.3.5. Reason Contact Ended 
 







Please add all other relevant details (inc. any changes in type of contact, etc.) 
 
  
a b c b a 
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CODES FOR USE OF OUTPATIENT/COMMUNITY SERVICES 
3.3.3. Source of Referral 
What was the source of referral resulting in contact with community/follow-up services? 
 
1=Psychiatric referral following discharge from hospital 
2=General practitioner 
3=Nurse, other health worker, or social worker 




8=Other specify  
 
 
3.3.4. Type of Contact 
Rate type of contact with community/follow-up services 
 
0=Maintenance  [Contact with services, inc. GP, at intervals of more than one month primary for 
prescription/monitoring of medication] 
1=Regular  [Contact with services at interval of less than one month] 
2=Intensive [Contact with assertive outreach services] 
3=Acute [Contact with acute home treatment/crisis intervention services] 
 
 
3.3.5. Reason Contact Ended 
Why was contact with community/follow-up services ended? 
 
0=Patient was discharged by service 
1=Patient was (re)admitted to hospital 
2=Patient did not attend follow-up appointments  
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OTHER TREATMENT ITEMS 
 
 
3.4.1. Overall Compliance/Attendance 
  EPJS 
Rate patient’s compliance/attendance at community/follow-up services 
 
1 = Regular compliance/attendance  [1-33% missed appointments] 
2 = Irregular compliance/attendance  [34-66% missed appointments] 
3 = None compliance/attendance  [67-100% missed appointments] 
 
 
3.4.2. Reason for Irregular or None Attendance 






  EPJS 
3.4.3. Current treatment status 
 
Patient’s treatment status at the time of interview 
 
0 = Not in any form of treatment 
1 = Inpatient psychiatric facility (includes general hospital psychiatric wards) 
2 = Standard outpatient/CMHT 
3 = Assertive outreach 
4 = Acute home treatment/crisis intervention 
5 = Other, specify 
6 = More than one above, specify 
 
 
3.4.4. Traditional treatment  
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SECTION 3: ANTI-PSYCHOTIC TREATMENT OVER FOLLOW-UP PERIOD 
1. Name of antipsychotic: …………………………………………… 
 
Dose and delivery method: ……………………/……………………… 
 
Date of commencement: ………………/………………/…………… 
 
Date of treatment discontinuation: ………………/………………/………….... 
 
Time on treatment (weeks): 
  
Reason for discontinuation: 
 
[1= change to alternative antipsychotic; 2= discontinued by treating physician; 
3=discontinued by patient; 4= discontinued by treating physician due to side effects; 5= discontinued by treating 
physician due lack of therapeutic effects; 6=other] 
 
Adherence to antipsychotic over this period: 
[1 (0-33%) ; 2 (33-67%) ; 3 (67-100%)] 
 
 
2. Name of antipsychotic: …………………………………………… 
 
Dose and delivery method: ……………………/……………………… 
 
Date of commencement: ………………/………………/…………… 
 
Date of treatment discontinuation: ………………/………………/………….... 
 
Time on treatment (weeks): 
  
Reason for discontinuation: 
 
[1= change to alternative antipsychotic; 2= discontinued by treating physician; 
3=discontinued by patient; 4= discontinued by treating physician due to side effects; 5= discontinued by treating 
physician due lack of therapeutic effects; 6=other] 
 
Adherence to antipsychotic over this period: 
[1 (0-33%) ; 2 (33-67%) ; 3 (67-100%)] 
 
 
3. Name of antipsychotic: …………………………………………… 
 
Dose and delivery method: ……………………/……………………… 
 
Date of commencement: ………………/………………/…………… 
 
Date of treatment discontinuation: ………………/………………/………….... 
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Time on treatment (weeks): 
  
Reason for discontinuation: 
 
[1= change to alternative antipsychotic; 2= discontinued by treating physician; 
3=discontinued by patient; 4= discontinued by treating physician due to side effects; 5= discontinued by treating 
physician due lack of therapeutic effects; 6=other] 
 
Adherence to antipsychotic over this period: 
[1 (0-33%) ; 2 (33-67%) ; 3 (67-100%)] 
 
 
4. Name of antipsychotic: …………………………………………… 
 
Dose and delivery method: ……………………/……………………… 
 
Date of commencement: ………………/………………/…………… 
 
Date of treatment discontinuation: ………………/………………/………….... 
 
Time on treatment (weeks): 
  
Reason for discontinuation: 
 
[1= change to alternative antipsychotic; 2= discontinued by treating physician; 
3=discontinued by patient; 4= discontinued by treating physician due to side effects; 5= discontinued by treating 
physician due lack of therapeutic effects; 6=other] 
 
Adherence to antipsychotic over this period: 
[1 (0-33%) ; 2 (33-67%) ; 3 (67-100%)] 
 
 
5. Name of antipsychotic: …………………………………………… 
 
Dose and delivery method: ……………………/……………………… 
 
Date of commencement: ………………/………………/…………… 
 
Date of treatment discontinuation: ………………/………………/………….... 
Time on treatment (weeks): 
  
Reason for discontinuation: 
 
[1= change to alternative antipsychotic; 2= discontinued by treating physician; 
3=discontinued by patient; 4= discontinued by treating physician due to side effects; 5= discontinued by treating 
physician due lack of therapeutic effects; 6=other] 
 
Adherence to antipsychotic over this period: 
[1 (0-33%) ; 2 (33-67%) ; 3 (67-100%)] 
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SECTION 4: SOCIODEMOGRAPHIC SCHEDULE 
5.1. Living arrangements 
00 = Living alone (excludes supervised accommodation) 
01 = Living alone with children (single parent) 
02 = Living with partner 
03 = Living with other family 
04 = Living with friends 
05 = Living with unrelated persons (exclude supervised accommodations) 
06 = Living in supervised accommodations (e.g. hospital, hostel, half-way house, etc.) 
07 = Patient is homeless and has no stable living arrangements 
99 = No information/not known/impossible to assess 
 
 
5.2. How many people do live with you?  
 
5.3. Approximate length of residence(rate to nearest week)  
88=Pateint a vagrant with no stable household 
 
5.4. Type of accommodation at follow-up? 
0 = Self/joint owner occupied 
1 = Family owner occupied 
2 = Private rented 
3 = Local Authority rented 
4 = Housing Association rented 
5 = Other (specify) 
 
5.5. Current Marital Status 
Rate the patient’s current marital status 
0 = Married or common law marriage 
1 = In steady relationship 
2 = Single, no partner 
3 = Divorced 
4 = Separated 
5 = Widowed 
6 = Other, specify 
 
5.6. Main Marital Status during follow up period  
Rate the patient’s current marital status 
0 = Married or common law marriage 
1 = In steady relationship 
2 = Single, no partner 
3 = Divorced 
4 = Separated 
5 = Widowed 
6 = Other, specify 
 
5.7.Current Parental Status   
Rate patient’s current parental status 
0 = No children 
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1 = Parent, living with partner 
2 = Single parent 
3 = Parent, children live with other parent 
4 = Parent, children live with relatives 
5 = Parent, children in care 
 
5.8. Past Parental Status 
Rate patient’s parental status during majority of follow-up period 
0 = No children 
1 = Parent, living with partner 
2 = Single parent 
3 = Parent, children live with other parent 
4 = Parent, children live with relatives 
5 = Parent, children in care 
 
5.9. Current Employment Status (LAST 30 days) 





5.10. Reason for the current unemployment (LAST 30 DAYS) 
If the patient has not had a paid job in the last 30 days, rate the reasons for unemployment 
0 = Related to the patient’s mental illness (inc.’s hospitalisation, simple refusal to work, etc.) 
1 = Unrelated to the patient’s mental illness 
2 = Other, specify 
3 = Combination of the above, specify 
 
5.11. Past Employment 
Rate employment (or earning job) since indec episode (exclude last 30 days)  
0=Has been employed 75-100% of the time 
1=Has been employed 50-75% of the time   
2=Has been employed 25-50% of the time 
3-Has been employed 0-25% of the time  
 
5.12. REASONS FOR PAST UNEMPLOYMENT 
Rate reason for unemployment since index episode (exclude last 30 days) 
0 = Related to the patient’s mental illness (inc.’s hospitalisation, simple refusal to work, etc.) 
1 = Unrelated to the patient’s mental illness 
2 = Other, specify 
3 = Combination of the above, specify 
 
5.13. EDUCATION: Since the index episode has the patient undertaken an educational programme (including 
vocational training), of at least 10 weeks duration? 
0 = No 
1 = Yes 
 
5.14. MONTHS IN PRISON DURING FOLLOW-UP PERIOD 
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5.15. ANY OTHER SUGGESTIONS OF ANTI-SOCIAL/OFFENDING BEHAVIOUR?  
0 = No 1 = Yes 
 
SOCIAL NETWORK: CHANGES 
5.16. HAS THE PATIENT’S RELATIONSHIP WITH FAMILY/FRIENDS BEEN AFFECTED BY HIS/HER 
ILLNESS? 
(NB: Friends here refers only to very close friends the patient had at baseline) 
1 = Yes 
2 = No 
 
5.17. IF YES, HOW 
1 = Increased frequency of contact 
2 = Decreased frequency of contact 
 
5.18. FOR EITHER OF THE ABOVE, DETERMINE THE DEGREE OF CHANGE 
 
1 = To a large extent (e.g. change from low to high frequency or vice versa) 
2 = To a moderate extent (e.g. change from medium to high frequency or vice versa) 
3 = To a small extent (e.g. change from low to medium frequency or vice versa) 
 
ENSURE THAT THE CHANGE IS FROM THE PRE-MORBID FUNCTIONING LEVEL. 
Check the definitions of frequency of contact below 
 
5.19. IF THE PATIENT SEES LESS OF ANY FAMILY MEMBER(S)/FRIEND(S), 
WHY IS THIS? 
 
0 = Because of illness 
1 = Family quarrels 
2 = Moved away 
3 = Drifted apart 
4 = Died 
5 = Other, specify 
 
SOCIAL NETWORK: CURRENT 
 
5.20. HOW OFTEN DO YOU VISIT OR SPEAK TO FAMILY/FRIEND(S)? 
0 = Daily  3 = Monthly 
1 = Weekly  4 = < than above 
2 = Fortnightly   5 = Never 
5.21. DO YOU HAVE ANY CLOSE CONFIDANTS?  
1 = Yes 2 = No 
 
5.22. HOW OFTEN DO YOU VISIT/SPEAK TO CONFIDANTS?  
0 = Daily  4 = < than above 
1 = Weekly  5 = Never 
2 = Fortnightly 
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SECTION 5: DRUG ABUSE/DEPENDENCE 
 
a) Rate illicit drug taking and/or abuse of illicit drugs over life course 
 
0= None 
1= Sporadic drug taking or occasional abuses reported, no evidence for frequent or regular use (i.e. less than 
one month) 
2= Sporadic drug taking or occasional abuses reported, but there is reason to suspect frequent or regular use 
(i.e. more than one month) 
3= Frequent or regular use definitely present (i.e. more than one month) 
4= Substance abuse (Maladaptive use leading to any of the following (1) failure to fulfil major role 
obligations due to substance (2) substance exacerbating or leading to social or interpersonal problems (3) recurrent abuse 
when physically hazardous (e.g. driving) or substance related legal problems) 
5= Substance dependence (Maladaptive use leading to 3 of the following (1) increased tolerance (2) 
symptoms of withdrawal (3) substance taken in larger amounts over a longer period than originally intended (4) 
persistent desire or unsuccessful attempts to cut down (5) much time spent in activities to obtain the substance or 
recovering from effects (6) impairment of social, occupational or recreational activities due to substance (7) persistent 
use despite harmful physical or psychological effects of substance. 
7= Drug taking a definite possibility but impossible to assess the frequency and extent of use 
 
 
b) If a rating of 1, 2, 3, 4,5 or 7 was made above, specify whatever information is available about the nature of the 
substance(s) taken by the patient. For each substance used, specify age of first use. 
 
0 = No                   1 = Yes 
2 = Suspected/uncertain                   8 = Not applicable/not inquired 
9 = No information/impossible to assess 
 
 Age 1st Used Follow Up  
Morphine or heroin  __________ ……  
Opium  __________ ….... 
Amphetamines or derivatives   __________ …… 
Hashish or marijuana  __________ …… 
Hallucinogens (LSD and others)   __________ …… 
Cocaine and cocopaste   __________ …… 
Barbituates   __________ …… 
Non-barbiturate sedatives and tranquillisers   __________ …… 
Other, specify   __________ …… 
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SECTION 6: ALCOHOL ABUSE/DEPENDENCE 
 
a) Rate the patient’s drinking habits over life course 
 
0= Does not drink at all 
1 =  Only occasional social drinking (mean 10 units or less per week) 
2 =  Moderate alcohol use (mean 21 units or less per week) 
3 =  Excessive alcohol use (mean more than 21 unit per week regularly) 
4 =  Alcohol abuse (Maladaptive use leading to any of the following (1) failure to fulfil major role obligations 
due to alcohol (2) substance exacerbating or leading to social or interpersonal problems (3) recurrent abuse when 
physically hazardous (e.g. driving) or alcohol related legal problems) 
5 =  Alcohol dependence (Maladaptive use leading to 3 of the following (1) increased tolerance (2) symptoms 
of withdrawal (3) alcohol taken in larger amounts over a longer period than originally intended (4) persistent desire or 
unsuccessful attempts to cut down (5) much time spent drinking the substance or recovering from effects (6) impairment 
of social, occupational or recreational activities due to alcohol (7) persistent use despite harmful physical or 
psychological effects of alcohol 
9 =  No information/Not known 
 
 
b) If a rating of 3, 4, 5 or 7 was made above, specify whatever information is available about the nature of the 
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